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Adjuvant therapy of superficial bladder cancer with Mycobacterium bovis bacillus Calmette-
Guerin (BCG) is the most successful immunotherapy for solid tumors to date. The local 
immune response induced following BCG instillation is believed to be related to its anti-
tumourigenic activity However, not all patients respond well to BCG immunotherapy and long 
term monitoring of the patients are needed to survey for tumour recurrence. Continued 
research in BCG induced anti-tumour mechanisms is vital for discovering ways to improve the 
clinical outcome of the disease. In clinical practice, a commercial lyophilized preparation of 
BCG is used in adjuvant BCG immunotherapy. Since published studies with BCG in the field 
of immunology and vaccination involve the use of mostly live BCG, it is important to compare 
the cellular responses induced by the two BCG preparations before correlating in vitro 
observations with BCG immunotherapy in the bladder. 
The first part of this dissertation is focused on comparisons between live BCG and lyo BCG 
responses in mice and human bladder cancer cell lines. Healthy C57BL/6 mice were given 
once weekly live BCG instillations in the bladder for 4, 5 and 6 consecutive weeks. Expression 
of TH1 and TH2 genes were analyzed. Live BCG treatment induced cytokine and chemokine 
gene expression at all treatment schedules. Also, analysis of immune cells influx in the bladder 
showed that gene expression correlated well with immune cell recruitment. However, live 
BCG did not induce significant increase in IL12p40, IFNγ, IL2 and IL10 gene expression as 
has been reported to occur with lyophilized BCG.  
Before lyo BCG and live BCG treatment in vitro with human bladder cancer cell lines were 
compared, the integrin α5 and β1 expression and BCG internalizing capacity of the cell lines 
(MGH, J82, UMUC3, RT4 and SW780) were characterized. Integrin α5 expression correlated 
with BCG internalization capacity and this in turn correlated with the cytotoxic effects of 
BCG. When de novo protein synthesis was blocked, BCG internalization was maintained up to 





The ability of both BCG preparations to modify cellular reactive oxygen species (ROS) and 
gene expression were investigated. Live BCG increased while lyo BCG decreased ROS levels 
in the cell lines studied and for lyo BCG this correlated with cellular uptake of BCG. 
However, blocking direct BCG interaction with MGH cells using a transwell device induced 
ROS increase by both BCG preparations. Gene expression analysis showed that at 2 hours 
treatment, lyo BCG is better at inducing gene expression than live BCG in the MGH cell line. 
Significant increases in GSTT2, TNFα and IL1β transcripts were observed after exposure to 
lyo BCG. Only Tollip transcripts were up-regulated in RT4 cells after live BCG treatment. 
Untreated MGH cells expressed TNFα, IL12A, CSF2, Cxcl6, Ccl20, GSTT2, MGST1 and 
MGST2 at a significantly higher level than RT4 cells. When direct BCG interactions with 
MGH cells were blocked via a transwell apparatus, the expression of GSTT2 and TNFα were 
significantly down-regulated with respect to control, suggesting the presence of secreted 
mycobacterial factors that can affect cellular ROS and gene expression. Using a general 
protein tyrosine phosphatase inhibitor reduced the inhibitory effect of BCG on GSTT2 
expression indicating a possible role for mycobacterial protein tyrosine phosphatase (Mptp).  
The role of GSTT2 in lyo BCG treated cells was further investigated in using siRNA. In the 
absence of GSTT2, lyo BCG treatment induced greater ROS reduction (44.2% reduction 
compared to 22.1% reduction in DOTAP control) and increased basal NO levels in MGH 
cells. Lyo BCG treatment increased NO concentration in DOTAP and non-targeting siRNA 
control samples, but significantly reduced NO in GSTT2 knockdown samples. GSTT2 
knockdown also enhanced TNFα production in vitro after lyo BCG treatment. 
The second part of this study involved the purification of recombinant untagged MptpA to 
investigate the possible signaling and immune regulatory functions of the recombinant protein 
on human bladder cancer cell line and on purified mouse DCs and neutrophils. MptpA 
treatment reduced EGF induced EGFR phosphorylation in culture with MGH cell line. 





not regulate the phosphorylation levels of p38α, Akt and ERK but lyo BCG with MptpA up-
regulated p38α phosphorylation in MGH cells. Live BCG with MptpA up-regulated p38α and 
Akt phosphorylation and decreased phospho-ERK levels. MptpA was also confirmed to be a 
possible factor contributing to GSTT2 gene down-regulation but did not cause an increase in 
ROS in MGH cells. MptpA did not display immunostimulatory functions with respect to 
cytokine productions and DC expression of activation surface markers. 
In conclusion, lyo and live BCG induce similar but not identical effects in vivo and opposing 
effects in vitro on human bladder cancer cell lines. MptpA modulates the cellular effects of 
BCG on bladder cancer cells but not on DC-neutrophils interactions. The removal of MptpA 










A scientist in his laboratory is not a mere technician: he is also a child 







1.1  The prevalence and challenges of bladder cancer 
In 2009, in the United States there will be approximately 70,980 new cases of bladder cancer 
and in the United Kingdom, bladder cancer is the 4th most common cancer amongst males. In 
Singapore, it is the 9th most common cancer afflicting males. The tumour incidence and 
mortality rate of bladder cancer is generally higher in males than in females, probably due to 
the fact that habitual smoking, a risk factor, is more prevalent amongst men. Bladder cancer 
accounts for approximately 90% of cancers occurring in the urinary collecting system and is 
the 2nd most common malignancy among the genitourinary tract cancers.  
Approximately 74% of bladder cancers are superficial, confined only to the urothelial lining of 
the bladder. The initial treatment for superficial bladder cancer is the transurethral resection 
(TUR) of the tumour with electrofulguration to burn the residual visible tumours. For some 
patients, post-surgery procedures such as chemotherapy or radiotherapy will be given to 
eradicate any remaining tumours. However, despite a promising 80% surgical success rate and 
complete removal of visible tumour, two-thirds of the patients will ultimately develop disease 
recurrence within 5 years and by 15 years, 88% of patients will develop recurrence or 
metastatic disease [1]. The high rate of recurrence and disease progression in turn requires 
long term monitoring for bladder cancer patients. Coupled with the high cost of surveillance 
and surgical procedures, bladder cancer is the costliest cancer to treat on average per patient. 
1.1.1  The stages of bladder cancer. 
Determining the clinicopathologic stages of bladder cancer is important in planning specialised 
treatment to eradicate the cancer cells. The TNM staging system was devised by Pierre Denoix 
in the 1940s and it describes tumour development with respect to size (T), lymph nodes 
involvement (N) and distant metastasis (M). Most medical facilities use the TNM staging 







Figure 1.1: The staging of bladder cancer. Tis, also known as Carcinoma in situ (CIS), are 
characteristically flat high grade tumours, and may occur throughout the entire bladder 
mucosa. The most superficial state of the disease is the Ta stage, where the tumour is confined 
and visible as a polyp. T1 stage- Tumour invading into the lamina propria; T2-Tumours that 
have reached the muscularis propria (bladder muscle) and T3- tumours that penetrate the 
bladder walls into the perivesicle tissue layer. T4 staged tumours metastasize and invade 
adjacent organs. 
 
1.1.2 Superficial bladder cancer 
Superficial transitional cell carcinoma (TCC), also called non muscle invasive bladder cancer, 
includes the Tis or CIS, Ta and T1 stages with varying natural histories. CIS tumours are flat 
moss-like tumours along the thin urothelial layer of the bladder lining. Approximately 10% of 
diagnosed bladder cancer is CIS. CIS tumours are highly malignant cancerous lesions and are 
often associated with poor prognosis, with a 54% probability of progressing to muscle invasive 
disease and a 73% disease recurrence rate [2]. 
Ta lesions account for approximately 70% of superficial TCC presented and are typically low 
grade, composed of a branching fibrovascular core and a mucosa of multiple cancer cell layers. 





quite rare [3]. High grade Ta lesions do occur however, with a 39% progression rate to muscle 
invasiveness [2].  
Stage T1 bladder lesions are high grade tumours characterized by invasion of the lamina 
propria layer. Although many T1 lesions respond very well to TUR and adjuvant intravesical 
therapy, it has a high propensity for progression at a rate of up to 50% [3] as well as a high 
recurrence rate. Thus, the more aggressive approach of radical cystectomy (surgical removal of 
all or part of the bladder) is often chosen as a treatment option to improve survival for patients 
with T1 lesions.  
1.1.3 Advanced bladder cancer 
 Stages T2 and T3 of cancer development are still localised within the bladder while the T4 
stage denotes the advanced stage of bladder cancer, where cancer cells metastasize and 
infiltrate nearby organs such as the lymph nodes, prostate, womb, or the pelvic wall and 
abdomen. The gold standard treatment for invasive bladder cancer is radical cystectomy with 
lymphadenactomy, although bladder sparing strategies are used to manage patients with 
advanced metastatic disease or other medical complications, such as cardiovascular disease.  
1.2 BCG immunotherapy of superficial bladder cancer 
Intravesical immunotherapy with live Mycobacterium bovis, bacillus Calmette-Guèrin (BCG) 
is successful in reducing the recurrence and progression of superficial bladder cancer. A 
significant proportion of the patients are refractory to therapy and adverse side effects are also 
common. While the majority of the failures in patients are usually from superficial and low-
grade tumours, BCG failures in high risk T1 and CIS are problematic as they can progress to 
muscle invasive disease. There are no current gold standards for BCG failure salvage therapy 





1.2.1 Mechanisms of action 
Many groups have demonstrated that BCG induces direct effects on tumour cells. The 
interaction of BCG with urothelial and tumour cells is necessary for the activation of the local 
immune response in the bladder.  
1.2.1.1 Interactions of BCG with the bladder wall. 
1.2.1.1.1 Adhesion of BCG with the urothelium 
The interaction between BCG and the bladder wall can be mediated by specific, receptor-
ligand mediated events or by non-specific physicochemical interaction with the layer of 
hydrophilic, highly sulphated glycosaminoglycans (GAGs) on the luminal side of the bladder. 
A crucial role for fibronectin in the specific binding of BCG to the bladder wall has been 
postulated. Fibronectin is a glycoprotein present on many cell surfaces with structural and 
immunological functions. It acts as an opsonin, linking fibronectin receptors on the cell surface 
to fibronectin attachment proteins (FAP) present on the bacterial surface. Chen et al in 2003 
identified the signalling mechanisms involved after BCG attachment to the cell. Using a 
competitive peptide inhibitors to block  fibronectin binding to α5β1 integrin receptors as well 
as antibody cross-linking to activate α5β1, they demonstrated that BCG binding to tumour 
cells in vitro initiates signal transduction by cross- linking α5β1 integrin receptors present on 
the cell surface [4]. Studies done in the laboratory of Ratliff and Zhao have demonstrated that 
contact between BCG and the bladder mucosa is required for the initiation of signalling 
mechanisms resulting in immune responses in the murine bladder mucosa [5,6]. Using purified 
human fibronectin coated BCG, they demonstrated inhibited expression of delayed type 
hypersensitivity in the bladder and reduced anti-tumour activity when BCG attachment to the 
bladder was inhibited. This contact is mediated by the BCG FAP that links BCG to cellular 
receptor bound fibronectin (Figure1.2). Inhibiting BCG attachment to the bladder wall using 





BCG as it prevents the binding of BCG to the urothelium [6]. Since BCG adherence to tumour 
cells is the critical primary step in the initiation of a therapeutic response, research efforts 
investigating the effects of direct contact between BCG and tumour cells may further elucidate 
intracellular signalling mechanism which may indicate ways to improve response to therapy. 
 
Figure 1.2: BCG attachment to the bladder mucosa. The interaction is mediated by a 
fibronectin bridge that links integrin α5β1 receptors on the bladder urothelial or tumour cells 
with Fibronectin Attachment Protein (FAP) that is located on the thick cell envelope of BCG. 
 
The GAG layer of the urothelium, which protects the bladder from toxic compounds and 
microorganisms, is negatively charged like the BCG cell wall. In a normal healthy bladder, 
BCG accumulates on the bladder wall without adherence [7]. Due to the high electrostatic 
repellent forces between the surfaces, the adherence is highly reversible. However, damage to 
the GAG layer or the bladder wall after electrocautery can reduce the negative charges and 
increase BCG adherence and docking as observed in studies by Raitliff et al using murine 
bladders [8]. This adherence was also durable as the microbes were still observed 48 hours 
after instillation. Thus, BCG can easily accumulate in areas of the urothelium that may be 





1.2.1.1.2  Internalization of BCG by urothelial cells 
While guinea pig studies have shown that there is little or no adherence of BCG to the normal 
urothelium, malignant cell lines are able to internalize BCG in a grade dependent manner 
[9,10]. Studies done by Bevers et al, with a panel of TCC cell lines, showed that poorly 
differentiated cell lines internalize BCG better. Pook et al demonstrated that internalization of 
BCG by α5β1 integrins leads to cytotoxicity in vitro in MGH and RT4 cells [11]. Chen et al 
found that BCG exerts direct cytostatic effects on human urothelial carcinoma cell lines (253J 
and T24). BCG induces cell cycle arrest at the G1/S interface and this effect can be duplicated 
by antibody mediated cross linking of α5β1 [12]. BCG immunotherapy augments Nitric oxide 
(NO) production and up-regulated urothelial inducible nitric oxide synthase, leads to DNA 
damage as well as cytostatic/cytotoxic effects [13].  
1.2.1.1.3  Secretion of cytokines and chemokines by urothelial tumour cells 
While the immune cells may be the major source of cytokines produced following BCG 
therapy, urothelial cells are also induced to secrete cytokines. Incubation of human TCC cell 
lines with BCG induces the production of cytokines such as IL-6, IL-8, IL-10, GM-CSF, 
TNFα and IFNα [9,14]. Luo et al demonstrated that BCG induced the production of 
chemokines MCP-1 and MIP-1α by a normal transformed urothelial cell line (SV-HUC-1) but 
not from malignant cell lines (RT4 and T24) though the latter cells could be induced to secrete 
chemokines by incubation with BCG derived cytokines [15]. Expression of MDC and IP10 
chemokines were found on human bladder clinical specimens by histological staining [16]. In 
human bladder cancer cell lines, BCG induced IL6 production were found to be partly 
mediated by cAMP dependent protein kinase pathway [17].  
1.2.1.1.4  Antigen presenting properties of uroepithelial tumour cells 
In 1992, Lattime et al demonstrated the ability of a murine bladder carcinoma cell line (MB49) 





BCG antigen to CD4+ T cells via MHC Class II molecules and induce IL-2 and TNFα 
production from BCG specific CD4+ T cells [18]. In patient studies, BCG treatment was 
observed to induce the expression of MHC Class II on normal urothelia and bladder tumour 
cells [19-23]. Serial bladder biopsies and urinary cytospins taken before and after BCG therapy 
revealed an up-regulation of MHC class II and ICAM-1 expression on urothelial tumour cells 
[24]. In vitro, Ikeda et al demonstrated that the expression of MHC Class II, CD1, CD80 and 
ICAM-1 were augmented in a panel of bladder cancer cell lines (MBT-2, T24 and J82) 
following BCG treatment, with higher grade TCC cell lines expressing higher levels of the 
major co-stimulatory molecules [25]. In the same study, they showed that BCG treated MBT-2 
cells could stimulate BCG sensitized murine lymph nodes cells to secrete significant amounts 
of IL-2 and IFNγ. Thus TCC cells can function as APCs in the presence of BCG and present 
antigens to immunocompetent cells.  
1.2.1.2 Cell mediated anti-tumour effects in BCG immunotherapy. 
The final step in BCG induced immune response is the infiltration of activated immune 
cytotoxic effector cells that can directly or indirectly eradicate the remaining tumours in the 
bladder. Normally, the bladder is not infiltrated by large numbers of immune cells. After BCG 
therapy in patients, possibly due to the production of chemotactic chemokines and cytokines 
by the urothelial and tumour cells, an early accumulation of neutrophil granulocytes can be 
observed, followed by the influx of macrophages and lymphocytes [23,26,27]. CD4+ T cells 
are the dominant cell population in the observed granulomas. Raitliff et al using athymic nude 
mice showed that the anti-tumourigenic effects of BCG were lost in these mice in contrast to 
wild type mice [28]. Several in vitro studies have shown evidence for the involvement of 
several nonspecific cytolytic cells such as NK cells and BCG-activated killer cells (BAKs) 
[29]. NK cells activated in vitro by BCG treatment showed anti-tumour activity with T24 and 
Jurkat cell line by perforin mediated lysis [30-32]. Furthermore, in vivo studies done with 





deficiency abrogated BCG anti-tumour efficacy, suggesting a key role for NK cells in BCG 
immunotherapy [33]. 
1.2.1.3 TH1 versus TH2 dynamics 
Studies involving bladder cancer patients undergoing BCG immunotherapy reveal dynamic 
increases in cytokine production in the urine and bladder of these patients. The cytokines 
detected include TNFα, GMCSF, IFNγ, IL-1, IL-2, IL-5, IL-6, IL-8, IL10, IL-12 and IL-18 
[34-36]. The pattern of urinary cytokines suggests the predominance of a TH1 type of immune 
response in the bladder. TH1 cytokines are responsible for the initiation and maintenance of 
inflammatory responses. However, the cytokine response varies from patient to patient and it 
is observed that a higher TH1 (IFNγ) vs TH2 (IL-10) ratio of cytokine corresponds to 
favourable anti-tumour response and BCG therapy success. IFNγ and IL12, but not IL10 and 
IL4, are suggested to be required for intrinsic anti-tumour responses and effective 
immunotherapy in an orthotopic murine bladder cancer model [37-39]. Detectable urinary IL2, 
a TH1 cytokine, after BCG therapy was associated with associated with favourable response, 
with improved recurrence and progression-free survival [40,41]. The combined treatment of 
BCG and recombinant pro-inflammatory IFN-α2B enhanced TH1 cytokine production and 
decreased IL10 in patients with bladder cancer receiving BCG immunotherapy [42]. Taken 
together, the TH1 vs. TH2 dynamics bears significant influence in BCG immunotherapy in the 
bladder [30].  
1.2.2  The role of neutrophils in BCG immunotherapy of bladder cancer 
Neutrophils are components of innate immunity that respond quickly to microbial invasion by 
homing rapidly to the site of infection to phagocytose the invading microorganisms and 
consequently die by apoptosis and are removed by longer-lived phagocytes. They can generate 
reactive oxygen intermediates, a process involved in intracellular microbial killing, and release 





are the first immune cells to leave the blood vessels and infiltrate the mycobacteria infected 
tissue [44]. Similarly in bladder cancer, they are the first and most abundant immune cell 
population to infiltrate the bladder wall immediately after BCG instillation [26,27]. A recent 
study by Suttmann et al in 2006 provided the first compelling evidence for the importance of 
neutrophil granulocytes in BCG immunotherapy of bladder cancer using a syngeneic murine 
orthotopic bladder cancer model. Polymorphonuclear neutrophil (PMN) depleted mice exhibit 
abolishment of CD4+ T cells trafficking in the bladder wall after BCG therapy and abrogation 
of anti-tumour efficacy [45]. Figure 1.3 summarizes neutrophil functions in BCG 
immunotherapy and immune responses. 
 
 
Figure 1.3: The roles of neutrophils in BCG immunotherapy of bladder cancer. BCG 
activated neutrophils, primed by interferons in the bladder microenvironment,  release 
TRAIL which could directly lead to the apoptotic cell death of tumour cells [46-48].  BCG 
activated neutrophils secrete chemotactic cytokines and chemokines that mobilize other 
effector immune cells to the bladder wall [49-51].  They are critical activators of NK cells 
[52].  Neutrophils co-operate with DCs to produce specific T-cell responses in humans and 
mice [53].  BCG infected neutrophils migrate to the lymph nodes via the lymphatics system 





1.3 Reactive Oxygen Species (ROS) 
ROS were originally recognized as being instrumental in mammalian host defence. Its 
stimulated production was first described in phagocytic cells such as neutrophils and 
macrophages, during the bactericidal process and was named “the respiratory burst” due to the 
transient consumption of oxygen. Since then, it has been identified as by-products of cellular 
respiration in aerobic cells during mitochondrial electron transport or by several 
oxidoreductases and metal catalysed oxidation of metabolites. It is now clear that ROS have a 
role to play in biological processes such as apoptotic cell death, necrosis, regulation of gene 
expression and the activation of signalling cascades. 
 
1.3.1 The generation of ROS during cellular respiration 
During cellular respiration where molecules are catabolised along with the consumption of 
oxygen, a net gain of energy is produced in the form of ATP and the release of CO2. However, 
5% of the time, oxygen is reduced to reactive superoxide (O2-) anions due to the “leakage” of 
single electrons at a particular site of the mitochondrial electron transport chain. The 








Figure 1.4: ROS production during cellular respiration. Ground state oxygen (O2) may be 
converted to much more reactive ROS forms either by energy transfer or by electron transfer 
reactions.  The primary ROS is a superoxide (O2-), which is formed by the one electron 
reduction of molecular oxygen [55]. Several enzymes are recognized to catalyse this reaction 
but the most important of all has to be NADPH oxidase, first discovered in neutrophils [56].  
Further reduction of the superoxide anion produces hydrogen peroxide which arises by the 
dismutation of superoxide.  Further reaction of hydrogen peroxide with metal ions such as 
copper, nickel, iron and cobalt leads to the formation of the hydroxyl radicals (OH•), by the 
Haber-Weiss or Fenton reactions [57,58]. Hydroxyl radicals are extremely reactive and will 
probably react with the first biological molecule (RH) they encounter from whence they 
extract a hydrogen atom to yield a free radical molecule (R•) which is much more stable. As 
such, hydroxyl radicals are extremely short lived, with a half life of nanoseconds and do not 
diffuse from their site of production [58].  Proton transfer to O2- leads to the formation the 
hydroperoxyl radical.  The breakdown of H2O2 is catalysed by the reaction of peroxidases 
and catalase. In neutrophils, myeloperoxidase enzyme can catalyse the formation of 
hypochlorous acid (HOCl) from hydrogen peroxide [59].  In systems where nitric oxide 





1.3.2 The detrimental effects of ROS 
Reactive oxygen species generated at very high levels have been implicated in various clinical 
conditions such as malignant diseases, atherosclerosis, infertility and diabetes [61-65]. The 
effect of ROS is due to its interactions with the macromolecules in the cells via oxidative 
modifications. The damaging effects of excessive cellular ROS are due to its effects on 
activating lipid peroxidation, cross-linking and inactivating proteins and oxidative damage of 
DNA. 
1.3.2.1  Lipid peroxidation  
The unstable hydroxyl radical, can react with all cellular macromolecules and amongst these, 
polyunsaturated fatty acids (PUFAs) exhibit the highest sensitivity to oxidative damage. 
Membrane phospholipids are particularly susceptible to oxidation due to their high PUFA 
content and because of their association in the cell membrane with nonenzymatic and 
enzymatic systems capable of generating prooxidative free radical species [66]. Lipid 
peroxidation can cause structural damage to the membrane, modifying its physicochemical 
properties such as fluidity, permeability, changes in thermotropic phase properties and 
membrane protein activity [67-74]. The early primary products of lipid peroxidation are lipid 
hydroperoxides and when the hydroperoxides break down, a wide variety of aldehydes are 
formed. These aldehydes are highly reactive and may be considered as secondary toxic 
messengers that disseminate and initiate the propagation of free radical events [75-77]. 
However, they may also act as signal transduction mediators and not just toxicity inducing 
molecules. 4-hydroxynonenal (HNE) and malondialdehyde (MDA) are the major end products 
of lipid peroxidation [75]. Of the two, HNE is the most studied, with roles in pathogenesis of 
neurodegenerative disease [78,79], apoptosis [79-81], differentiation, proteasomal damage 
[82,83] and modification of signal transduction which includes the activation of adenylate 
cyclase, JNK, PKC and caspase 3[76,84]. HNE are also involved in gene expression control 





myc and c-jun oncogenes [86,87]. MDA adduct formation with thiobarbituric acid have been 
used to measure lipid peroxidation for the past 30 years and is associated with connective 
tissue and coronary artery diseases [88,89] 
1.3.2.2 Cross linking and inactivation of proteins 
The end products of lipid peroxidation can cause protein damage by reaction with the lysine 
amino groups, cysteine sulfhydryl groups and histidine imidazole groups to produce stable 
carbonyl adducts [75]. Oxidation of the polypeptide chain can also lead to cleavage and to 
formation of cross-linked protein aggregates which are detrimental or deleterious to their 
normal functions [90]. ROS induced damage of DNA polymerases may alter their fidelity 
[91,92] and also affect the activity of DNA damage repair enzyme [93]. 
1.3.2.3 Oxidative DNA damage  
ROS can cause structural alterations in DNA by inducing base pair mutations, rearrangements, 
deletions, insertions and sequence amplification, producing gross chromosomal alterations 
[94-98]. Thus ROS could be involved in the inactivation and loss of the second wild type allele 
of a mutated proto-oncogene or tumour suppressor gene that can occur during tumour 
promotion and progression, allowing the expression of a mutated phenotype [99]. DNA 
methylation involves the addition of a methyl group to the 5 position of cytosine, which occurs 
in the context of CpG (cytosine followed by guanine) dinucleotides. Methylation of cytosines 
in DNA is important in the regulation of gene expression. ROS attack frequently results in the 
conversion of guanine to 8-hydroxyguanine (8-OHG) which alters the enzyme catalysed 
methylation of the adjacent cytosines [100]. The levels of 8-OHG, or its nucleoside 8-
hydroxydeoxyguanosine (8-OHdG), is often measured as an index of oxidative DNA damage 
[101]. Since the mitochondrial electron transport chain generates ROS in vivo, mitochondrial 
DNA can also be damaged by ROS and is in several fold higher than in nuclear DNA [102-





lack of protective histone proteins and inefficient repair mechanisms in the mitochondria are 
other factors contributing to the higher base levels of oxidative mitochondrial DNA damage. 
The pattern of DNA damage has suggested that the OH• radical is responsible for the process 
[95]. However, in the nucleus, the OH• radical has to be in close proximity since it is so 
reactive and cannot diffuse from its site of formation. The peroxynitrite radical (ONOO−) or its 
stable organic forms, is capable of directly damaging DNA by the deamination and nitration of 
guanine residues [105-107].  
1.3.3 Defence mechanisms against ROS  
Oxidative stress occurs in cells due to the imbalance of prooxidant/antioxidant systems, 
resulting in injurious effects to the susceptible biomolecules. Superoxide and hydrogen 
peroxide are much less reactive than the OH• radical of which there are no known scavengers. 
Hence, the only way to avoid oxidative damage resulting from the highly reactive OH• radical 
is to control the reactions leading to its generation. Cells have evolved mechanisms to control 
the concentrations of superoxide, hydrogen peroxide and transition metals that initiate the 
formation of OH• radical. 
1.3.3.1 Non enzymatic ROS scavenging mechanisms 
Cellular redox buffer systems exist as antioxidants to maintain the oxidative balance in the 
cells and include glutathione (GSH), ascorbate (Vitamin C) and α-tocopherol (Vitamin E) 
[108]. GSH is oxidized by ROS, forming oxidized glutathione (GSSG) while ascorbate is 
oxidized to monodehydroascorbate and dehydroascorbate. Through the ascorbate glutathione 
cycle, the GSSG,  monodehydroascorbate and  dehydroascorbate can be reduced, reforming 
the GSH and ascorbate [108]. α-tocopherol is lipophilic and its major role is to block the chain 
of reaction in lipid peroxidation. α-tocopherol and ascorbic acid were shown to cooperate in 
the cellular defence against ROS [109,110]. GSH is a very important component of ROS 





ratio has been recognized by Schafer and Buettner as a good indicator of cellular redox 
environment [111]. Glutathione is an essential element of the glutathione redox cycle system 
and it participates as a conjugate in the detoxification of xenobiotics by glutathione-S-
transferases to form thioether conjugates. GSH can also protect the thiol group of proteins and 
maintain the ascorbate levels through the ascorbate glutathione cycle. 
1.3.3.2 Enzymatic ROS scavenging mechanisms 
Enzymes involved in ROS scavenging mechanisms serve to detoxify the superoxide radical 
and the hydrogen peroxide formed as well as those involved in the antioxidant redox cycle. 
Superoxide dismutase acts as the first line of defence, dismutating the superoxide to H2O2. 
H2O2.is detoxified by the catalytic actions of ascorbate peroxidase , glutathione peroxidase  
and catalase  [108]. 
1.3.3.3 Glutathione-S-transferases 
The adaptive response to lipid peroxidation products includes the transcriptional regulation of 
antioxidant genes, including enzymes related to glutathione synthesis and glutathione-S-
transferase (GST). GSTs are a family of enzymes with cytosolic, mitochondrial and 
microsomal distribution. To date, at least 16 cytosolic GST subunits exist in humans. Those in 
the alpha and mu class are capable of forming heterodimers hence a significantly larger 
number of isoenzymes can be generated from these subunits. A list of known human and 
mouse GST homodimers is summarized in Table 1.1 along with observations of knockout 
effects in mice.  
GSTs catalyse a variety of reactions including the conjugation of GSH by its nucleophilic 
attack on nonpolar compounds with an electrophilic carbon, nitrogen or sulphur atom [112]. 
The GSH conjugation detoxifies endogenous compounds such as lipid hydroperoxides,α, β-
saturated aldehydes, quinones and epoxides formed during oxidative stress. GSH conjugation 





pollutants and anti-tumour agents [113]. GSTs are also involved in the biosynthesis of 
leukotrienes, prostaglandins, testosterone and progesterone as well as the degradation of 
tyrosine.[114-116] As such, GSTs have been an area of focus for pharmacologists and 
toxicologists as a potential target for anti-asthmatic and anti-tumour drug therapies as they 
metabolize cancer chemotherapeutic agents, carcinogens and by products of oxidative stress. 
Table 1.2 summarizes the known signalling pathways or cellular processes modulated by the 





Table 1.1: Human and mouse glutathione transferases and knockout observations in mice 
Family Class Human Mouse Summary of knockout observations in mice References 
Cytosolic 
Alpha GSTA1-A5 GSTA1-A5 
GSTA4-/- mice: 
• Reduced GSH-conjugating activity towards 4-HNE 
• Increased 4-HNE and MDA in livers 
• Increased GSTA1/2, GSTA3, GSTM1, CAT*, SOD1,SOD2* and GPx1* mRNA in 




Mu GSTM1-M5 GSTM1-M7 
GSTM1-/- mice: 
• Decreased GSTA3 mRNA 




Pi GSTP1 GSTP1 and GSTP2 
GSTP1/2-/- mice: 
• Liver contain higher AP1* levels 
• Yield 3 fold more papillomas in 7,12-dimethylbenzanthracene initiated skin 
tumourigenesis regimen 





Sigma GSTS1 Ptgds2 GSTS1
-/- mice: (GSTS1 encodes for GSH dependent prostaglandin D2 synthase) 
• Allergic reaction weaker than wild type mice. 
 
[121] 
Theta GSTT1 GSTT2 GSTT1-T3 
GSTT1-/- mice: 
• Cytosolic samples from liver and kidney showed reduced activity towards EPNP*, 
DCM* and BCNU*. 
 
[122] 
Omega GSTO1 and GSTO2 
GSTO1 and 
GSTO2 
GSTO1 /2-/- mice 
• Intramuscular injection with arsenate leads to accumulation of arsenic containing 








Family Class Human Mouse Summary of knockout observations in mice References 
Cytosolic Zeta GSTZ1 GSTZ1 
GSTZ-/- mice: 
• Rapid weight loss when 2% phenylalanine is provided in drinking water, death occurs 
within 5 to 50 days. 
• Under normal dietary conditions, mice had enlarged liver and kidneys and displayed 
splenic atrophy 



















• Unable to make leukotrienes. High PGE2* and thromboxane B2 in peritoneal mφ*. 
• No metabolites of the 5-lipoxygenase pathway found in lavage. 
LTC4S-/- mice 
• Reduced in vitro conjugation of LTA4* methyl ester with GSH in colon, spleen, lung, 
brain and tongue preparations. 
•  LTC4 production by IgE abolished in bone marrow derived mast cells (BMMC). 







GpIV MGST1, PGES1 
MGST1 
PtgeS1 
PtgeS1 -/- mice 
• mφ cultured in the presence of LPS* did not synthesize PGE2 but produced IL6. 
• In vivo examination of arthritic response to chicken type II collagen showed protection 






*Abbreviations: SOD (Superoxide Dismutase), CAT (catalase) Gpx1 (Glutathione peroxidise 1), 1,2-dichloro-4-nitrobenzene (DCNB), 1-chloro-2,4-dinitrobenzene 
(CDNB), Activator protein-1 (AP1), 1,2-epoxy-3-(p-nitrophenoxy)propane (EPNP), dichloromethane (DCM), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 





Table 1.2: Modulation of signalling pathways and cellular processes by GSTs 
GST Observations References 
Class Alpha • Binds azo-dyes, bilirubin, heme, steroids and thyroid hormones for disposal. [130] 
Class M1 
• Inhibits Ask1during non-stressed conditions through physical 
interactions with the kinases. 
• Negative regulator of MEKK1, inhibits stimulation of MEKK1 






• Activates Peroxiredoxin VI (Prx VI) activity by physical 
interaction through glutathionylation of the oxidized Prx VI. 
• Inhibits JNK during non-stressed condition. 
• Confers low level resistance to cisplatin in MCF-7 cells by 
inhibiting cisplatin induced phosphorylation of c-Jun thus 





GSTs • GSH conjugation of 15d-PGJ2 promotes NF-κB, inhibits Nrf2 and PPARγ dependent gene expression [136-140] 
 
1.3.4  ROS in tumour progression and signal transduction 
ROS production occurs in non-phagocytic cells as a result of various signalling pathways such 
as receptor tyrosine kinases (RTKs), which become activated by growth factors, as well as 
cytokines such as TNF, IFNγ and interleukins. In turn, ROS generation regulates the 
intracellular tyrosine phosphorylation cascade from the Mitogen activated protein Kinase 
(MAPK) and the redox sensitive kinase family [141]. The MAPKs signalling pathways are 
involved in processes leading to carcinogenesis such as mitosis, proliferation, differentiation 
and apoptosis. Members of the MAPK family includes the extracellular signal regulated kinase 
(Erk1 and 2), the c-Jun NH2-terminal kinase (JNK1, 2, and 3) and the p38MAPK (p38α, β, γ 
and δ) [142]. Erk and JNK activation balance seems to be a key in regulating apoptosis, a 
response tipping towards Erk being vital for survival.  
The redox sensitive signalling factors use cysteine residues as redox sensitive sulphydryl 





cytoplasmic thioredoxins and the nuclear signalling factors such as Ref-1(Redox-factor 1) and 
transcription factors such as AP-1, NF-κB, Nfr-1 and Egr-1 [143]. These transcriptions factors 
are pro-survival and thioredoxin pathways regulate multiple processes involved in 
proliferation, cell division and survival. NF-κB activation has been linked to carcinogenesis 
because of its role in inflammation, differentiation and growth. NF-κB regulates the expression 
of several genes such as bcl-2 and bcl-xL that promote survival by inhibiting apoptosis [144].  
Thus, the role of ROS in tumour initiation and progression is a complex one, as it modulates 
and alters several cellular components that facilitate carcinogenesis, proliferation and survival 
(Figure 1.5). 
 
Figure 1.5: ROS and its pro-carcinogenesis mechanisms. ROS can cause cancer through 
initiating damage of intracellular biomolecules and DNA as well as promoting pro-survival, 






1.3.5 BCG and ROS 
Studies done on the relationship between BCG and ROS are mostly in the context of 
antimicrobial immunity of immune cells, such as neutrophils and macrophages, as the first 
line of cellular defence against microbial invasion. Mononuclear phagocytes contain potent 
cytocidal mechanisms that enable the killing of pathogenic bacteria by respiratory burst and 
presentation of the bacterial antigen to other effector immune cells. Mycobacterium 
tuberculosis (Mtb) infected macrophages showed impaired antigen processing, inhibition of 
cytokine production and respiratory burst [145-147]. In contrast, attenuated strains of 
mycobacteria such as BCG and H37Ra are significantly more potent inducers of apoptosis 
[148]. BCG has also been shown to induce ROS production in A549 epithelial human 
alveolar carcinoma cell line [149] and in mouse bone marrow derived macrophages [150]. In 
the latter studies, Jae et al demonstrated that BCG induced ROS production is highly TLR2 
dependent and led to a robust activation of Apoptosis signal-regulating kinase1 (ASK1) which 
acts upstream of the JNK and p38 pathways. ASK1 is essential for TNFα and IL-6 production 
by macrophages and it limits intracellular growth of BCG in the macrophages in vitro. 
1.4 Epidermal growth factor receptor [EGFR] and bladder cancer 
EGFR mutations at exon 18-21 (the kinase domain of EGFR) and expression of the EGFR 
variant III mutant (the most frequent alteration of EGFR  that lacks 276 amino acids from its 
extracellular domain) are found to be very rare in bladder cancer [151]. However, up-
regulation of EGFR expression and EGFR pathway polymorphisms have been associated with 
bladder cancer susceptibility and poor prognosis [152]. Hence, targeting EGFR in bladder 
cancer has been an area of focus. 
EGFR activation by its ligands (EGF, TNFα, Amphiregulin, HG-EGF, Epiregullin) activates 
signalling cascades such as the Ras-MAP kinase and PI-3 kinase pathways that transduce 






Figure 1.6: Epidermal growth factor receptor pathway. Activation of EGFR by its ligands 
such as EGF initiates signalling cascades that regulate the transcription of genes involved in 
survival, proliferation and invasion. 
 
1.5 Mycobacterial secreted factors 
1.5.1 BCG secreted proteins 
BCG secreted proteins have been found in the culture filtrate and are studied due to their 
potential to initiate immune response. These proteins can also manipulate the host 
environment to confer survival advantage to the bacteria. Table 1.3 list the proteins that are 





Table 1.3: Mycobacteria secreted proteins. 








M. bovis BCG 
• Surface Ag 85 facilitates binding to 
human fibronectin and may have a role to 
play in phagocytosis of mycobacteria. 
 
• Possess mycolyltransferase activity and 
catalyse the synthesis of the cord factor, 
which is the most abundant glycolipid in 








M. africanum,  
M.bovis, 
M,microti, 




• Mycobacterial CuZnSOD (encoded by the 
sodC gene, expressed on the periphery of 
Mtb) confers protection against exogenous 
ROS  
 
• sodC mutant Mtb displayed enhanced 
susceptibility to killing by IFNγ activated 
murine peritoneal macrophages. 
 
• Function of FeSOD (encoded by the sodA 







1.5.2 Mycobacterial protein tyrosine phosphatases (Mptps) 
Intracellular pathogenic bacteria are known to strategically manipulate host signalling 
pathways to facilitate infection and its own survival. Protein tyrosine phosphatases (Ptps) are 
thought to be secreted by the microbes into the host cells to interfere with the host signalling 
pathways in response to infection. Several microorganisms have been shown to express and 
secrete protein tyrosine phosphatases as virulence factors which affect the host equilibrium by 
modulating dephosphorylation/phosphorylation status of the host signalling proteins. The 
Sptp protein of Salmonella typhimurium has been previously demonstrated to inhibit infection 
stimulated activation of Erk signalling by interfering with the translocation of the upstream 
Raf protein to the membrane [158] and it can reverse the actin cytoskeletal changes induced 





dephosphorylates focal adhesion proteins [160] and suppresses reactive oxygen species 
production in infected cells [161].  
The Mtb genome sequence analysis reveals the presence of genes that encodes for two 
tyrosine phosphatases (MptpA and MptpB) but no tyrosine kinase was found [162]. In the 
absence of an endogenous tyrosine kinase, it is highly likely that the Mptps interfere with host 
signalling pathways. While MptpA is a low-molecular weight (LMW) phosphatase, MptpB is 
a dual-specificity phosphatase (DSP) and can dephosphorylate phospho-serine, phospho-
threonine and phospho-tyrosine residues. LMW phosphatase only acts on phospho-tyrosine 
residues. Despite the absence of any known export signal, MptpA and MptpB are secreted 
into the culture medium [163]. Expression and secretion of MptpB is restricted to members of 
the M. tuberculosis complex suggesting a key role in the infection processes. The 
mycobacterial protein tyrosine phosphatases may be translocated into host phagocytic cells 
where they manipulate the host signalling mechanisms. Table 1.4 summarizes current 



















Characteristics MptpA MptpB References 



















M. bovis BCG 
[163] 
Observed roles in 
vitro and in vivo 
Inhibits phagocytosis and increase actin 
polymerization in macrophages 
Interact with and dephosphorylate human vacuolar 
protein sorting 33B (VPS33B) to prevent phagosome 
lysozome fusion. 
Facilitates survival of pathogen in the host 
Macrophage J774.1 cells infected with mutant MptpB 
Mtb strain have accelerated mycobacterial cell death 
Guinea pigs infected with mutant MptpB Mtb strain 









1.6  Live versus lyophilized BCG 
Lyophilized BCG (lyo BCG) is a preparation of live BCG that has been freeze dried for use in 
clinical practice. After lyophilisation, a certain percentage of the bacteria remain viable. Pook 
et al demonstrated that treatment of MGH, a human epithelial bladder cancer cell line, with lyo 
BCG for 2 and 24 hours induced significant ROS decrease in the cells [169]. , In contrast, 
treatment of A549 human lung epithelial cancer cells and bone marrow derived macrophages 
with live BCG results in rapid ROS production in vitro [149,150] . It is possible that there are 
differences between live BCG and lyophilized BCG preparations in mediating signalling 
pathways and gene expression in human cancer cells. While whole live BCG may secrete 
mycobacterial proteins that are essential for host manipulation and its survival, lyophilized 
BCG preparation may contain a wide range of free cytosolic bacterial proteins and cell wall 
components.  Also, there is a mixture of degraded, dead and viable bacteria in the lyophilized 
preparation that may induce a plethora of responses on human epithelial cells. This might be 
the cause of the strong immune response engendered by BCG immunotherapy. While 
lyophilized BCG preparations are used clinically due to its convenience, it may not be the best 
form of BCG for therapy. Many studies with regards to BCG and the immune response are 
done with live BCG. Thus, correlating the literature findings to BCG immunotherapy of 







1.7 Aims of this study 
To date, there is a lack of literature comparing the responses induced by cultured live BCG and 
lyophilized BCG on human urothelial cancer cell lines. However, there are published studies 
done with lyophilized BCG in vivo in mice and in humans. This study aims to delineate the 
differences and similarities of the responses engendered by live and lyophilized BCG and 
evaluate their cellular mechanisms of action.  The interaction between BCG and urothelial 
cells is dynamic and besides studying host responses, we will also study the role of a 
mycobacterial secreted factor on cellular signal transduction pathways. Thus, this work is 
separated into 3 sections.  
1. To elucidate the effects of intravesical live BCG instillation in vivo in mice with 
respect to local immune responses (expression of chemokines and cytokines as well as 
localization of immune cells to the bladder and the draining lymph nodes). We will 
compare our results with the published studies done previously in vivo in human and 
in mice.  
2. Comparing the effects of live and lyophilized BCG treatment of five human bladder 
cancer cell lines with respect to ROS production and gene expression in vitro. 
3.  Isolate and purify mycobacterial protein tyrosine phosphatase A (MptpA), a secreted 
mycobacterial protein, and characterize its effects on MGH cells along with BCG 









Materials and Methods 
Nothing has such power to broaden the mind as the ability to investigate 
systematically and truly all that comes under thy observation in life. 






2.1     Materials  
2.1.1 Cell Lines/Cells/Bacteria  
J82 ATCC, (Manassas, VA, USA) 
UM-UC-3 ATCC, (Manassas, VA, USA) 
SW780 ATCC, (Manassas, VA, USA) 
RT4 ATCC, (Manassas, VA, USA) 
MGH ATCC, (Manassas, VA, USA) 
ImmuCyst BCG Aventis, (Ontario, Canada) 
DH5α Invitrogen,(Carlsbad, CA, USA) 
BL21 Invitrogen,(Carlsbad, CA, USA) 
  
2.1.2 Cell and bacteria Culture Reagents  
Foetal Bovine Serum Biowest, (Nuaillè, France) 
RPMI Media Biowest, (Nuaillè, France) 
Dulbecco’s Modified Eagle’s Medium 
(DMEM) Sigma, (St. Louis, MO, USA) 
L-glutamine Gibco, (Carlsbad, CA, USA) 
Penicillin-Streptomycin solution Gibco, (Carlsbad, CA, USA) 
10X Trypsin EDTA solution Gibco, (Carlsbad, CA, USA) 
Cell Dissociation Solution Sigma, (St. Louis, MO, USA) 
Middlebrook 7H9 broth BD, (Franklin Lakes, NJ, USA) 
Middlebrook 7H10 Agar BD, (Franklin Lakes, NJ, USA) 
Bacto Tryptone BD, (Franklin Lakes, NJ, USA) 
Bacto Yeast Extract BD, (Franklin Lakes, NJ, USA) 
Difco Agar Granulated BD, (Franklin Lakes, NJ, USA) 
  
2.1.3 Chemicals  
Agarose (Molecular Biology Grade) 1st Base (Singapore) 
Dimethyl sulfoxide (DMSO) Sigma, (St. Louis, MO, USA) 
2-β-Mercaptoethanol  Merck, (Darmstadt, Germany) 
Bovine Serum Albumin Sigma, (St. Louis, MO, USA) 
Ethanol Thermo Fischer ( Waltham, MA, USA) 
Ethidium Bromide Bio-Rad, (Hercules, CA, USA) 
Paraformaldehyde Sigma, (St. Louis, MO, USA) 
Methanol Merck, (Darmstadt, Germany) 
Polyoxyethylenesorbitan monooleate 
(Tween80) Sigma, (St. Louis, MO, USA) 
Triton X-100 Sigma, (St. Louis, MO, USA) 





Propidium Iodide Sigma, (St. Louis, MO, USA) 
Glycine Bio-Rad, (Hercules, CA, USA) 
Methyl-β-cyclodextrin stabilised 
cholesterol Sigma, (St. Louis, MO, USA) 
N,N,N',N'-Tetramethylethylenediamine 
(TEMED) Sigma, (St. Louis, MO, USA) 
Sodium Chloride Merck, (Darmstadt, Germany) 
Dextrose Sigma, (St. Louis, MO, USA) 
Glycerol Merck, (Darmstadt, Germany) 
Fluorescein Isothiocyanate Merck, (Darmstadt, Germany) 
Sodium bicarbonate US Biological ( Swampscott, MA, USA) 
Ethylenediaminetetraacetic acid, sodium 
salt Sigma, (St. Louis, MO, USA) 
Sodium Azide Sigma, (St. Louis, MO, USA) 
Cycloheximide Sigma, (St. Louis, MO, USA) 
5-bromo-2-deoxyuridine (BrdU) Sigma, (St. Louis, MO, USA) 
Hydrochloric acid Merck, (Darmstadt, Germany) 
Sodium tetraborate Merck, (Darmstadt, Germany) 
Trizol Reagent  Invitrogen, ( Carlsbad, CA, USA) 
Chloroform Merck, (Darmstadt, Germany) 
Isopropanol Sigma, (St. Louis, MO, USA) 
Nuclease free water Ambion, (Austin, TX, USA) 
Biotin-16-UTP Roche, (IN, USA) 
Tris Base 1st Base (Singapore) 
Magnesium chloride Merck, (Darmstadt, Germany) 
Potassium chloride Merck, (Darmstadt, Germany) 
Deoxynucleotide triphosphates (dNTPs) Promega, (Madison, WI, USA) 
Dithiothreitol (DTT) Bio-Rad, (Hercules, CA, USA) 
1M HEPES Buffer Gibco, (Carlsbad, CA, USA) 
Flavin Adenine Dinucleotide (FAD) Sigma, (St. Louis, MO, USA) 
β-Nicotinamide adenine dinucleotide 
reduced (β-NADPH) Sigma, (St. Louis, MO, USA) 
Sodium pyruvate Sigma, (St. Louis, MO, USA) 
Sulfanilamide Sigma, (St. Louis, MO, USA) 
Napthylethylenediamine Sigma, (St. Louis, MO, USA) 
Phosphoric acid Merck, (Darmstadt, Germany) 
Sodium nitrate Sigma, (St. Louis, MO, USA) 









Dimethylformamide Merck, (Darmstadt, Germany) 
Butylated hydroxytoluene Sigma, (St. Louis, MO, USA) 
Glacial acetic acid Merck, (Darmstadt, Germany) 
Thiobarbituric acid Sigma, (St. Louis, MO, USA) 
Sodium hydroxide Merck, (Darmstadt, Germany) 
n-butanol Sigma, (St. Louis, MO, USA) 
Pyridine getrocknet Merck, (Darmstadt, Germany) 
Ampicillin Sigma, (St. Louis, MO, USA) 
Isopropyl β-D-1-thiogalactopyranoside Sigma, (St. Louis, MO, USA) 
Reduced Glutathione Calbiochem, (La Jolla, CA, USA) 
  
2.1.4 Antibodies and Enzymes  
Polyclonal rabbit anti BCG antibodies DAKO, (Glostrup, Denmark) 
TRITC conjugated swine anti rabbit 
antibodies DAKO, (Glostrup, Denmark) 
FITC rat x ms CD3 BD, (Franklin Lakes, NJ, USA) 
PE rat x ms CD4 (L3T4) BD, (Franklin Lakes, NJ, USA) 
PE rat x ms CD8a (Ly-2) BD, (Franklin Lakes, NJ, USA) 
FITC rat x ms Mac 3 BD, (Franklin Lakes, NJ, USA) 
PE x ms Pan NK cells BD, (Franklin Lakes, NJ, USA) 
FITC x ms Foxp3 eBiosciences, (San Diego, CA, USA) 
FcR blocking Reagent Miltenyi, ( Bergisch Gladbach, Germany 
FITC rat IgG2b, κ isotype ctrl BD, (Franklin Lakes, NJ, USA) 
PE rat IgG2a, κ isotype ctrl BD, (Franklin Lakes, NJ, USA) 
PE rat IgG2a, κ isotype ctrl BD, (Franklin Lakes, NJ, USA) 
FITC Rat IgG1, κ isotype ctrl  BD, (Franklin Lakes, NJ, USA) 
PE rat IgM, κ isotype ctrl BD, (Franklin Lakes, NJ, USA) 
Rat anti mouse IgG (H+L) HRP conjugate Pierce, (Rockford, IL, USA) 
Goat anti rabbit IgG (H+L) HRP 
conjugate Pierce, (Rockford, IL, USA) 
Donkey anti rat IgG (H+L) HRP 
conjugate Assay Designs, (Ann Arbor, MI, USA) 
Rabbit anti hu p-p53 (Ser392) Santa Cruz, (Santa Cruz, CA, USA) 
Rabbit anti hu p-paxillin (Tyr118) Santa Cruz, (Santa Cruz, CA, USA) 
Rabbit anti hu p-p38 (T180/Tyr182) Santa Cruz, (Santa Cruz, CA, USA) 
Rabbit anti hu p-ERK(T202/Y204) Cell Signalling(Danvers, MA, USA)  
Rabbit anti hu p-Akt (Thr308) Cell Signalling(Danvers, MA, USA)  
Mouse anti hu p53  Santa Cruz, (Santa Cruz, CA, USA) 
Rabbit anti hu paxillin  Santa Cruz, (Santa Cruz, CA, USA) 





Rabbit anti hu ERK Cell Signalling(Danvers, MA, USA)  
Rabbit anti hu Akt  Cell Signalling(Danvers, MA, USA)  
Mouse anti hu β actin Chemicon, (Billerica, MA, USA) 
Anti-Ly6G mouse microbeads kit Miltenyi, ( Bergisch Gladbach, Germany 
FITC anti mouse MHCII Biolegend, (San Diego, CA, USA) 
FITC anti mouse CD80 Biolegend, (San Diego, CA, USA) 
PE anti mouse CD40 Biolegend, (San Diego, CA, USA) 
PE anti mouse CD83 BD, (Franklin Lakes, NJ, USA) 
PE anti mouse CD86 eBiosciences, (San Diego, CA, USA) 
PE and FITC anti mouse Ly6G Biolegend, (San Diego, CA, USA) 
APC anti mouse CD11c BD, (Franklin Lakes, NJ, USA) 
Mouse IgG2a κ isotype PE conjugate eBiosciences, (San Diego, CA, USA) 
Rat IgG2a κ Isotype PE conjugate BD, (Franklin Lakes, NJ, USA) 
Rat IgG1 Isotype FITC conjugate BD, (Franklin Lakes, NJ, USA) 
Armenian Hamster IgG FITC conjugate eBiosciences, (San Diego, CA, USA) 
SuperScriptII Reverse Transcriptase Invitrogen, ( Carlsbad, CA, USA) 
DNAse Roche, (IN, USA) 
RNaseA Sigma, (St. Louis, MO, USA) 
RNAsin Promega, (Madison, WI, USA) 
Catalase Sigma, (St. Louis, MO, USA) 
DyNAzyme DNA polymerase Finnzymes, (MA, USA) 
DpnII NEB, ( Ipswich, MA, USA) 
Lysozyme Roche, (IN, USA) 
Factor Xa GE Healthcare (Buckinghamshire, England) 
Recombinant murine GM-CSF BD, (Franklin Lakes, NJ, USA) 
L-lactic dehydrogenase (LDH) Sigma, (St. Louis, MO, USA) 
Rainbow Molecular weight markers GE Healthcare (Buckinghamshire, England) 
Myelin Basic Protein (MBP) Sigma, (St. Louis, MO, USA) 
Recombinant SrcNI Kinase Sigma, (St. Louis, MO, USA) 
Rat anti bov MBP Abcam (Cambridge, UK) 
Recombinant human EGF Invitrogen, ( Carlsbad, CA, USA) 
  
2.1.5 Kits, Materials and Reagents  
PE Mouse Anti- BrdU Set BD, (Franklin Lakes, NJ, USA) 
Foxp3 staining buffer set eBiosciences, (San Diego, CA, USA) 
Oligotex mRNA midi kit Qiagen, (Valencia, CA, USA) 
Inflammatory Cytokine and Receptors 
microarray (Mouse OMM011, Human 
OHS011) 





Toxicology and Drug Resistance 
microarray (OHS401) SABiosciences (Frederick, MD, USA) 
TrueLabelling-AMPTM Linear RNA 
Amplification Kit SABiosciences (Frederick, MD, USA) 
ArrayGrade cRNA Cleanup Kit SABiosciences (Frederick, MD, USA) 
Riboclone cDNA synthesis system Promega, (Madison, WI, USA) 
Microspin S-300 HR columns GE Healthcare (Buckinghamshire, England) 
pGEMT Easy Vector system Promega, (Madison, WI, USA) 
Wizard Plus SV DNA Promega, (Madison, WI, USA) 
BigDye ver 3.0 Applied Biosystems (Foster City, CA, USA) 
ON-TARGETplus  SMARTpool 
siRNA Dharmacon, (Lafayette, CO, USA) 
ON-TARGETplus  Non-targeting 
siRNA #1 Dharmacon, (Lafayette, CO, USA) 
Dotap Liposomal Transfection Reagent Roche, (IN, USA) 
TaqMan Gene Expression Assay probes Applied Biosystems (Foster City, CA, USA) 
TaqMan Universal PCR Master Mix Applied Biosystems (Foster City, CA, USA) 
Complete mini protease inhibitors 
tablets Roche, (IN, USA) 
Glutathione Sephrose  4B GE Healthcare (Buckinghamshire, England) 
HiTrap Benzamidine FF GE Healthcare (Buckinghamshire, England) 
Slide-A-Lyzer Dialysis Cassettes, 3.5K 
MWCO Pierce, (Rockford, IL, USA) 
Restore Western Blot Stripping Buffer Pierce, (Rockford, IL, USA) 
SuperSignal West Pico 
Chemiluminescent Substrate Pierce, (Rockford, IL, USA) 
SuperSignal West Dura 
Chemiluminescent Substrate Pierce, (Rockford, IL, USA) 
Human Phosphokinase Array Kit R&D Systems, (MN, USA) 
Micro BCA Protein Assay Kit Pierce, (Rockford, IL, USA) 
Albumin Standards Pierce, (Rockford, IL, USA) 
HyBond ECL Nitrocellulose membrane GE Healthcare (Buckinghamshire, England) 
Mini MACS Cell Separation column Miltenyi, ( Bergisch Gladbach, Germany 
Immuno MaxiSorp modules ThermoFischer, (Waltham, MA, USA) 
Ready-SET-Go! Mouse IL-10 ELISA Kit eBiosciences, (San Diego, CA, USA) 
Ready-SET-Go! Mouse IL-2 ELISA Kit eBiosciences, (San Diego, CA, USA) 
Ready-SET-Go! Mouse TNFα ELISA Kit eBiosciences, (San Diego, CA, USA) 
Ready-SET-Go! Mouse IL12-p70 ELISA 
Kit eBiosciences, (San Diego, CA, USA) 
OptEIA mouse IL-12p40 ELISA Kit BD, (Franklin Lakes, NJ, USA) 







2.1.6 Equipments  
UV 2000 Spectrophotometer Shimadzu, (Japan) 
Polytron Handheld homogenizer Daigger, ( Illinois, USA) 
Sunrise plate reader Tecan, (Salzburg, Austria) 
GENios plate reader Tecan, (Salzburg, Austria) 
7500 Real Time PCR System Applied Biosystems (Foster City, CA, USA) 
PTC Thermo Cycler MJ Research, (Ramsey, MN, USA) 
Microson Ultrasonic Cell Disruptor Misonix, (Farmingdale, NY, USA) 
Vacuum gel dryer system Hoefer, (Holliston, MA, USA) 
5810R Centrifuge Eppendorf, (Hamburg, Germany) 
Ultracentrifuge Beckman Coulter, (Fullerton, CA, USA) 
G:Box imaging gel documentation system Syngene, (Cambridge, UK) 
FACS Canto Flow Cytometer BD, (Franklin Lakes, NJ, USA) 
Epics Altra Flow Cytometer Beckman Coulter, (Fullerton, CA, USA) 
  
2.1.7  Softwares  
Magellan 5 Tecan, (Salzburg, Austria) 
SPSS 17 SPSS, (Chicago, IL, USA) 
GeneTools ver 3.0 Syngene, (Cambridge, UK) 
WinMDI ver 2.9 Scripps Res Institute, USA 
BD FACSDiva ver 6.0 BD, (Franklin Lakes, NJ, USA) 






2.1.8  Buffer compositions 
Buffers Composition 
1x PBS Buffer 137mM NaCl, 2.7mM KCl and 10mM phosphate pH 7.4 
PBA Buffer 1xPBS with 1% BSA and 0.01% sodium azide 
TE Buffer 20mM Tris.Cl pH 8.0, 1mM EDTA 
1x Laemmli Buffer 62.5mM Tris.Cl pH 6.8, 10% glycerol, 2% SDS, 0.05% Bromophenol blue, 5% β-mercaptoethanol 
2YT media 1.6% Bacto Tryptone, 1% Bacto Yeast Extract, 0.5% NaCl 
LB media 1% Bacto Tryptone, 0.5% Bacto Yeast Extract, 1% NaCl 
LB agar 1% Bacto Tryptone, 0.5% Bacto Yeast Extract, 1% NaCl, 1.5% Difco Agar 
RIPA Buffer 50mM Tris.Cl pH 7.4, 150mM NaCl, 1% IGEPAL, 0.1% SDS, 1% sodium deoxycholate 
IP Lysis Buffer 50mM Tris.Cl pH 7.4, 0.15M NaCl, 1% IGEPAL, 1% Triton X-100, 1mM EDTA, 1mM EGTA 
Boiling Lysis Buffer 10mM Tris.Cl pH 7.4, 1% SDS, 1mM Na3VO4, 10mM NaF 
Glucose Sample Buffer 1xPBS, 0.1% glucose 
TBST  10mM Tris.Cl pH 7.4, 100mM NaCl, 0.1% Tween 20 








2.2  Methods 
2.2.1  Cell Culture and BCG preparations 
2.2.1.1  Growth and Maintenance of bladder cancer cell lines 
Human transitional cell carcinoma cell lines MGH, RT4, J82 and SW-780 were routinely cultured 
in RPMI supplemented with 10% heat inactivated foetal bovine serum, 2mM L-glutamine, 
50U/ml Penicillin G and 50µg/ml streptomycin while UM-UC-3 cells were cultured in DMEM 
containing the supplements as RPMI above. Cells were maintained at 37⁰C in a 5% CO2 
atmosphere and routinely passaged when 85-90% confluent. 
2.2.1.2  Preparation of lyo BCG and live BCG 
BCG was prepared for experiments as previously described by de Boer et al [10]. BCG from a 
commercial lyophilized preparation (lyophilized BCG) was reconstituted in the buffer provided. 
1ml of the BCG preparation is then washed with 9ml of blank RPMI and centrifuged at 75 x g for 
3minutes to remove large bacteria clumps and debris. 6ml of the supernatant was transferred in 
another centrifuge tube and the absorbance at 440nm was measured. The cfu was determined with 
the formula of OD440nm 0.2 is equivalent to 3x106 cfu/ml. Freshly cultured live BCG (live BCG) 
was obtained by growing colonies from the serially diluted commercial lyophilized BCG grown 
on 7H10 Middlebrook agar. M. bovis BCG is maintained in 7H9 Middlebrook medium 
supplemented with 10% ADC supplement (0.85% NaCl, 5% bovine serum albumin fraction V, 
2% dextrose and 0.003% catalase), 0.05% Tween 80 and 0.2% glycerol. BCG culture used in the 
experiments is harvested at OD600nm of 0.7 to 0.8 at the exponential phase. The formula OD600nm 
0.1 = 2.6 x 106 cfu/ml is determined by plating serial dilutions of BCG culture on 7H10 
Middlebrook agar supplemented with 10% ADC, 0.05% Tween 80 and 0.5% glycerol and is used 






2.2.1.3  Preparation of FITC labelled BCG 
In all experiments, BCG internalization was done with live BCG to ensure a suspension free of 
debris and dead bacteria. For internalization comparison with lyophilized BCG treatment of MGH 
cell line, the total cfu of live BCG and lyophilized BCG needed was calculated using formulae in 
Section 2.2.1.2. The BCG suspension to be used for labelling were pelleted at 3200 x g for 10 
minutes at 4⁰C and washed twice with 1xPBS containing 0.05% Tween 80. For every 1x108 cfu 
of BCG, the bacteria pellet was incubated with 1ml of 0.3mg/ml FITC in a buffer containing 
50mM Na2CO3 and 100mM NaCl at pH 9.2 for 30 minutes at 20⁰C. The labelled bacteria were 
washed 3x with 1xPBS containing 0.05% Tween 80 to remove any remaining excess FITC label 































Figure 2.1: A schematic representation of the RDA procedure. 
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2.2.2  Investigating genes that are up-regulated in MGH cell line after 2 hours lyo BCG 
treatment using Representational Differential Analysis (RDA) 
RDA was performed as that previously described by Pastorian et al [170] (Figure 2.1). The same 
primer sequences were used for the driver synthesis and the rounds of subtractive hybridizations 
as recommended by the group. Briefly, 6x105 MGH cells were plated on a 10mm cell culture dish 
overnight before treatment with 6x107 cfu of lyo BCG the following day for 2 hours. Total RNA 
were extracted from the samples using Trizol Reagent as in Section 2.2.4.4 followed by the 
isolation of Poly A+ population using Oligotex mRNA midi kit. The Poly A+ samples were 
converted to cDNAs with Riboclone cDNA Synthesis System. The cDNA samples were then 
subjected to restriction enzyme digest with DpnII to create RDA compatible restriction sites. 
Digested samples were used as templates to create driver populations by ligating a 24mer PCR 
primer using a 12mer bridge. Ligated fragments were purified using Microspin S-300 HR 
columns and PCR amplified using the same 24mer primers used for driver synthesis. Driver 
amplicons were digested with DpnII restriction enzyme to cleave the 24mer PCR primer 
sequences, purified through spin columns and aliquoted for subsequent tester synthesis and 
agarose gel analysis. The amplicon samples were ligated with a new set of 24mer and 12mer 
primers to create the tester samples. The driver and tester samples were then placed through a 
round of subtractive hybridization in a 1:10 tester to driver ratio. The hybridized products were 
PCR amplified with the 24mer primer used in the tester synthesis, cleaved with DpnII and used as 
template for another set of tester synthesis with new 24mer and 12mer primers. The subtractive 
hybridization rounds were repeated another 2x in subsequent of 1:100 and 1:5000 of tester to 
driver ratios. Products of previous hybridization rounds always serve as tester for subsequent 
rounds. Only products that are up-regulated in the tester population are PCR amplifiable. The 
PCR amplified third round of hybridization products were ligated into pGEMT Easy Vector, 
transformed into DH5α cells and positive clones were selected on LB agar plates with 100µg/ml 





SV DNA purification system. Plasmids were sequenced with -21M13 forward primers using the 
BigDye version 3.0 system and the sequence results were identified using the BLAST algorithm. 
2.2.3  α5β1 analysis and BCG internalization assay 
2.2.3.1  Integrin α5β1 receptor analysis 
Cells were plated at a density of 1x105 cells in 24-well plates and left overnight before harvesting 
with cell scrapers and collection by centrifugation. The pellet was resuspended in 100µl of PBA 
with 0.2ug of antibodies to either α5, β1 integrins or isotype controls and incubated for 20 
minutes at 4⁰C. Cells were washed to remove unbound antibodies by the addition of 900µl of 
PBA followed by centrifugation at 7500 x g for 1 minute. The pellet was resuspended in 50µl of 
PBA and incubated with 2µl of secondary antibody (rabbit anti mouse IgG RPE conjugated) at 
4⁰C for 20 min. Cells were washed of the unbound antibodies and fixed with 0.1% formalin 
before flow cytometry.  
2.2.3.2  BCG internalization assay 
Cells were plated at a density of 1x105 cells per well in a 24-well plate. After 6 hours, the media 
was removed and replaced with blank media overnight. The following day, cells were treated for 
2 hours and 24 hours with FITC labelled live BCG at a 1:100 cells to bacteria ratio. Treated cells 
were harvested with a cell scraper, pelleted by centrifugation at 7500 x g for 1 minute and 
resuspended in 100µl PBS buffer containing 0.2% bovine serum albumin, 0.02% Na-EDTA and 
0.01% sodium azide (PBEA). To this was added 1µl of polyclonal rabbit anti-BCG antibodies or 
isotype controls and incubated for 30 minutes at 4⁰C. Cells were washed by adding 900µl of 
PBEA and collected by centrifugation. Cells were then incubated with secondary TRITC 
conjugated swine anti-rabbit antibodies (1:50 dilution) for 30 minutes at 4⁰C. Cells were washed 
again as above and fixed in 0.1% formalin before analysis by flow cytometry. A profile of the 






Figure 2.2: Flow cytometry dot plot profile of BCG internalization assay with MGH cell 
line. Surface bound BCG were quantified from the addition of the values from quadrant 1and 2 
and internalized BCG from addition of quadrant 2 and 3. 
 
2.2.3.3  Treatment of bladder cancer cell lines with live BCG and lyo BCG for ROS and 
cytokine comparisons. 
Bladder cancer cell lines were plated at a density of 3x105 cells per well in a 6-well plate and 
incubated overnight at 37⁰C. The next day, cells were treated with 3x107 cfu BCG preparation in 
a total of 3ml of fresh media and incubated for 2 and 24 hours. For BCG transwell blocking 
studies with MGH cell lines, 0.5ml BCG preparation was added on the top layer of the transwell 
device separating the direct interaction. Total fresh media was kept at 3ml volume. For ROS 





2.2.3.4  Cycloheximide treatment, BCG internalization and cytotoxicity studies.  
MGH cells were plated in 6 well plates at a density 1x105 cells per well. After 6 hours when most 
of the cells were attached, the media were removed and replaced with blank media overnight. The 
following day, the media were replaced with complete RPMI media with 1μl of 10% ethanol in 
the control wells and 1μl of 1 mg/ml cycloheximide (10mg/ml stock dissolved in ethanol, diluted 
with RPMI to 1mg/ml) in the cycloheximide treated wells. FITC labelled BCG (1x107 cfu) were 
added to each respective well and incubated with the cells at 37˚C for 2, 24 and 48 hours. To 
harvest, the cells were washed 3x with 1x PBS, scraped and assayed for BCG internalization 
(Section 2.2.3.2). Harvested cells were also enumerated with a haemocytometer to observe anti-
proliferative or cytotoxic effects. 
 
2.2.3.5 Cell proliferation assay with BrdU 
1x106 cells were labelled with 20µM BrdU in 25cm2 for 6 hours before plating at a density of 
2x105cells in 6-well plate overnight. The following day, BCG was added to the cells at a 1:100 
cells to bacteria ratio and left to incubate for 24 hours. Cells were harvested the next day with a 
cell scraper. All the following steps were done at room temperature. Briefly, cells were pelleted 
and fixed in 70% ethanol for 30 minutes. Cells were pelleted by centrifugation at 12 500 x g for 5 
minutes and the supernatant was removed. Cell pellets were resuspended in 1ml of 2N HCl for 30 
minutes. The cells were pelleted again and washed with wash buffer (1xPBS buffer containing 
0.5% BSA) before incubation with 0.5ml of 0.1M sodium tetraborate buffer pH 8.5 for 5 minutes. 
Cells were pelleted, washed with 1ml of wash buffer and centrifuged again. The pellets were 
resuspended in 50µl of 1xPBS containing 0.5% Tween 20 and incubated with 20µl of anti-BrdU 






2.2.4  Animal experiments and SuperArray analysis 
2.2.4.1  Live BCG instillation in mice 
Female C57BL/6 mice (aged 4-6 weeks old) were purchased from the Centre for Animal 
Resources (CARE), Singapore. All animal work adhered to the guidelines on animal use and 
handling from the Institutional Animal Care and Use Committee (IACUC), National University 
of Singapore. The mice were allowed to acclimatize for 1 week before treatment. Before all 
procedures, animals were anaesthetized by intraperitoneal injection with 0.1mL of ketamine and 
medetomidine per 10g of animal weight and then divided into groups which were intravesically 
instilled once a week for four, five or six weeks with viable 1x107cfu/ml live BCG (treatment 
groups) or phosphate buffered saline (control group).  
2.2.4.2  BCG treatment of MGH cells for RNA isolation and SuperArray analysis 
MGH cells were plated at a density of 2x105 cells per well in 6 well plates and left to incubate 
overnight before treatment with 2x107cfu of live BCG or lyo BCG for 2 hours. For BCG 
transwell blocking studies with MGH cell lines, 0.5ml BCG preparation was added on the top 
layer of the transwell device. In phosphatase inhibition studies, 100µM sodium orthovandate was 
added to the media before use in transwell blocking experiment. Total fresh media was kept at 
3ml fresh volume. Total RNA were isolated from the samples according to Section 2.2.4.4. 
2.2.4.3  Harvesting bladder and iliac lymph nodes for Immune cells recruitment analysis 
After each instillation schedule, the mice were sacrificed and their bladders and ILN were 
harvested 6 hours after the last instillation, cut up and teased with the rubber end plunger from a 1 
ml syringe to obtain single cells. The single cells were aspirated with a 5 ml pipette and passed 
through a 18G needle 3 times. The cells were transferred to a 15ml tube and pelleted by 
centrifugation at 450 x g for 10 min at 4ºC. The pellets were resuspended in 900ul of water for 30 





osmolarity. The cell suspensions were centrifuged again, supernatants discarded and the cells 
were resuspended in 1ml of 1xPBS followed by filtration through a nylon microfilament mesh 
with 60µ sized opening. The cell suspensions were pelleted by centrifugation and resuspended in 
900µl of PBA followed by the gentle addition of 100µl 1% formaldehyde for fixation. The fixed 
cells were left overnight at 4ºC before antibody staining. After fixing, cells were centrifuged at 
7500 x g for 1 min to collect the cell pellet and resuspended in 1ml of PBA. A 100µl volume of 
the cell suspension was used for analysis of lymphocyte subsets: CD3, CD4 and CD8, 
macrophage, mature DCs, activated DCs, Foxp3 and natural killer cell infiltrates. The cells were 
stained with fluorochrome-conjugated monoclonal antibodies for 20 min at 4ºC followed by a 
wash with 900µl of PBA and the samples were centrifuged for 1 minute at 7500 x g to collect the 
pellet. The pellet was resuspended in 300µl of PBA before flow analysis with Epics Altra 
flow cytometer. The cells were also labelled with the appropriate isotype controls for analysis. 
For Foxp3 staining, cell suspensions were collected by centrifugation and incubated in 100µl of 
FcR blocking reagent for 15 minutes at 4°C followed by further incubation with anti mouse 
Foxp3 for 20 minutes before washing with 900µl of PBA. 
2.2.4.4  RNA isolation 
Each bladder sample harvested from mice was cut up into fine pieces in a 2ml cryovial with a 
clean pair of scissors and homogenized on ice in 1 ml of Trizol Reagent with a handheld 
homogenizer. The homogenates were transferred to new microfuge tubes and 0.2ml of chloroform 
was added to each sample tubes. The tubes were shaken up and down 4-5 times to mix gently and 
left for 3 minutes at room temperature. The samples were centrifuged at 12 000 x g for 15 
minutes and the top aqueous layers were transferred to new microfuge tubes followed by the 
addition of 0.5ml of isopropanol for 10 minutes at room temperature. The samples were 
centrifuged at 12 000 x g for 10 minutes and the supernatant was discarded. The RNA pellets 
were washed with 1ml of 75% ethanol and centrifuged at 7500 x g for 5minutes. The supernatants 





of nuclease-free water. To aid resolubilization, the samples were heated at 65ºC for 15min. The 
RNA samples were then quantified using a UV spectrophotometer in glass cuvettes at optical 
density 260nm and 280nm and concentration obtained using the formula below: 
Concentration (µg/ml) = OD260 x 40 x dilution factor 
For cultured cell line samples grown in 6 well plates, the cells were washed 3x with ice cold 1x 
PBS and lysed with 1ml of Trizol Reagent for 5 minutes before addition of chloroform. All 
subsequent steps are as described above 
2.2.4.5  Gene expression studies with SuperArray’s pathway specific OligoArrays. 
2.2.4.5.1  Preparation of poly A+ mRNA from bladder and MGH samples 
After the 4th, 5th and 6th instillation, the mice were sacrificed. The bladders were harvested 6 hours 
after the last instillation, placed in cryotubes, snap frozen in liquid nitrogen and kept in -80ºC till 
ready for use. One bladder sample from control and live BCG treated sets were chosen for 
SuperArray analysis. The total RNA from the bladders were isolated as described in Section 
2.2.4.4 and the mRNA population were purified with Oligotex mRNA midi kit according to the 
manufacturer’s protocol. RNAse free water was added to the samples to a total volume of 250µl 
along with 250µl of buffer OBB (20mM Tris.Cl pH 7.5, 1mM NaCl, 2mM EDTA, 0.2% SDS) 
and 15µl of Oligotex suspension. The mixtures were heated in a water bath at 70°C for 3 minutes 
to disrupt the secondary structure of RNA and then left at room temperature for 10 minutes for 
the hybridization of the oligodT30 of the Oligotex particles to the polyA tail of the mRNA. The 
Oligotex:mRNA complex was then pelleted by centrifugation at 13 500 x g for 2 min. The pellets 
were resuspended in 400µl Buffer OW2 (10mM Tris.Cl pH 7.5, 150mM NaCl, 1mM EDTA) and 
transferred to a small spin column placed in a microfuge tube. Samples were centrifuged for a 
minute and the flow through discarded. 30µl of Buffer OEB (5mM Tris.Cl pH 7.5) maintained at 
70°C was added to the resins in the column and centrifuged for a minute. The flow through 





the resins, mixed by repeat pipetting and centrifuged for another minute. The repeated flow 
through from the same samples were combined and kept at -80°C till ready for use.  
2.2.4.5.2  Linear amplification of poly A+ mRNA and preparation of Biotin-16-UTP labelled 
cRNA 
The mRNA samples were converted to Biotin-16-UTP labelled cRNA using the TrueLabelling-
AMPTM Linear RNA Amplification Kit. For each sample, 9µl of mRNA was added to 1µl of 
Component G1 of the kit, incubated at 70°C for 10 minutes and immediately placed on ice. 10µl 
of cDNA synthesis Master Mix consisting of (per sample) 1µl of cDNA synthesis enzyme mix 
(G2),; 1µl of RNase Inhibitor (RI),; 4µl of 5x cDNA Synthesis Buffer (G3) and 4µl of RNase free 
water, was added to each sample and incubated in a 42°C water bath for 50 minutes. The contents 
were collected by brief centrifugation and labelled by adding 20µl of Amplification Master Mix 
consisting of (per sample) 16µl of 2.5x RNA amplification Buffer (G4), 2µl of Biotin-16-UTP 
from Roche and 2µl of Amplification Enzyme Mix (G5). The contents were incubated for 18 
hours at 37°C. 
2.2.4.5.3  Purification of synthesized cRNA 
The labelled cRNA were purified from interfering free Biotin-16-UTP using the ArrayGrade 
cRNA Cleanup Kit. To each sample, 60µl of RNAse free water was added followed by 350µl of 
Binding Buffer (G6) and 350µl of ACS-Grade 100% ethanol. The samples were gently mixed by 
repeated pipetting and loaded onto the top of separate spin columns placed in collection tubes. 
The tubes were centrifuged for 30 seconds at 7500 x g and the flow through were discarded. The 
samples in the spin columns were washed with 600µl of Washing Buffer (G7) and centrifuged for 
30 seconds at 7500 x g. The wash was repeated with another 200µl of Washing Buffer and 
centrifuged for 3 minutes at 10 000 x g. Finally, the spin columns were transferred to a new 
Elution tube. 50µl of RNAse free water was added and incubated in the centre of the spin 





to collect the eluates which were diluted 350x with deionized water. The diluted cRNA samples 
were quantified by measuring OD260nm using a UV spectrophotometer. The yield of cRNA 
samples were quantified using the formula below: 
Concentration (ug/ml) = OD260 x 40 x dilution factor (350) 
 
2.2.4.5.4  Array Hybridization 
The arrays were provided in hybridization tubes from the supplier. The arrays were pre-wetted by 
adding 5 ml of deionized water in the tubes for 5 min. The water was discarded, 2 ml of 60°C pre-
warmed GEAhyb Hybridization solution was added to each tube and left to incubate overnight at 
60°C in a rotator oven. The next day, the pre-hybridization solution was discarded and 5µg of 
labelled cRNA samples dissolved in 1ml of 60°C pre-warmed Hybridization solution was added 
to each tubes. The membranes were left to incubate overnight at 60°C with continuous gentle 
rotation. The hybridization mixes were removed and membranes were washed in 5 ml of Wash 
Buffer 1 (2X SSC, 1% SDS) for 15 minutes at 60°C with vigorous rotation. The washes were 
discarded and 5 ml of Wash Buffer 2 (0.1X SCC, 0.5% SDS) was added to each membrane for 
another 15 minutes vigorous washing. Chemiluminescence detection was done with 
SABiosciences Chemiluminescent Detection Kit and the steps were all done at room temperature. 
The membranes were incubated with 2 ml of Blocking Solution Q for 40 minutes with vigorous 
rotation. The blocking solution was discarded and 2ml of Alkaline phosphatase conjugated 
Strepavidin (AP-SA) reagent diluted 1:8000 in 1X Buffer F was added and incubated for exactly 
10 minutes with gentle rotation. The membranes were then washed 4 times with 4ml of 1X Buffer 
F for 5 minutes with gentle rotation and exposed to 1 ml of CDP-Star chemiluminescent substrate 
for 2 minutes with gentle rotation. The membranes were wrapped in Saran wrap and the signal 
detected with X-ray films exposed for 2-15 minutes. Sample images from the same time X-ray 
exposure time point were chosen for blot intensity analysis using SABiosciences GEArray 





2.2.4.6.  cDNA conversion 
Approximately, 5µg of RNA was converted to cDNA with SuperScript II Reverse 
Transcriptase. Briefly, 5µg of RNA was pre-treated in a 10µl total volume with 1u of DNAse in 
1xDNAse Buffer (20mM Tris.Cl pH 8.4, 20mM MgCl2, 500mM KCl) and 40u of RNAsin for 15 
minutes at room temperature. The reaction was terminated by the addition of 1µl of 25mM 
EDTA. At the same time 1µl of 500µg/ml OligodT and 1µl of 10mM dNTPs were added to the 
tubes. The reaction mixtures were heated at 65ºC for 10 minutes and quick chilled on ice for at 
least 5 minutes before adding the cDNA synthesis mix (7µl). The cDNA sysnthesis mix 
consisting of (for a total volume of 20µl) 1xSSII buffer (50mM Tris.Cl pH 8.3, 75mM KCl, 3mM 
MgCl2), 10mM DTT, 8u RNAsin, and 200u of SuperScript II enzyme, was added to the chilled 
mixture and incubated at 42ºC for 50 minutes. The reaction was terminated by heating at 70ºC for 
15 minutes. To each tube, 180µl of TE buffer (20mM Tris.Cl pH 8.0, 1 mM EDTA) was added 
and 5µl of the cDNAs were used for the polymerase chain reaction with gene specific primers. 
2.2.4.7  Polymerase chain reaction 
cDNAs (5µL) were used as template for the cycle reaction with 0.5µM of gene specific primers, 
0.2mM of dNTPs, 0.5u of DyNAzyme DNA polymerase in 1x buffer (10mM Tris.Cl pH 8.8, 
50mM KCl, 1.5mM MgCl2, 0.1% Triton X-100). The PCR products were run on a 1.5% 
agarose gel and the relative density of housekeeping genes (GAPDH or Rps27a) and the gene 
specific products were determined using GeneTools densitometry software. Table 2.1 and Table 







Table 2.1: List of primers for mouse gene expression analysis 







No of cycles 
IL1β Forward: ctg tcc aga tga gag cat Reverse: agg aag aca ggc ttg tgc 55 630 40 
FCεR1γ Forward: cgg agc cag gag aca tat ga Reverse: ttg agt cag gtc tct ggc ag 57 344 35 
Cxcl10 Forward: cgt ggt cac atc agc tgc ta Reverse: tag aac tga cga gcc tga gc 57 244 35 
Cxcl2 Forward: gaa cat cca gag ctt gag Reverse: aac tct cag aca gcg agg 55 278 35 
Ccl7 Forward: tct gtg cct gct gct cat ag Reverse:cct cct cga ccc act tct ga 60 230 35 
Xcl1 Forward: cca tgg gtt gtg gaa ggt gt Reverse: cag tca ggg tta tcg ctg tg 58 294 35 
iNOS Forward: aaa gcc acg agg ctc tga ca Reverse: gtg aga ggc aaa gga gga ga 58 259 40 
FcγR1 Forward: acc tcc ctc agg tcc aga ta Reverse:gtg aca ccc atg taa gcc gt 57 264 35 
Ccl6 Forward: atc ctt gtg gct gtc ctt gg Reverse:ggc acc tct gaa ctc tcc ga 60 268 35 
Ccl5 Forward: ggt acc atg aag atc tct gc Reverse: cta tcc tag ctc atc tcc 55 287 40 
TNFα Forward: tgc acc acc atc aag gac tc Reverse: cag ctc agc tcc gtt ttc ac 58 360 35 
Ccl8 Forward: acg cag tgc ttc ttt gcc Reverse: gct gtc tct taa ctc agg tg 60 900 35 
Ccl2 Forward: gca tcc acg tgt tgg ctc ag Reverse: cac act ggt cac tcc tac ag 60 378 35 
Ccr2 Forward: gag cct gat cct gcc tct ac Reverse:ggc act gtt tga aga gac gt 58 371 35 
Ccl21a Forward: ctg gac ctg gct ctc tgc at Reverse:atc agg ttc tgc acc cag cc 60 227 35 
Cxcl14 Forward: agg aca agg gaa gat gca gg Reverse:aac ctg cat gca gca ctc ag 58 327 40 
Cxcl9 Forward: atg cac aac agc tgt ctg gc  Reverse:tgc cac taa gct aca gcc ac 57 369 35 












No of cycles 
IL2 Forward: tga tgg acc tac agg agc tcc tga g Reverse:gag tca aat cca gaa cat gcc gca g 60 168 40 
IFNγ Forward: act gcc acg gca cag tc Reverse:ccg ctt cct gag gct g 60 389 40 
IL10 Forward: act gct atg ctg cct gc Reverse:cac ctt ggt ctt gga gc 58 446 40 
IL12p35 Forward: cca tcg atg agc tga tgc ag Reverse:atg ctg agg tag ctg tgc ca 58 340 35 
IL12p40 Forward: cag aag cta acc atc tcc tgg ttt g Reverse:tcc gga gta att tgg tgc ttc aca c 59 396 35 
IL1r2 Forward: gtg gtt ggc taa cag cac gt Reverse:ctg gtt gtc agt ccg tag ct  58 356 35 
IL16 Forward: gac cca agg caa gct gtg at Reverse:ctg gag gct ggt cct tct ga 58 399 40 
IL18 Forward: ggc cca gga aca atg ctg cc Reverse:ggg tca cag cca gtc ctc tta ac 60 155 35 
Ccl17 Forward: ggt cac ttc aga tgc tgc tc Reverse: tct gca cag atg aga ttg cc 58 220 40 
Ccl22 Forward: gca tcc acg tgt tgg ctc ag Reverse:cac act ggt cac tcc tac ag 60 383 40 
GM-CSF Forward: tgg cct ggg ctt cct cat Reverse:gga tga cat gcc tgt cac 60 312 40 
TGFβ Forward: ctg caa gac cat cga cat  Reverse:aca aga gca gtg agc gct 55 580 40 
Foxp3 Forward: tcg  tag cca cca gta ctc ag Reverse:atc tac ggt cca cac tgc tc 57 386 40 
GAPDH Forward: cac cct gtt gct gta g Reverse: gtc ggt gtg aac gga 60 956 
Same cycles 







Table 2.2: List of primers for human gene expression analysis 







No of cycles 
TNFα Forward: gtg tgg cct gca cag tga  Reverse: gga gca gag gct cag caa 56 550 35 
IL1β Forward: aca tgc ccg tct tcc tgg Reverse: ggg aag cgg ttg ctc atc 56 421 30 
TOLLIP Forward: gga cag gct tgt ctg cca Reverse: cgc acg ttc tga gac cac 56 317 40 
Ccl20 Forward: gcc aat gaa ggc tgt gac Reverse: aca agt cca gtg agg cac 54 262 35 
CSF2 Forward: cag gag ccg acc tgc cta Reverse: tca ggg tca gtg tgg ccc 58 388 35 
IL10RB Forward: cct tag agg tcg agg cag Reverse: gtc cgt gct ctg tgt agc 56 420 35 
Cxcl6 Forward: cca gtc ttc agc gga gca  Reverse: cct ccc tca aca gca cac 54 384 30 
IL12A Forward: aat ggg agt tgc ctg gcc Reverse: acg gtt tgg agg gac ctc 56 364 40 
Cxcl5 Forward: gga cca gag aga gct tgg Reverse:gtg tgt ccc acc agg act  56 373 40 
IL11RA Forward: tct ggc tga ggc tga gac Reverse:tcc ctg cct cac aga cac 56 370 40 
IL15RA Forward: agc ttc cca gga gag acc Reverse:tcc cag gtc cct gtc cat 56 279 40 
SCYE1 Forward: tgg aga gag gaa gtt gcc Reverse:gtc agg gtt act ctg gca 54 357 40 
GSTA4 Forward: cgt gga ggg gac act gga Reverse:ggc aga gac tgg agg gga 58 779 35 
GSTA3 Forward: atg gac ggg gca gaa tgg Reverse:gga gat aag gct gga gtc 54 497 40 
GSTT2 Forward: agg ctc gtg ccc gtg ttc Reverse: ggc ctc tgg tga ggg tgt 58 428 35 
GSTM5 Forward: cag aag atg gga ggg agg Reverse:ggg gga ctt tga tgg agg 56 207 40 
MGST1 Forward: gca gag ccc acc tga atg Reverse:tcc tct gct ccc ctc cta 56 354 35 












No of cycles 
MGST2 Forward: aga cct gcc tgc ctt cct Reverse:cca ccc agc cat cca caa 56 392 40 
HSPA6 Forward: cag tgg cat ccc tcc tgc Reverse:gcg ggc ttg agt gcc aca 58 499 40 
NOS2A Forward: cct ggc aag ccc aag gtc Reverse:cac cca ctt gcc agg cct 58 587 40 
NAT2 Forward: gtg acc att gac ggc agg Reverse:cgt gag ggt aga gag gat 54 630 40 
NAT5 Forward: cct tta cct gcg acg acc Reverse:gga gga gac tgg agc aag 56 830 40 
β-actin Forward: aaa tcg tgc gtg aca tta agg Reverse:agc act gtg ttg gcg tac ag 50 277 35 
GAPDH Forward: gga agg act cat gac cac  Reverse:ggt ctc tct ctt cct ctt 53 546 35 
Rps27A Forward: ctc gag gtt gaa ccc tcg  Reverse: gca ctc tcg acg aag gcg  56 321 
Same cycles 
as gene of 
interest 
 
2.2.5  GSTT2 silencing and its effects on lyo BCG treatment of MGH cells 
2.2.5.1  GSTT2 siRNA transfection and lyo BCG treatment 
MGH cells (2x105) were plated overnight in 6 well plates before gene silencing using 
Dharmacon ON-TARGETplus SMARTpool siRNA (L-011181-00-0005) in which a mixture 
of four duplex siRNAs are targeted for GSTT2 knockdown. The target sequences are: J-11181-
05(GCUCAAGGAUGGUGAUUUC), J-011181-06(GCACCGUGGAUUUGGUCAA), J-
011181-07(AGGCUAUGCUGCUUCGAAU), J-011181-08(ACACUGGCUGAUCUCAUG). 
ON-TARGETplus Non-targeting siRNA #1 (NNUGGUUUACAUGUCGACUAA) was used 
as a non targeting siRNA control. Transfection of the siRNAs was accomplished with a 
DOTAP Liposomal Transfection Reagent. The cells were washed 3x with blank RPMI and 
then left in 850µl of blank RPMI. Approximately 30 pmol of siRNA was complexed with 





(20mM HEPES, 150mM NaCl, pH 7.4). The transfection mixtures were left to stand for 10 
minutes at room temperature before addition to the cells and incubated for 2 hours at 37ºC in a 
total of 1 ml volume. The liposome mixtures were removed and cells were washed once with 3 
ml of blank RPMI and 3ml of fresh complete media was added to the cells before further 
incubation for 24 hours. The next day, the cells were washed 3x with 1xPBS and incubated 
with 2x107 cfu lyo BCG for 2 hours in phenol-red free RPMI. The supernatants were passed 
through a 0.22µ filter and kept at -20ºC for ELISA detection of cytokine production and nitrite 
measurement. The cells were harvested and assayed for ROS levels as in Section 2.2.6.1. For 
validation of GSTT2 silencing, a set of transfected samples were harvested for RNA, reverse 
transcribed and probed for GSTT2 expression using real time assay. 
2.2.5.2  Real time validation of GSTT2 silencing 
Approximately 2µl of 10x diluted Superscript II reverse transcribed cDNAs were used for real 
time analysis of GSTT2 expression. Predesigned TaqMan Gene Expression Assays probes 
were obtained for GSTT2 (Hs00168315-m1) and the endogenous control GAPDH 
(Hs99999905-m1). The 20x pre-formulated mix consists of 2 unlabeled PCR primers (900nM 
final concentration) and 1 FAM dye-labelled TaqMan MGB probe (250nM final 
concentration). The assay was done in a 96-well plate format with 2µl of cDNAs, 0.5x 
TaqMan Universal PCR Master Mix and 0.5x Gene Expression Assay probe. GAPDH 
endogenous control samples were used for normalization during the real time assay. Real time 





2.2.6 Oxidative stress: ROS, Nitrite/Nitrate and Lipid Peroxidation Assay 
2.2.6.1  ROS measurement 
MGH cells were plated and treated as in Section 2.2.5.1. The cells were washed thoroughly 3x 
with ice cold 1x PBS and scraped in a final volume of 1ml 1xPBS. The cells were filtered 
through a 60µ nylon microfilament placed on top of a flow tube. To each sample 10µl of a 
1mg/ml concentration of H2DCF-DA in DMSO was added and the tubes were vortexed gently 
to mix. The cells were incubated at 37ºC for 10 min before immediate flow analysis. The 
fluorescence signal was detectable at an excitation wavelength 488nm and emission 
wavelength 535nm (FITC channel) with FACS Canto flow cytometer. There are 2 peaks 
observed consistently during analysis and are designated as low and high ROS peaks. The 
control samples are used to set the markers for low and high ROS and the shift in the peaks are 
measured after BCG treatment. For our analysis, only the high ROS measurements are 
reported as a decrease in the percentage of high ROS results in a corresponding increase in low 
ROS and vice versa (Figure 2.3).  
 
Figure 2.3: A typical histogram of MGH cell line. 
2.2.6.2 Nitrate/Nitrite assay 
To measure the total nitrite values, supernatants were treated with nitrate reductase (0.1u/ml) 





was then incubated with 0.1ku/ml of LDH and 0.3mM sodium pyruvate for 15 minutes at 
room temperature to minimize the interference from FAD. To a 100µl of supernatant, the 
Griess reagent [50µl of 1% sulfanilamide in 5% phosphoric acid and 50µl of 0.1% 
napthylethylenediamine] was added sequentially and the tubes were incubated for 10 minutes 
at room temperature. Sodium nitrate standards (0 to 150µM) were prepared and treated as 
above (Figure 2.4). The absorbance at 540nm was measured with Tecan Sunrise plate reader 
using the Magellan 5 software. To measure endogenous nitrite, 100µl of unreduced 
supernatants were assayed directly with the Griess reagents with sodium nitrite solutions as 
standard (0-100µM). The nitrate concentrations were obtained by subtracting the endogenous 
nitrite values from the total nitrite assay values. 
 
Figure 2.4: A typical standard curve for the nitrate assay. 
2.2.6.3  Preparation of cells for lipid peroxidation assay 
MGH cells (2x106 cells) were plated in a 10mm culture dish. The following day, cells were 
treated with 1:100 ratio of cells to cfu of BCG (2x108 cfu BCG per dish) for 2 hrs in a 10ml 
volume. Before harvesting, cells were washed 3 times with 1x PBS to remove all traces of 
spent media and collected with a cell scraper in 5ml of 1x PBS. The cells were centrifuged at 





Butylated hydroxytoluene (dissolved in ethanol). The cells were then lysed by sonication on 
ice with Microson Ultrasonic cell disrupter at a power output of 5 watts for 3 rounds of 5 
seconds. After each round of sonication, the cells were rested on ice for 10 seconds. The 
homogenate was centrifuged at 1250 x g for 10 minutes and the supernatant was transferred to 
another centrifuge tube for protein determination and the lipid peroxidation assay. For 
transwell blocking of BCG interaction, 4x105 MGH cells were plated in 6 well plates. The next 
day the cells were treated with BCG (4x107cfu per well) with a transwell device blocking the 
direct interaction. Cells from 3 wells were pooled together and prepared as above for the assay. 
2.2.6.4  Lipid Peroxidation Assay 
Lipid peroxidation levels were measured by the detection of thiobarbituric acid (TBA) 
malondialdehyde (MDA) adduct formed in the following assay. To the sample homogenate 
prepared in Section 2.2.6.3, 200µl of 8.1% SDS, 1.5ml of 20% glacial acetic acid (pH 3.5), 
1.5ml of 0.8 % thiobarbituric acid (dissolved in 50mM NaOH) and 0.6 ml of water was added. 
The mixture is then heated at 95ºC for 1 hour and cooled to room temperature with tap water. 
To this is added 1ml of water followed by 5ml n-butanol: pyridine (15:1 ratio) mixture and 
mixed vigorously to extract the chromogen. The samples are centrifuged at 1250 x g for 10 
min and the organic top layer was read at 532nm with a glass cuvette using a UV 
spectrophotometer. The concentration of MDA, expressed in nmol per mg protein, is 
calculated based on the following formula: 
Absorbance (OD532nm) = ε x concentration x 1(path length) 





2.2.7  Isolation and characterization of mycobacterial MptpA 
2.2.7.1  Expression and purification of MptpA 
The plasmid construct pGEX mptpA was provided by Axel Ullrich (Martinsreid, Munich) 
from the Department of Molecular Biology, Max-Planck-Institut für Biochemie. Untagged 
MptpA was purified with a protocol illustrated in Figure 2.5. E.coli strain BL21 was 
transformed with pGEX mptpA. A starter culture of successful transformant colony was grown 
in 2YT media with 100µg/ ml ampicillin overnight at 37ºC. The starter culture was diluted 10x 
and grown at 37ºC for 2hrs before the addition of IPTG to a final concentration of 0.2mM, and 
cultures were further grown for another 3 hrs at 37ºC with shaking. Cells were harvested by 
centrifugation at 7500 x g for 15 minutes at 4ºC and resuspended in 25ml of sonication buffer 
(50mM Tris pH 7.4, 150mM NaCl, 1mM EDTA, 10% glycerol, 5mM DTT, 1mg/ml 
lysozyme, 1x complete mini protease inhibitors) per 500ml of bacteria pellet. The bacteria 
suspension was left on ice for 30 minutes. RNAse A (5µg/ml) and DNAse (2u/ml) were added 
to the bacteria suspension on ice for 15 minutes. The cells were sonicated on ice at a power 
output of 10 watts for 6 short bursts of 5 seconds followed by a 10 seconds rest on ice between 
sonications. To each sonicate 1% Triton X-100 was added and mixed vigorously by pipetting. 
The mixture was passed through a 21G needle and the lysate was centrifuged at 13 000 x g for 
15 minutes at 4ºC. The supernatant was transferred to a fresh centrifuge tube and incubated 
overnight with 250µl of prepared 50% Glutathione Sepharose slurry beads with gentle 
rotation at 4ºC. The beads were centrifuged at 1250 x g for 5 min and washed 6x with RIPA 
buffer followed by a wash with 1ml of Factor Xa Cleavage buffer (50mM Tris.Cl pH 8.0, 
100mM NaCl, 1mM CaCl2). The beads were resuspended in 0.95ml of Factor Xa cleavage 
buffer and incubated with 50u of Factor Xa overnight in a microfuge tube at room temperature 
with shaking. The beads were collected by centrifugation at 1600 x g for 5 minutes and the 
supernatant was transferred to a fresh tube. The beads were washed once with 1ml Factor Xa 





500mM NaCl, 1mM CaCl2). The supernatants from the overnight incubation and the washes 
were collected, pooled together and kept at -20ºC till ready for benzamidine sepharose 
separation from bound Factor Xa. Before fractionation with HiTrap™ Benzamidine, the 
syringe driven columns were washed with 5ml (5 column volumes) of water followed by 
equilibration with 5 ml of Binding Buffer (20mM sodium phosphate, 0.15M NaCl). The 
pooled supernatants were passed through the column at a flow rate of 1ml/min and eluates 
were collected in 1ml fractions in microfuge tubes. To collect the eluates containing purified 
MptpA, 40ml of High Salt elution buffer (20mM sodium phosphate, 1 M NaCl) was passed 
through the column. To confirm the protein isolation, 30µl from each fraction was boiled at 
95ºC with 1x Laemmli buffer for 5 min and resolved on 12.5% SDS-PAGE gel followed by 
Rapid Coomasie staining of the acrylamide gels. The fractions with the MptpA proteins were 
pooled and incubated with 10mM dithiothreitol for 30 minutes at room temperature to reverse 
any oxidation in the cysteine active site of the phosphatase enzyme. Then, 10ml of the pooled 
fractions were dialysed for 12 hours in a 3500 MWCO 12ml dialysis cassette (Pierce) with 
2.5L of 20mM sodium phosphate buffer pH 7.5. The buffer was changed every 3 hours and the 
dialysed proteins were assessed for protein concentration with the Micro BCA Protein Assay 











2.2.7.2  Rapid Coomasie Staining 
Acrylamide gels were soaked in isopropanol fixing solution (25% isopropanol, 10% acetic 
acid) for 15 minutes before overnight staining in Coomasie solution (0.006% w/v Brilliant 
Blue G-250 in 10% acetic acid). The background stain was removed by washing the gels in 
destaining solution (10% acetic acid) with small pieces of cut sponges to speed up the 
destaining process. Once the background has cleared, the gels are dried between cellophane 
sheets with a vacuum gel dryer system. 
2.2.7.3 Preparation of phosphorylated Myelin basic protein 
Myelin basic protein (MBP) substrate was phosphorylated at tyrosine residues using 
recombinant SrcN1 Kinase (Sigma). MBP (10µg) was incubated with 0.2µg of recombinant 
SrcN1 in 20µl of kinase buffer (20mM HEPES pH 7.5, 10mM MgCl2, 1mM DTT, 0.2mM 
Na3VO4, 1mM ATP) for 30 minutes at 30ºC. Excess unincorporated ATP was removed by the 
addition of 20µl of 50% trichloroacetic acid to terminate the reaction. The reaction was 
incubated on ice for 30 minutes before centrifugation at 12500 x g for 10 minutes at 4ºC. The 
pellet obtained was washed with 0.3ml of acetone and centrifuged again. The pellet was air 
dried (~10 minutes) and resuspended in 20µl of 20mM Imidazole pH 7.4. 
2.2.7.4  Phosphatase Assay with Myelin Basic Protein 
Phospho-MBP (0.5µg) was incubated with 0.5µg of purified MptpA in phosphatase buffer A 
(6.7mM PIPES, 5mM MgCl2, pH 7.0) and 10nM staurosporine, with or without the addition 
2mM DTT in a total of 30µl volume. The reaction mixture was incubated at 37ºC for 2hours. 
A time dependant assay (5, 10, 15 and 30 mins) was also performed. The reaction was 
terminated by boiling at 95ºC with Laemmli buffer (62.5mM Tris.Cl pH 6.8, 10% glycerol, 
2% SDS, 0.05% Bromophenol blue, 5% β-mercaptoethanol) and the samples were separated 





2.2.7.5  Treatment of MGH cells with epidermal growth factor (EGF) and MptpA 
MGH cells were seeded at a density of 0.5x105 cells per well in a 6 well plate and left to 
incubate for 3 days in a total volume of 3ml of RPMI. Then 10ng/ml of recombinant human 
EGF was added to each well in fresh RPMI media and incubated for 30 minutes. Purified 
MptpA was added to the culture at a 0.5µg/ml and 5µg/ml concentration for 2 hours. To 
harvest, the cells were washed 3x with ice-cold 1x PBS and scraped in 1ml of 1x PBS. The 
yield from 3 wells were combined and lysed in IP lysis buffer with 1mM Na3VO4, 1mM NaF, 
1mM PMSF and 1x protease inhibitor cocktail from Roche, for 30 minutes on ice. The lysates 
were centrifuged at 10 000 x g for 10 minutes at 4ºC and the supernatants were transferred to 
fresh microfuge tubes. The total protein content was measured using the MicroBCA Protein 
Assay Kit (Section 2.2.7.9). 
2.2.7.6  Treatment of MGH cells with purified MptpA for immunoblotting  
MGH cells were plates as mentioned in Section 2.2.7.5 and treated with 100µM of sodium 
orthovanadate (Na3VO4, prepared as 100mM stock in deionized water) for 1 hour before 
treatment with purified MptpA at 0.1, 0.5, 1, 5 and 10µg/ml concentration in fresh media. For 
BCG co-treatment, 2x107 cfu bacteria were added. The cells were rinsed 3 times with ice-cold 
1x PBS before lysing directly on culture plates with 200µl boiling lysis buffer. The viscous 
lysates were scraped from the wells and the DNA lysed by passaging 3-5 times through a 27G 
needle and syringe into microfuge tubes heated at 100ºC and boiled for 5 minutes to inactivate 
any remaining proteases. Samples were centrifuged at 13000 x g for 5 minutes at 4ºC to 
remove any insoluble materials. Protein concentrations were determined with the MicroBCA 
Protein Assay kit (Section 2.2.7.9). Approximately 0.5µg of proteins were boiled at 95ºC for 5 
minutes in Laemmli buffer, resolved on a 7.5% SDS-PAGE gel and transferred to a 





2.2.7.7  Immunoprecipitation of EGFR 
Approximately 250µg of cell lysate (from Section 2.2.7.5) was incubated with 2µg of 
monoclonal anti human EGFR for 1 hour at 4ºC on a rocking platform. 20µl of Protein A 
conjugated agarose beads that was pre-washed with IP lysis buffer were added to the lysate 
and incubated for another 1 hour. The agarose beads were collected by centrifugation at 10 000 
x g for 5 minutes and washed with pre-chilled IP lysis buffer 3 times. Then 30µl of 1x 
Laemmli buffer was added to the beads and boiled at 95ºC for 5 minutes followed by loading 
on 7.5% SDS-PAGE gel. The resolved proteins were transferred to a nitrocellulose membrane 
and probed with HRP conjugated anti-phosphotyrosine antibodies followed by anti-EGFR 
antibodies. 
2.2.7.8  Immunoblotting with phosphotyrosine, EGFR, MBP, actin and phospho-specific 
antibodies. 
Membranes were blocked in blocking buffer overnight at 4ºC with blocking buffer (TBST 
with 1% BSA) and probed with horseradish peroxidase (HRP) conjugated anti 
phosphotyrosine antibodies at a 1:5000 dilution for 1hr at room temperature. The membranes 
were then washed 6 times with 30 ml of TBST for 5 minutes with agitation. The blots were 
then incubated with 1 ml of Supersignal West Pico chemiluminescent substrate for 1 min 
before signal detection with SynGene G-box machine. The blots were then stripped with 
Restore Western Blot Stripping buffer for 10 minutes at room temperature (with gentle 
agaitation) and washed 2 times with 30 ml of TBST before overnight blocking with 5% non fat 
milk in TBST. The membranes were then probed with anti-EGFR (1:1000), anti-MBP 
(1:1000) or anti-actin (1:1500) antibodies for 1hour at room temperature followed by 6 washes 
with TBST as mentioned above. Secondary antibody probing was done at 1:10000 dilution 
(for Pierce HRP conjugated secondary antibodies) or 1:5000 (HRP conjugated donkey anti rat 





For phospho-specific antibodies, the membranes were probed with a 1:1000 dilution (1:2000 
for ERK) of antibodies in TBST with 1% BSA (p38, ERK and paxillin). Phosphorylated Akt 
(1:2000 dilution) and phosphorylated p53 (1:1000 dilution) antibody probing was done in 
TBST with 5 % non fat milk. Membranes were stripped of the antibody signal with Restore 
Blot and then were washed twice with TBST before overnight blocking followed by probing 
with specific antibodies (p38, Akt, ERK, p53 and Paxillin) in TBST with 5% non fat milk at a 
1:1000 dilution. 
2.2.7.9  Measuring protein concentration with MicroBCA Assay Kit 
Protein samples to be assayed were diluted 100 times in water and 100µl of diluted samples 
and prepared albumin standards were aliquoted in a 96 well plate before the addition of 100µl 
of working reagent. A similar dilution of the lysis/ resuspension buffer was used as a blank for 
the assay. The working reagent is prepared by adding MicroBCA Reagent A, B and C in a 
25:24:1 ratio. The mixture was incubated at 37ºC for 2 hours and the absorbance read at 
570nm using the Tecan GENios machine with the Magellan 5 software. The concentrations of 
the protein samples were determined using the albumin standard curve from the same assay 
plate (Figure 2.6). 
 





2.2.8  In vitro effects of MPTPA on bladder cancer cell line and ex vivo on mouse 
Neutrophil-DC interactions 
2.2.8.1  The signalling and cell cycle regulatory effects of MPTPA on MGH cell line 
2.2.8.1.1  Cell Cycle analysis 
MGH cells were seeded at a density of 2x105 cells per well in 6 well plates overnight and 
treated with purified MptpA at 0.1, 0.5, 1, 5 and 10µg/ml in fresh RPMI the next day for 24 
hours. The cells were washed 3 times with ice-cold 1x PBS and harvested by treating the cells 
with cell dissociation solution at 37ºC for 5-10 minutes. Cells were centrifuged at 7500 x g for 
5 minutes at 4 ºC and fixed overnight with ice-cold 70% ethanol. The next day, the pellet was 
collected by centrifugation at 12 500 x g for 10 minutes and resuspended in 300µl of PI 
staining solution containing 50µg/ml propidium iodide, 100U/ml RNAse A in glucose sample 
buffer. The cells were stained at room temperature for 30 minutes and filtered through a nylon 
monofilament mesh screen with 44µ openings to remove any multicellular aggregates before 
flow cytometry analysis using the FACS Canto machine. A typical PI staining profile is 
provided in Figure 2.7. 
 





2.2.8.1.2  Effects of MPTPA on MGH gene expression of GSTT2 and TNFα . 
MGH cells were plated as in Section 2.2.4.2 overnight at 37ºC and treated with purified 
MPTPA at a 0.5µg/ml and 5µg/ml concentration in total 3 ml volume of RPMI media for 2 
hours. Total RNA were isolated and converted to cDNAs followed by PCR amplification of 
GSTT2, TNFα, and Rps27A genes according to the protocols in Sections 2.2.4. 
2.2.8.1.3  Preparation of cells for Human Phosphokinase Array. 
MGH cells were seeded as in Section 2.2.7.5. Recombinant human EGF (10ng/ml) were added 
to each well and incubated for 30 minutes followed by treatment with 100µM sodium 
orthovanadate for 1 hour. Then 5µg/ml purified MPTPA, 2x107 cfu lyo BCG or both were 
added to each well and incubated for 2hrs in a total volume of 3ml. The cells were washed 3x 
with ice cold 1x PBS and harvested with a cell scraper in 1 ml 1x PBS. To obtain enough 
samples, 6 wells of the same sample were combined together and centrifuged at 450 x g for 5 
minutes. The pellet obtained was then lysed in 200µl of Lysis Buffer 6, which was provided in 
the Human Phosphokinase array kit, for 30 min in the cold room with gentle shaking. The 
lysate was centrifuged at 14,000 x g for 5 min and the supernatant was transferred to a new 
tube. The amount of total proteins in the lysate was determined with MicroBCA Protein 
Assay Kit (Section 2.2.7.9). The lysates were kept in -80ºC till ready for use. For western blot 
validation of phosphokinase array data, the cells are plated and treated as above, with 2 
additional treatment groups of 2x107 cfu live BCG and live BCG with MPTPA co-treatment. 
Proteins were harvested as in Section 2.2.7.6 and immunoblotting with phospho-specific 
antibodies were carried out as in Section 2.2.7.8. 
2.2.8.1.4  Human Phosphokinase array assay 
The Human Phosphokinase array was used according to manufacturer’s instructions. Briefly, 
the arrays are blocked in 1ml of Array Buffer 1 for 1hr at room temperature on a rocking 





Buffer 1 was then added to each membrane. The lysate was incubated with the membrane 
overnight in the cold room on a rocking platform. The arrays were then rinsed briefly with 
deionized water before washing 3 times for 10min with 1x Wash buffer. The arrays were 
incubated with 1ml of Detection Antibody Cocktail A diluted with 1x Array Buffer 2/3 for 2 
hours at room temperature on a rocking platform. The membranes were washed 3 times with 
1x wash Buffer and incubated with 1ml of Strepavidin-HRP diluted in 1x Array Buffer 2/3 for 
30 min at room temperature with shaking. The membranes were then washed in a container 
with 20ml of 1x Wash buffer followed by a brief rinse with deionized water and another 3 
washes with 1x wash Buffer for 10 minutes on a rocking platform. The membranes were 
incubated with 1ml of SuperSignal West Pico substrate and the chemiluminescent signal was 
detected by X-ray exposure. Densitometry analysis of the spots on the array was quantified 
using GeneTools image analysis software. 
2.2.8.2  Effects of MptpA on Neutrophil-DC interactions 
2.2.8.2.1  Mouse bone marrow cells preparation 
Mouse bone marrow cells were obtained from healthy female C57BL/6 mice (aged 8-10 weeks 
old) from the femur and tibia of euthanized mice. The muscles and tendons were removed 
thoroughly from the bones using a scalpel blade and scissors on a Petri dish. The femur was 
cut near the joint and all the bone marrow contents were flushed out with 10ml complete 
RPMI media (per mouse) using a syringe attached to a 22G needle. The flushing procedure 
was repeated for all harvested bones. The flushed bone marrow cells were passed through a 
22µm cell strainer to yield single cells. The cells were centrifuged at 800 x g for 5 min. 
Supernatant was removed and cells were resuspended in 1ml (per mouse) of RBC lysis buffer 
(150mM NH4Cl, 10mM KHCO3 and 0.1mM EDTA) for 5 min at room temperature. The cells 
were centrifuged again for 5 min and washed 2x with 1x PBS. The cells were resuspended in 





2.2.8.2.2  Purification of Neutrophils and Dendritic cells (DC) from bone marrow cells 
preparation 
Mouse bone marrow neutrophils were purified by positive magnetic selection using anti-Ly6G 
mouse microbeads kit according to manufacturer’s protocol. Briefly, mouse bone marrow cells 
were incubated with anti-Ly6G biotin antibody in MACS buffer followed by incubation with 
anti-biotin microbeads antibodies. Cells were washed with 5ml of MACS buffer after 
incubation and centrifuged at 300xg for 10 min. Pelleted cells were resuspended in 500µl of 
MACS buffer and positive cells were isolated using magnetic selection. Mouse DC was 
prepared by culturing the prepared bone marrow cells in HEPES buffered RPMI media 
supplemented with 1% MEM, 50µM β-mercaptoethanol, 0.1% sodium pyruvate, 10% FBS 
and 40ng/ml recombinant murine GM-CSF at a density of 1x106 cells/ml in petri dishes. The 
media was changed once every 3 days with the non- adherent cells consistently centrifuged at 
300 x g for 10 min to pellet it down for continuous culture. The non-adherent cells were 
collected on the 9th day of culture, enumerated and used for experiments. Neutrophil purity 
was determined with anti-Ly6G RPE staining, while mouse DC purity was ascertained with 
anti-CD11c APC antibodies. FACS analysis was performed on BD FACS Canto Flow 
Cytometer. Combined percentage purity profiles of DCs and purified neutrophils in all the 







Figure 2.8: Percentage purity of a) cultured DCs and b) purified neutrophils isolated ex 
vivo for Neutrophil-DC interaction studies. 
 
2.2.8.2.3 BCG internalization comparisons between purified neutrophils and generated 
DCs. 
Neutrophils (5x105) and DCs (2.5x105) were plated overnight before treatment with FITC 
labelled live BCG in a 1:5 cell to bacteria ratio and incubated for 2 and 24 hours. Cells were 
harvested by scraping and analysed for internalized and membrane bound FITC BCG by flow 
cytometry. The signal for internalized BCG was obtained by quenching surface FITC BCG 
signal with 0.2% trypan blue and crystal violet in sodium acetate buffer (pH 5.2) for 5 minutes. 
10000 cells were collected for analysis with the BD FACS Canto flow cytometer. Mean 
Fluorescence Intensities (MFI) were analysed with the WinMDI software. 
2.2.8.2.4  Mouse Neutrophil-DC co-cultures 
Both 5x105 neutrophils and 2.5x105 DCs were co-cultured (2:1 ratio) in 1.5ml of complete 
DMEM supplemented with 10% FBS, 5mg/ml Penicillin G, 2mM L-Glutamine, 50µM β-
mercaptoethanol and 40ng/ml recombinant mouse GM-CSF in a 24 well plate format. For 2 
hours bacteria pre-treatment, neutrophils and DCs were treated with 2.5 x106 cfu live BCG for 





at 37ºC. Killed bacteria were removed by washing the cells 3x with 1x PBS followed by the 
addition of 1.5ml fresh media. For BCG treated neutrophil-DC co-culture, fresh DCs were 
added to the neutrophils and the media were kept to 1.5ml total volume. The cells were 
incubated for 18 hours before the cells and supernatants were harvested for cell surface marker 
staining and cytokine analysis respectively. 
2.2.8.2.5  DC surface marker expression analysis 
Mouse DCs were doubly stained with anti-CD11c APC antibodies and with RPE or FITC 
conjugated antibodies specific for MHCII, CD80, CD40, CD83, and the appropriate isotype 
controls. Staning protocol was done as in Section 2.2.4.3. For analysis 10000 CD11c positive 
cells were collected with the BD FACS Canto flow cytometer. Analysis was done with the 
FACSDiva software and only CD11c+ cells were analysed for surface marker expression.  
2.2.8.2.6  Cytokine analysis 
Murine IL10, IL2, TNFα, IL12p70 and IL12p40 as well as human TNFα were measured with 
ELISA kits. Immuno-MaxiSorp ELISA modules were coated overnight with the capture 
antibody provided in the kits according to manufacturer’s protocol. The plates were washed 
with Wash Buffer (1x PBS with 0.05% Tween 20) the following day and blocked with 300µl 
of Reagent Diluent (1xPBS with 1% BSA). A 100µl of supernatants and standards were added 
in each well and left to incubate for 2 hours at room temperature. The cytokines in the 
supernatant were then detected with polyclonal biotin conjugated anti-human/mouse cytokine 
specific antibodies for 2 hours at room temperature followed by Strepavidin-HRP enzyme 
conjugate incubation. A 100µl of substrate solution [1:1 mix of 3,3´,5,5´-tetramethylbenzidine 
(TMB) and hydrogen peroxide] was added to each well and the colour reaction was monitored 





2.2.9  Statistical analysis 
Comparisons among three or more groups were performed with descriptive ANOVA with 
Bonferroni analysis using SPSS software. For comparisons between two groups, an 











Studying the effects of intravesical 
live BCG instillations in mice  
 
There's two possible outcomes: if the result confirms the hypothesis, then 
you've made a discovery. If the result is contrary to the hypothesis, then 
you've made a discovery. 






Intravesical immunotherapy with commercial lyophilized Mycobacterium Bovis bacillus 
Calmette-Guerin (BCG) has been the gold standard for treatment of superficial bladder 
carcinomas. The local immune response induced following BCG instillation had been 
attributed to its anti tumourigenic activity and a TH1 polarized immune response is thought to 
be largely implicated in clinical efficacy.  
de Boer et al examined the TH1 and TH2 cytokines expressed after 6 once weekly intravesical 
of commercial lyophilized BCG (Connaught strain) instillations in healthy C57BL/6 mice and 
found significantly elevated expression of IFNγ, IL2, TNFα, IL12p40 (TH1), IL10 and IL4 
(TH2) transcripts. When heat killed BCG was used in their study in a modified protocol, 
production of TH1 cytokines were abrogated compared to standard treatment with viable 
BCG. Hence, a live viable BCG preparation is required for the expression of TH1 cytokines. 
The response of normal mice to BCG therapy was similar to that of tumour bearing mice and 
unlike tumour bearing mice which succumbed to the disease during the course of the study, 
there is reduced loss of sample size as normal mice survive better [171]. 
Since there are no published studies done on the effects of live BCG, from continuous culture 
source, in vivo in mice bladder, we investigated the ability of live BCG to induce the same 
levels of immune response. Healthy C57BL/6 mice (n=6 per group) were instilled with live 
BCG in our study once a week for 6 weeks and samples were analyzed after the 4th, 5th and 6th 
instillations. Inflammatory cytokines, chemokines and receptor gene expression in the bladder 
were evaluated using a membrane based microarray and the results were validated by RT-
PCR. At the same time, bladders and iliac lymph nodes were harvested from another set of 





3.1. BCG treatment induces phenotypic changes in the iliac lymph nodes. 
BCG treated mice were found to have enlarged iliac lymph nodes compared to control 
(Figure3.1) at all time points. Single cell suspensions from the bladder and lymph nodes were 
prepared and enumerated. The lymph nodes from the BCG treated mice had significantly 









Figure 3.1: Morphological change of the iliac lymph nodes after BCG treatment. 
Representative pictures documenting the difference in lymph node sizes between control and 




Table 3.1: Average cell numbers in the bladder and lymph node with and without BCG 
instillation in the bladder. 
 
  Sample cell counts ( x 104 cells) 
 Group 4 weeks 5 weeks 6 weeks 
Bladder Control 30.23 ± 5.7 28.96 ± 5.25 38.54 ± 8.32 
BCG 33.4 ± 5.6 40.67 ± 3.84 56.1 ± 6.78 
Iliac Lymph 
Node 
Control 14.17 ± 3.8 141.2 ± 34.75 25.85 ± 5.08 
BCG 209.2 ± 69.4* 739.8 ± 172.1* 751.3 ± 238.1* 





3.2 Expression of immune related genes induced by BCG instillations in the 
bladder 
3.2.1 Pathway specific array analysis of mouse bladder specimens. 
One bladder sample from each group after the 6th week was used to study the expression 
profile of inflammatory cytokines and receptor genes with a membrane based microarray. The 
membrane probed with labelled BCG cRNA shows up-regulated genes compared to that 
probed with control sample (Figure 3.2). After analysis and normalizing with endogenous 
control genes, only the transcripts that show more than 2-fold increased expression were 
considered for further RT-PCR validation. BCG was found to induce the expression of 13 
genes with respect to PBS instilled control (Table 3.2).  
 
Figure 3.2: X-Ray images of OligoArray differential gene analysis. Mice were treated with 
BCG or 1xPBS (control) in a once weekly instillation schedule for 6 weeks. The bladders 
were harvested from 6 hours after the last instillation schedule and were used for preparing 
the biotinylated cRNA for the microarray procedure. The signal was detected by X-ray 
exposure to the membrane. Live BCG membrane reveals up-regulation of inflammatory 





Table 3.2: Genes that were found to be more than 2-fold up-regulated in the BCG 
treated samples from the microarray analysis 
Symbol RefSeq No Fold Increase 






































3.2.2 RT-PCR analysis of BCG induced gene up-regulation in the mouse bladder 
Semi-quantitative RT-PCR was performed on 31 genes to validate the microarray data. The 
genes that were selected include genes that were not found on the microarray analysis as well 
as the housekeeping GAPDH gene. The bladders from the mice treated for 4 and 5 
consecutive weeks were also analysed.  
The transcripts analysed from the BCG treated bladder samples at all time points revealed 
expression of several inflammation and TH1 associated chemokines and cytokines (Figure 
3.3). At 4 weeks, the expression of lymphocyte attracting chemokines IL1β, Cxcl2, Cxcl9, 
Cxcl10, Ccl2 and Ccl7 were observed. The expression of Xcl, iNOS, Ccl5 and TNFα was 
observed at 4 weeks and were maintained at significantly higher levels in the BCG treated 
samples at the 5th and 6th week of treatment. The expression of FcεR1g, a surface receptor 





significantly in the BCG treated samples at 4 weeks. Expression of Cxcl9 was found to be 
significantly enhanced in the BCG treated bladders at all time points and significant Cxcl10 
levels were maintained up to 5 weeks.  
Increased expression of Cxcl2 was observed again at 6 weeks along with the expression of 
macrophage attractant Ccl6 and the surface receptor FcγR1. Besides IL1β and TNFα, the 
expressions of other pro-inflammatory cytokines were also observed. However, IL2, IFNγ, 
IL12p35 and IL12p40 transcripts were only detectable at the 6th week and BCG treatment did 
not significantly modulate the expression levels of these cytokines (Table 3.3). Expression of 
the anti-inflammatory TH2 cytokine IL10 was also observed at 6 weeks.  
IL16, IL18 and IL1r2 expressions were observed at all the time points but were not found to 
be significantly regulated by BCG treatment (Table 3.3). Levels of GMCSF, as well as the 
TH2 associated chemokines, Ccl17 and Ccl22 were undetectable in all the bladder cDNA 
samples. In order to investigate the possible immune suppressive functions associated with 
BCG treatment, the expression of Foxp3 and TGFβ were analysed and were found to be 






Table 3.3: Intensity analysis of RT-PCR bands from the cDNA samples of mice bladders  
 4 weeks 5 weeks 6 weeks 
Gene Control BCG Control BCG Control BCG 
Ccl8 0.91 ± 0.21 6.43 ± 4.19 1.21 ± 0.23 1.15 ± 0.4 2.82 ± 1.57 1.44 ± 0.84 
Ccl2 ND 0.17 ± 0.1* 0.76 ± 0.69 1.28 ± 0.43 0.06 ± 0.04 0.09 ± 0.06 
Ccr2 ND ND ND ND 0.01 ± 0.01 0.09 ± 0.04 
Ccl21a 0.16 ± 0.11 0.12 ± 0.07 0.15 ± 0.2 0.3 ± 0.3 0.21 ± 0.41 0.53 ± 0.32 
Cxcl10 0.61 ± 0.17 4.74 ± 2.81* 0.12 ± 0.06 0.09 ± 0.08 2.47 ± 1.8 1.27 ± 0.38 
Cxcl14 ND ND ND ND 0.88 ± 1.2 0.45 ± 0.24 
Cxcl2 0.31 ± 0.11 1.44 ± 0.64* 0.09 ±0.08 0.18 ± 0.22 0.38 ± 0.36  0.82 ± 0.14* 
Cxcl9 0.06 ± 0.05 2.29 ± 0.34* 0.13 ± 0.14 1.26 ± 0.39* 0.12 ± 0.09 0.59 ± 0.44* 
Fcεr1g 0.56 ± 0.1 3.97 ± 2.13* 0.5 ± 0.42 0.6 ± 0.46 2.63 ± 1.92 1.22 ± 0.29 
Fcγr1 0.09 ± 0.02 0.2 ± 0.08 0.04 ± 0.02 0.11 ± 0.11 0.09 ± 0.04 0.36 ± 0.21* 
iNOS 0.04 ± 0.04 1.54 ± 0.53 0.63± 0.13 0.95 ± 0.22* 0.07 ± 0.04 0.75± 0.33* 
Xcl1 ND 0.25 ± 0.28 0.07 ± 0.3 0.58 ± 0.25* 0.03 ± 0.02 0.18 ± 0.11* 
Ccl5 0.12 ± 0.01 2.2 ± 1.18 0.03 ± 0.02 0.13 ± 0.06* 0.52 ± 0.34 1.08 ± 0.24* 
Ccl6 0.21 ± 0.2 0.59 ± 0.25 0.59 ± 0.35 0.27 ± 0.12 0.24 ± 0.24 0.57 ± 0.23* 
Ccl7 0.37 ± 0.31 2.21 ± 0.75* 0.17 ± 0.09 0.24 ± 0.06 1.52 ± 1.9 0.92 ± 0.27 
TNFα 0.1 ± 0.05 1.08 ± 0.87 ND 0.09 ± 0.07* 0.27 ± 0.2 0.56 ± 0.19* 
IL2 ND ND ND ND 0.01 ± 0.09 0.45 ± 0.56 
IFNγ ND ND ND ND 0.05 ± 0.08 0.11 ± 0.14 
IL10 ND ND ND ND 0.72 ± 1.3 0.59 ± 0.63 
IL12p35 ND ND ND ND 0.05 ± 0.07 0.11 ± 0.11 
IL12p40 ND ND ND ND 0.1 ± 0.21 0.17 ± 0.11 
IL1β 0.02 ± 0.01 0.24 ± 0.09* 0.01 ± 0.01 0.03 ± 0.03 ND ND 
IL1r2 0.31 ± 0.07 2.5 ± 1.3 1.33 ± 0.64 0.97 ± 0.57 0.67 ± 0.2 0.4 ± 0.18 
IL16 0.02 0.11 ± 0.1 0.28 ± 0.07 0.3 ± 0.14 0.6 ± 0.55 0.3 ± 0.19 
IL18 0.42 ± 0.1 1.77± 1.26 0.03 ± 0.02 0.04 ± 0.04 0.38 ± 0.2 0.26 ± 0.2 
Data represented as mean ± SD. * denotes significant difference from control (p<0.05). `ND’ 
indicates not detectable. Ccl17, Ccl22, GM-CSF, TGFβ and Foxp3 were not detected during 









Figure 3.3: RT-PCR gel analysis of the various genes that were significantly up-regulated compared to control. The array data analysis was verified by 
PCR analysis of the cDNA samples from the bladders of mice treated once weekly for 4, 5 and 6 weeks with BCG or 1xPBS (control). The genes above were 






3.3 Increased lymphocytes were observed in the bladder and iliac lymph nodes 
(ILN) after BCG instillation 
BCG treatment augments the increase in the percentage of cytotoxic T cells (CD3+CD8+) at 
the 4th and 6th week in the bladder significantly. Cytotoxic T cells levels were also increased 
in the ILN of BCG treated mice at 6 weeks treatment. NK cell numbers was significantly up-
regulated in both the bladder and ILN at 6 weeks. Macrophage population in the ILN was not 
regulated by BCG treatment but was increased significantly in the bladder at 5 weeks (Table 
3.4a). BCG treatment increased the CD8+/CD4+ population in the bladder, indicating a 
response towards cytolytic activity in the bladder. 
Regulatory T cell populations were studied by analysing the Foxp3+ population. Foxp3+ 
population did not appear to be modulated by BCG treatment in the bladder. However, the 
percentage of Foxp3+ cells was significantly increased in the ILN at 4 weeks (Table 3.4b).  
Due to the enlargement of the LN, even though the populations of some of the immune cells 
were not significantly increased in terms of percentage, the total numbers of cells were 
generally increased in the BCG treated samples when compared to control. There is an 
observed increase in levels of all the immune cell populations studied from 4 weeks to 6 
weeks with time. However, this increase is not associated with BCG treatment and it may be 






Table 3.4: Percentage of immune cell recruited to the bladder and iliac lymph nodes. 
Data represented as percentage mean ± SEM. * denotes significantly different from control 
(p<0.05). 


















Control 1.4 ± 0.74 13.5 ± 0.56 10.7 ± 1.7 
BCG 0.61 ± 0.1 11.3 ± 0.99 12.9 ± 2.7 
ILN 
Control 0.77 ± 0.37 8.3 ± 1.1 18.4 ± 3.0 


















Control 0.18 ± 0.02 11.7 ± 0.55 7.9 ± 1.3 
BCG 0.32 ± 0.04* 12.3 ± 0.83 13.4 ± 0.75* 
ILN 
Control 0.13 ± 0.06 9.47 ± 1.7 14.1 ± 3.6 






Control 1.3 ± 0.25 31.1 ± 3.0 23.0 ± 3.1 
BCG 1.9 ± 0.28 16.7 ± 0.93* 45.6 ± 1.9* 
ILN 
Control 0.91 ± 0.34 9.9 ± 2.8 22.2 ± 2.4 









Control 5.9 ± 1.2 8.0 ± 1.6 46.2 ± 7.2 
BCG 7.2 ± 1.6 13.6 ± 0.93* 46.0 ± 1.9 
ILN 
Control 3.4 ± 0.52 11.5 ± 1.3 49.0 ± 5.0 









Control 0.34 ± 0.08 6.1 ± 1.3 4.6 ± 1.2 
BCG 0.3 ± 0.02 9.5 ± 1.6 4.5 ± 0.5 
ILN 
Control 0.38 ± 0.09 2.1 ± 0.37 1.8 ± 0.28 

















Control 1.04 ± 0.29 13.79 ± 1.2 10.3 ± 2.5 
BCG 2.21 ± 0.73 6.19 ± 1.9* 8.9 ± 1.4 
ILN 
Control 2.82 ± 1.4 10.0 ± 1.1 8.3 ± 0.83 



















Control 0.97 ± 0.21 3.98 ± 1.09 10.3 ± 2.3 
BCG 3.12 ± 0.1 1.64 ± 0.28 9.7 ± 2.3 
ILN 
Control 0.51 ± 0.2 11.2 ± 1.62 7.24 ± 1.1 





3.4 Discussion 1 
 Gene expression in the bladder was monitored from 4 to 6 weeks as it has been previously 
demonstrated that using a weekly dosing schedule there are observable chemokine and 
cytokine responses in patients and in mice by the 4th week [15,38,171]. While the GAPDH 
expression appeared downregulated at on the 4th week in the BCG treated samples, it may be 
a RNA quality issue as GAPDH levels were consistently similar to control levels on the 5th 
and 6th week of treatment.  
We found that correlation of the pathway specific microarray with RT-PCR results was 
generally very poor. In our in vivo studies, we used one bladder sample from 6 weeks live 
BCG treated mice to perform the array analysis and out of the 13 genes that was found to be 
more than 2-fold up-regulated by live BCG, only 4 were significantly increased from the RT-
PCR analysis (31%). This could be due to unsual or unpredictable hybridizations leading to 
false positive results on the array. Also, the microarray was performed once with a one 
sample from each group whereas the RT-PCR result is the sum of all the animals in the 
sample group.  
Gene expression analysis revealed that live BCG treatment induced a vast chemokine 
response in the bladder that is maintained till 6 weeks, even though the expression profile for 
each week is different. The chemokine response appears to be pro-inflammatory in general. 
Live BCG up-regulates chemokines Cxcl9, Cxcl10, Cxcl2, Ccl2, Ccl7, Xcl1, Ccl5 and Ccl6 
as well as TNFα and IL1β cytokines. FcεR1γ, FcγR1 and iNOS transcripts were also up-
regulated. Ccl5, Ccl2 and Cxcl10 have previously been detected in the urine of patients after 
BCG therapy [172,173]. Certain chemokines like Cxcl9 and Cxcl10 were progressively up-
regulated in the bladder from 4-6 weeks. These chemokines are known to have angiostatic 
effects, and may have a role in containing the tumour within the bladder microenvironment as 
well as to attract and stimulate the activation of CD8+ T cells and NK cells [174]. Ccl7 are 





cooperate with Cxcl10 to orchestrate the recruitment of neutrophils [175]. Ccl2 and Cxcl2 
attracts macrophages and polymorphonuclear cells and Ccl6 are chemoattractants for NK 
cells[176]. Cytolytic cells such as NK and CD8+ T cells can co-release Ccl5 along with the 
contents of their cytolytic granules that can cause cytolysis [177]. Ccl5 is chemotactic for 
macrophages and monocytes. Activated NK cells can produce Xcl1 which can recruit T cells 
and neutrophils [176,178]. TNFα expression is possibly expressed by macrophages to control 
intracellular BCG growth [179]. IL1β is an important mediator of inflammation and has a role 
to play in attracting neutrophils [180]. The expression of iNOS and FcγR1 in the bladder 
correlates with the recruitment of macrophages which can phagocytose BCG. Increased 
FcεR1γ indicates the recruitment of mast cells, basophils and eosinophils to the bladder.  
The immune population profile in the bladder is consistent with previous findings that BCG 
induced anti-tumour activity are largely effected by CD8+ T cells and NK cells [26,31]. The 
ratio of CD8+/CD4+ T cells was increased in the bladder after BCG treatment and this is 
indicative of a predominantly cytotoxic response. The enlargement of ILN indicates that BCG 
treatment induced immune cell recruitment or proliferation in the ILN. The pattern of 
chemokine and receptor expression suggests the involvement of other immune effector cells 
such as neutrophils, basophils monocytes and antibody producing B-cells in BCG treatment 
(Figure 3.4). 
In comparison with the de Boer study [171], we did not detect the transcriptional up-
regulation of IL4, IL2, IL10, IFNγ and IL12p40 levels in the live BCG treated bladders. This 
may be attributed to the more potent effect of lyo BCG activity on immunostimulation, as 
there are more bacterial components exposed during treatment when compared to live BCG. 
However, live BCG recruited immune cells to the bladder as well as lyo BCG and this 
recruitment was mediated by chemokines. This does not mean that lyo BCG does not induce 
chemokine expression. Rather chemokine expression has not been as extensively evaluated as 





ability of both BCG preparations to recruit immune cells it would be interesting to evaluate 
their anti-tumour abilities. 
 
 
Figure 3.4: The cytokine and chemokine network involved in cultured BCG instillations 
in the bladder. The cytokines and chemokines in the bladder orchestrate the influx of 
immune cells to the instillation site.  IL1β and Cxcl2 are chemotactic for neutrophils, while 
Cxcl2 and Ccl2 are attractants for macrophages. Cxcl9 and Cxcl10 are chemotactic for 
neutrophils and CD8+ cytotoxic T cells and are also important angiostatic chemokines, while 
Ccl7 drives monocyte, mast cells, eosinophils and basophil trafficking. Expression of 
FcεR1γ (  ) indicates the IgE mediated uptake of BCG antigens.  iNOS and Xcl1 expression 
correlated with macrophage influx at 5 weeks. Cxcl2 and Ccl6 are chemoattractants for 
neutrophils and NK cells respectively.  Ccl5 have been known to be co-released from NK 
and CD8+ Cytotoxic T cells along with the contents of their cytolytic granules.  TNFα 
expression is an important regulator for macrophage control of intracellular growth of 
mycobacteria and Cxcl9 are chemotactic CD8+ cytotoxic T cells. Expression of FcγR1 (  ) 
indicated IgG mediated uptake of BCG particles, and are most probably expressed on 











Comparisons of live and lyophilized 
BCG treatment on gene expression 
and ROS production in human 







Previous studies done in our lab showed that lyophilized BCG treatment of a human bladder 
cancer cell line, MGH, caused a reduction in cellular ROS levels. A combination treatment of 
lyo BCG and NAC, a GSH donor, augmented its cytotoxicity. It was proposed that BCG 
induced cytotoxicity is mediated by ROS reduction and GSH played a role in the decrease in 
ROS [169]. The effect of GSH on the BCG induced cytotoxicity does indicate a possible role 
for glutathione-S-transferases in the responses induced by BCG.  Glutathione-S-transferases 
are a major group of detoxification enzymes which catalyse the conjugation of GSH to 
harmful electrophiles produced during oxidative stress such as 4-hydroxynonenal and to 
exogenous xenobiotics.  
As previously stated in the Chapter 1, live and lyophilized BCG exerted contrasting cellular 
ROS effects. However, these observations were made in separate publications using different 
cell lines and cell types [149,150,169]. Direct comparisons of the two BCG preparations have 
yet to be performed. In this section, we aim to elucidate and compare the direct effects of both 
lyophilized and live BCG on human urothelial bladder cancer cell lines with an emphasis on 







4.1 Integrin expression and BCG internalization profiles of human bladder cancer 
cell lines. 
4.1.1 Expression of Integrin α5 on human bladder cancer cells correlates with the ability 
to internalize BCG 
Expression of the intergrins α5 and β1 are required for BCG attachment to the bladder 
mucosa and anti-tumour responses. Five human bladder cancer cell lines were tested for the 
expression of integrins α5β1 and BCG internalization by flow cytometry. The cells were 
exposed to BCG for 2h to correspond to clinical therapy. A longer time point of 24h was done 
to observe effects of a longer exposure period as BCG particles have previously been found in 
the urine of up to 67.9% of patients 24 hours after therapy [181]. 
Expression of integrin correlates with the ability to internalize live BCG. UMUC3 cells, 
which expressed the highest level of integrin α5, had the greatest level of internalization of 
BCG at both 2 and 24 hours (Table 1). RT4 cells expressed the lowest level of integrin α5 
and internalized BCG poorly. However, RT4 cells had the highest percentage of cells with 
surface bound BCG at both time points.  
Table 4.1: Integrins α5 and β1 expression and live BCG internalization profiles of 
human bladder cancer cell lines. 
 Integrin α5β1  Surface bound BCG Internalized BCG 
Cell line α5 β1 2 hours 24 hours 2 hours 24 hours 
MGH 57.3 ± 3.3 78.5 ± 2.3 6.0 ± 1.0 9.78 ± 0.6 21.0 ± 1.9 43.1 ± 7.7 
J82 47.4 ± 2.7 57.1 ± 9.7 10.7 ± 1.9 11.6 ± 1.2 16.3 ± 3.1 27.2 ± 3.4 
UMUC3 76 ± 2.4 76.8 ± 3.7 16.7 ± 2.9 11.7 ± 4.6 60.2 ± 6.4  82.1 ± 4.4 
RT4 1.5 ± 0.5 57.5 ± 2.2 26.4 ± 4.7 24.9 ± 5.6 10.1 ± 0.5 11.1 ± 0.8 
SW780 6.4 ± 2.7 86.8 ± 2.9 11.1 ± 1.9 21.4 ± 7.6 5.7 ± 0.8 17.9 ± 1.1 
Data represented as mean percentage of cells ± SEM. Experiment was done twice in 





4.1.2 BCG internalizing cells are more susceptible to BCG induced cytotoxicity. 
To ascertain if the ability to ingest BCG correlates with cytotoxicity, two of the cell lines 
were chosen for antiproliferative study by BrDU labelling. UMUC3 and SW780 represent 
high and low BCG internalizing cells respectively. After 24 hours, BCG treatment induced 
significant cytotoxicity on UMUC3 cell line with 44% reduction in BrDU positive cells but 
had no significant cytotoxic effect on SW780 cells. 
 
Figure 4.1: UMUC3 cell are more susceptible to BCG induced cell death at 24 hours 
than SW780. Cells were labelled with 20µM BrDU for 6 hours before plating on 6 well 
plates and after 24h they were treated with live BCG for a further 24 hours. The cells were 
harvested and labelled with PE conjugated anti-BrDU antibody before flow analysis. The 
experiment was done thrice in duplicates (n=6) 
 
4.1.3 MGH cells internalize live BCG better at 2 hours than lyo BCG but there are more 
lyo BCG on the surface at 24 hours. 
Lyo BCG preparations contain degraded bacteria debris that can easily be taken in by the 
tumour cells during treatment while live BCG preparations contain mainly whole live 
bacteria. Hence, the ability of tumour cells to internalize the two BCG preparations may 





internalization of both BCG preparations was similar at 24 hours. However, there was more 
surface BCG detected with the lyo BCG preparation at 24 hours (Figure 4.2). 
 
Figure 4.2: Profile of live BCG and lyo BCG internalization by MGH cells. MGH cells 
were treated with FITC labelled live BCG or lyo BCG. Surface BCG was determined by 
labelling with anti-BCG antibodies followed by PE conjugated secondary antibody before 
analysis by flow cytometry. MGH cells significantly internalized live BCG better at 2 hours 
and more lyo BCG were found on the surface at 24 hour treatment. * denotes significant 
difference between samples (p<0.05). Experiment was done twice in triplicates (n=6). 
Fluorescence intensity of more than 10,000 cells were analysed for lyo BCG treatment during 
flow cytometry (20,000 cells for live BCG).  
 
4.1.4 Blocking mammalian protein synthesis does not affect BCG internalization but 
abrogated BCG induced cytotoxicity of MGH cells. 
To further characterize the internalization mechanisms, MGH cells were pre-treated with 
cycloheximide for 2 hours before lyo BCG treatment for 2, 24 and 48 hours. Internalized 
BCG levels and cell numbers were obtained by flow cytometry and enumeration respectively. 
Cycloheximide treatment reduced the levels of internalized BCG significantly. However, it 
did not completely block internalization as the percentage of MGH cells with internalized 
BCG increases with time in the cycloheximide treated group. BCG treatment induces 
significant cytotoxicity at 48 hours treatment (Table 4.2) but pre-treatment with 
cycloheximide prevented BCG induced cell death and cell proliferation. Hence, BCG 





sufficient to maintain BCG internalizing capacity. However, protein synthesis is necessary for 
BCG induced cell death to occur. 





BCG Internalization (%) 
Sample 2hrs 24hrs 48 hrs 
Control BCG treated 27.6 ± 5.0 49.3 ± 0.7 55.8 ± 0.9 
Cycloheximide + BCG 18.4 ± 0.6 32.6 ± 3.1* 45.8 ± 2.6* 
 Cell proliferation ( x 105 cells) 
Sample 2hrs 24hrs 48 hrs 
Control  1.2 ± 0.1 2.9 ± 0.3 6.75 ± 0.2 
Control BCG treated 1.3 ± 0.1 2.6 ± 0.7 3.6 ± 0.2* 
Cycloheximide 1.24 ± 0.1 1.72 ± 0.1 1.6 ± 0.1 
Cycloheximide + BCG 1.1 ± 0.2 1.6 ± 0.1 1.7 ± 0.2 
Data represented as mean ± SEM. * denotes significance with respect to control 
(p<0.05). Experiments were done thrice in duplicates (n=6). 
 
4.2 Comparisons of live and lyo BCG treatment on ROS in human bladder cancer 
cell lines. 
4.2.1 Lyo and live BCG differentially regulate ROS levels in human bladder cancer cell 
lines. 
For MGH, J82 and UMUC3, treatment with lyo BCG reduced cellular ROS levels at both 2 and 
24 hours of treatment (Table 4.3a and Table 4.4). Treatment with live BCG increased cellular 
ROS levels in MGH and J82 cell lines at both 2 and 24 hours of treatment but did not 
significantly regulate ROS levels of UMUC3 cells at 2 hours (Table 4.3b and Table 4.4) but 
reduced UMUC3 cellular ROS levels at 24 hours. While live BCG treatment had no significant 
ROS regulatory effects on SW780 cell lines, it increased RT4 cellular ROS significantly at both 





To further delineate the mechanisms of BCG induced ROS changes, direct interaction of the 
bacteria with MGH cells was obstructed with a transwell device. MGH cells were chosen for 
the proceeding studies as they internalize the bacteria well and exhibited contrasting ROS 
changes with the two BCG preparations (Figure 4.3). Interestingly, blocking contact between 
BCG and cells results in increased cellular ROS levels in both live BCG and lyo BCG treated 
samples (Table 4.4 and Figure 4.3). This observation suggests that there are BCG factors that 
are secreted by live bacteria or present in the lyophilized preparation that initiated the increase 
in ROS. 
Table 4.3a: The profile of cellular high ROS changes in human bladder cancer cell lines 
after lyo BCG treatment. 
 
 2 hours 24 hours 
Cell Line Control Lyo BCG Control Lyo BCG 
J82 47.2 ± 2.0 39.4 ± 0.9** 50.4 ± 4.7 33.8 ± 4.5** 
UMUC3 76.3 ± 1.3 54.3 ± 3.8** 72.1 ± 2.2 48.4 ± 2.7** 
RT4 13.9 ± 1.9 15.2 ± 0.8 14.0 ± 0.5      16.5 ± 2.7 
SW780 13.3 ± 2.2 13.5 ± 1.8 22.8 ± 1.9 25.2 ± 2.12 
 
Table 4.3b: The profile of cellular high ROS changes in human bladder cancer cell lines 
after live BCG treatment. 
 
 2 hours 24 hours 
Cell Line Control Live BCG Control Live BCG 
J82 46.5 ± 2.0 71.2 ± 4.8** 39.6 ± 1.8 58.6 ± 0.8** 
UMUC3 57.7 ± 1.0 51.6 ± 3.3 67.4 ± 1.4 53.5 ± 2.3** 
RT4 16.4 ± 2.6 23.7 ± 1.4* 13.7 ± 1.8 21.6 ± 1.7* 
SW780 29.3 ± 2.1 29.4 ± 2.1 21.0 ± 2.3 21.7 ± 0.7 
Data represented as mean ± SEM. * denotes significance with respect to control (*p<0.05, ** 






Figure 4.3: Histogram representing the high ROS changes induced by treatment of MGH 
cell line with lyo BCG or live BCG. Solid black filled line represents untreated controls, green 
line represents BCG treated samples and red line represent insert blocked BCG treated samples. 
Fluorescence intensity of more than 20000 cells were analysed using the flow cytometer.  
 
 
Table 4.4: High ROS regulation in MGH cell line after BCG treatment and the effects of 
insert blocking on BCG induced ROS changes. 
 
 Live BCG 
No. of hours 2 hours 24 hours 
Control 59.1 ± 2.1 59.2 ± 1.8 
BCG treated 73.7 ± 1.2* 78.2 ± 2.0* 
BCG + insert blocking 83.1 ± 1.6*, b 75.2 ± 1.1* 
 Lyo BCG 
No. of hours 2 hours 24 hours 
Control 60.2 ± 2.4 62.5 ± 0.7 
BCG treated 36.9 ± 4.5* 46.9 ± 0.7* 
BCG + insert blocking 74.7 ± 1.0*, b 73.4 ± 0.8 *, b 
Data represented as mean ± SEM. * denotes significance with respect to control (p<0.001) and b 
denotes difference with respect to BCG treated (p<0.05 for live BCG and p<0.001 for lyo 






4.2.2 The BCG induced ROS changes in MGH cell line corresponds to lipid peroxidation 
levels. 
ROS generation can lead to the peroxidation of membrane lipids. 4-hydroxy-nonenal (4HNE), 
an end product of lipid peroxidation, can activate stress pathways and induce further 
formation of intracellular peroxides. Lipid peroxidation levels were monitored by the TBARs 
assay which measures the pink adduct of TBA•MDA formed during the assay. 
Although not statistically significant, lipid peroxidation levels corresponded to the ROS 
changes induced by the two BCG preparations and blocking direct BCG contact with cells 
increased cellular lipid peroxidation (Figure 4.4).  
 
Figure 4.4: Lipid peroxidation levels after 2 hours BCG treatment of MGH cell line. 200 
µl of lysates from 2x106 MGH cells were used for the assay that measures the pink 
TBA•MDA adduct formed. Amount of protein from each lysate samples were also estimated 
and the values were expressed as nmol MDA per gram protein. The experiment was done 





4.2.3  RDA analysis of up-regulated transcripts showed that Glutathione-S-Transferase 
mRNA levels increased in MGH cells after 2 hours of Lyo BCG treatment. 
Representational Differential Analysis (RDA) protocol was first employed in our efforts to 
elucidate the gene expression changes after lyo BCG treatment of MGH cell line for 2 hours. 
The 2 hour time point for gene expression studies was chosen to correlate with the clinical 
practice where bladder cancer patients receive BCG therapy for 2 hours. 
From the RDA procedure, the genes detected encode proteins of differing classes, from 
membranous proteins to transcription factors (Table 4.4). Lyo BCG treatment increased 
integrin β1 transcripts, which together with α5, is necessary for BCG interaction and 
internalization. Clathrin assembly protein transcripts were up-regulated in the lyo BCG 
treated sample, suggesting that BCG internalization is clathrin mediated. Lyo BCG treatment 
also up-regulates c-myc binding protein and protein kinase cAMP dependent regulatory type 
1α. Hence, it is possible that BCG induced regulation of cell signalling traverse down the 
pathways mediated by these proteins. 
 However, it was most interesting to find Glutathione-S-Transferase (GST) as one of the 
genes up-regulated in the lyo BCG treated samples because GST enzymes are known to be 
involved in redox regulation in the cells. Since the RDA procedure does not provide details on 
the classes of GSTs being regulated (Figure 4.5), a membrane based microarray was used to 






Table 4.5: Results of sequence similarity searches obtained using the BLAST algorithm 
from screened genes during the RDA procedure. 
 
Class of protein Control Sample Lyo BCG treated sample 
Membrane proteins/ 
Adhesion molecules 
• Chondroitin sulphate 
proteoglycan 6 
• Integrin β1 
• CD81 antigen 
• Connexin 45 
• Translocase of Inner mitochondrial 
membrane 17 
Detoxification, 
antioxidants and stress 
response 
• DiaphoraseNADH/ 
NADPH cytochrome b5 
reductase 
 
• Glutathione-S-Transferase subunit 
13 
• Heat Shock protein 70 protein5 
• Natural Killer cell enhancing 
factor 
Intracellular motility/ 
Cell structure integrity 
• Kinesin 
• Dyenein 
• Thymosin β4 




• Inhibitor of κ light 
polypeptide gene enhancer 
• Cytoplasmic antiproteinase 
38kDa 
• c-myc binding protein 
• Protein kinase cAMP dependent 
regulatory, type 1α 
• Ribophorin 















Figure 4.5: BLAST sequence alignment reveals Glutathione-S-Transferase as one of the 
up-regulated genes in lyo BCG treatment. DH5α colonies transformed with pGEMT 
vector ligated with the up-regulated products were selected for plasmid purification followed 
by sequencing with -21M13 primer using BigDye version 3.0. Sequence identity was obtained 
using BLAST sequence alignment search.  
RID: 1054524120-011901-13694 
 
>gi|7705703|ref|NM_015917.1|   Homo sapiens glutathione S-transferase subunit 
13 homolog (LOC51064), mRNA 
          Length = 1017 
 
 Score = 537 bits (271), Expect = e-150 
 Identities = 274/275 (99%) 
 Strand = Plus / Minus 
 
Query: 104 gatcttttccagaagtccctgggcttgttctgcagacataccagccttctctgcagccgc 163 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 520 gatcttttccagaagtccctgggcttgttctgcagacataccagccttctctgcagccgc 461 
 
                                                                        
Query: 164 caggatgctctgcggctcggtgatgtcttcattccttgaccaggcgcgcatccacagctc 223 
           ||||||||||||||||||||||||||||||||||||||||||| |||||||||||||||| 
Sbjct: 460 caggatgctctgcggctcggtgatgtcttcattccttgaccagacgcgcatccacagctc 401 
 
                                                                        
Query: 224 ccgggacgctttctccagcatctctggatgctccaagttcacggcggtgaggaaacgcat 283 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 400 ccgggacgctttctccagcatctctggatgctccaagttcacggcggtgaggaaacgcat 341 
 
                                                                        
Query: 284 ggcagacaaacttcctttttcaagcatcacagacaagaaatccttggggaagtggatggg 343 
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 340 ggcagacaaacttcctttttcaagcatcacagacaagaaatccttggggaagtggatggg 281 
 
                                               
Query: 344 aatctggagatggtgtctcaggagctttaagtcat 378 
           ||||||||||||||||||||||||||||||||||| 






4.2.4 Comparisons of gene expression regulation in MGH cells after treatment with live 
or lyo BCG for 2 hours. 
Both live and lyo BCG treated MGH samples were used for the microarray analysis with 
untreated MGH cells as a control. In order to study the cytokines and chemokine genes 
induced during BCG treatment, the human inflammatory cytokines and receptors microarrays 
were used. At the same time, the toxicology and drug resistance microarray which contains a 
panel of enzymes involved in oxidative responses, including the GST family of proteins were 
also probed.  
4.2.4.1 Pathway specific microarray analysis of genes induced in MGH cells after BCG 
treatment. 
Densitometry analysis of the spots on the arrays were done and after the values were 
normalized against the endogenous controls, only the genes that were found to be at least 2-
fold up-regulated were considered for further RT-PCR analysis. Live and lyo BCG were 
found to regulate gene expression in a similar fashion (Figure 4.6). 16 genes were found to be 
up-regulated from the inflammatory cytokines and receptors microarray and 129 genes were 
up-regulated from the toxicology and drug resistance membrane. From the OligoArray 
analysis, BCG treatment increased the expression of 4 cytosolic GSTs (GSTM5, GSTT2, 
GSTA3 and GSTA4) and 2 microsomal GSTs (MGST1 and MGST2). Table 4.6 summarizes 
and compares the fold difference of GST gene expression induced in MGH cell line after 







Figure 4.6: X-Ray images of the OligoArray. MGH cells were treated for 2 hours with 
either live or lyo BCG in a 1:100 cell to bacteria ratio. RNA samples were harvested and 
converted to biotinylated cRNA for microarray membrane probing. The hybridized signals 
were detected by chemiluminescence on an X-ray film. The two BCG preparations regulate 
gene expression similarly.  
 
 
Table 4.6: Classes of GSTs found during microarray analysis to be up-regulated in 
MGH cells during BCG treatment for 2 hours. 
 
Gene Symbol RefSeq No Live BCG Lyo BCG 
GSTM5 NM_000851 2.2 2.1 
GSTT2 NM_000854 5.1 6.3 
GSTA3 NM_000847 3.7 4.2 
GSTA4 NM_001512 8.1 9.6 
MGST1 NM_020300 4.7 2.2 






4.2.4.2 Lyo BCG induced increased expression of GSTT2, TNFα and IL1β whereas live 
BCG did not up-regulate these genes significantly. 
To confirm the microarray data, a total of 25 genes were chosen for RT-PCR analysis, 7 of 
the genes were from the inflammatory cytokine array and 15 were from the toxicology 
membrane. Three of the remaining genes were housekeeping genes: β-actin, GAPDH and 
Rps27A. Another human bladder cancer cell line, RT4, was chosen for the RT-PCR analysis 
to compare with the MGH cell response. As noted earlier, the RT4 cell line differs in the 
expression of integrin α5, BCG internalization and BCG induced ROS regulation (Table 4.1 
and Table 4.3).  
Initial experiments were conducted with the intent of using β-actin as an endogenous control. 
However, initial PCR analysis showed that BCG treatment increased the expression of β-actin 
in both MGH and RT4 cells (Figure 4.7D). Comparisons were then made with two other 
endogenous controls and it was observed that BCG similarly increased GAPDH transcripts as 
well but not Rps27A transcripts. Henceforth, RT-PCR analysis was done by normalizing with 
Rps27A.  
With MGH, lyo BCG treatment induced significant up-regulation of GSTT2, TNFα and IL1β 
transcripts with respect to control. While live BCG managed to increase GSTT2 and TNFα 
expression (Figure 4.7A), the statistical values compared to control were not significant 
(p=0.292 and p=0.104 respectively). Lyo BCG induced up-regulation of GSTT2 and IL1β 
expression is also significant when compared to live BCG values (Table 4.7). Statistical 
analysis also reveals significant difference in the expression of Ccl20 and Tollip between the 
two BCG preparations. Seemingly, lyo BCG treatment had reduced Ccl20 and Tollip 
transcripts compared to live BCG treatment (Figure 4.7A).  
From the panel of GST enzymes found on the microarray that were up-regulated (Table 4.6), 





and GSTA3). Of the remaining 6 genes, only GSTT2 levels were found to be up-regulated 
significantly by RT-PCR validation. 
4 genes (Cxcl5, IL11RA, IL1RA and SCYE1) from the inflammatory cytokine and receptors 
microarray as well as 6 genes (HSPA6, NAT2, NAT5, GSTM5, GSTA3 and NOS2A) from 
the toxicology and drug resistance microarray were not detectable during RT-PCR validation 
in all the cDNA samples tested. 
4.2.4.3 RT4 cells up-regulates Tollip after live BCG treatment for 2 hours. 
Lyo BCG treatment did not induce the same effects with RT4 cells that were observed in 
MGH cells. However, live BCG induced significant Tollip up-regulation when compared to 
control (Table 4.7). At the same time, GSTA4 and IL10RB expression levels differs 
significantly between the two BCG preparations. The transcripts levels of GSTA4 and 
IL10RB in live BCG cDNA samples were significantly higher than the levels in lyo BCG 
samples (Figure 4.7B).  
4.2.4.4 MGH and RT4 cells displayed significantly different basal gene expression 
profiles 
Another observation made in this study is that MGH cells showed higher basal expression of 
a panel of genes compared to RT4 cells. Basal levels of the GSTT2, MGST1 and Ccl20 were 
significantly greater in MGH cells (Table 4.7). RT4 cells did not express CSF2, Cxcl6, 
TNFα, IL12A and MGST2 whereas transcripts of these genes were found amplified in the 






Figure 4.7 (A-D): RT-PCR validation of microarray analysis with MGH and RT4 cell lines. 5µg of total RNA were reverse transcripted with 
SuperScriptII enzyme and the cDNA products were kept in TE buffer. 5µl of cDNA were used for the following PCR analysis. Agarose gel analysis of PCR 
products from (A) MGH and (B) RT4 cDNA samples. (C) Basal expression of genes that were found to be significantly lower (Ccl20, GSTT2 and MGST1) 
or were not expressed (CSF2, Cxcl6, TNFα, IL12A and MGST2) in RT4 cells compared to MGH cells. (D) PCR analysis of selected housekeeping genes at 
35 cycles showed that BCG treatment increased the intensity of β-actin and GAPDH transcripts in both MGH and RT4 cells. Intensity of RPS27A looked 
even in all the cDNA samples for both cell lines. Normalization of all densitometry analysis for expression comparisons henceforth used RPS27A as 





 Table 4.7: Densitometry analysis of RT-PCR products from microarray validation experiment with MGH and RT4 cell lines. 
 MGH RT4 
Gene Symbol Control Live BCG Lyo BCG Control Live BCG Lyo BCG 
GSTT2 0.55 ± 0.17 2.1 ± 1.1 5.5 ± 2.4* 0.1 ± 0.2♦ 0.3 ± 0.5 0.2 ± 0.1 
GSTA4 0.5 ± 0.4 0.3 ± 0.08 0.3 ± 0.2 0.4 ± 0.5 0.8 ± 0.4 0.1 ± 0.04• 
MGST1 2.5 ± 0.2 2.3 ± 0.3 2.6 ± 0.3 0.17 ± 0.04♦ 0.11 ± 0.03 ND 
MGST2 0.7 ± 0.4 1.2 ± 0.6 1.5 ± 0.5 ND ND ND 
CSF2 0.5 ± 0.4 1.2 ± 0.5 1.2 ± 0.6 ND 0.02 ± 0.02 ND 
Cxcl6 1.6 ± 0.3 2.5 ± 0.7 1.9 ± 2.2 ND 0.2 ± 0.2 0.1 ± 0.2 
Ccl20 1.02 ± 0.2 1.3 ± 0.3 0.6 ± 0.2• 0.2 ± 0.2♦ 0.4 ± 0.4 0.3 ± 0.3 
IL1β 0.41 ± 0.5 0.4 ± 0.2 2.3 ± 0.8*• 0.9 ± 1.0 2.3 ± 2.3 1.5 ± 1.5 
TNFα 0.9 ± 0.3 1.5 ± 0.5 1.7 ± 0.6* ND 0.03 ± 0.02 0.02 ± 0.02 
IL12A 0.07 ± 0.06 0.04 ± 0.02 0.07 ± 0.07 ND ND ND 
IL10RB 0.9 ± 0.4 1.6 ± 0.4 1.0 ± 0.5 0.5± 0.5 0.8 ± 0.3 0.2 ±0.2• 
TOLLIP 0.5 ± 0.2 0.7 ± 0.4 0.3 ± 0.3• 0.4 ± 0.5 1.3 ± 0.5* 0.6 ± 0.8 
Data represented as mean ± SD. * denotes significance with respect to control and • denotes significance with respect to live BCG. 
For comparisons between MGH and RT4 basal expression, ♦ denotes significance with respect to MGH control values. Statistical 





4.2.4.5 RT-PCR analysis of GSTT2, TNFα and IL-1β expression in J82 cell line. 
To reconfirm the effects of BCG are related to BCG internalization and uptake, another cell 
line that internalizes BCG well was evaluated namely J82 cells. J82 cell line was chosen 
because it is similar to MGH cell line in terms of integrin α5 expression, BCG internalization 
and ROS response to BCG treatment. Upon densitometry analysis, the levels of GSTT2 were 
found to be significantly up-regulated in J82 samples that were treated with lyo BCG for 2 
hours. Unlike MGH, lyo BCG treatment did not increase TNFα and IL1β transcripts in J82 
cell line (Table 4.8). 
Table 4.8: Expression of BCG regulated genes in J82 cell line. 
 
Gene Control Live BCG Lyo BCG 
GSTT2 0.8 ± 0.04 0.84 ± 0.02 0.96 ± 0.05* 
TNFα 0.67 ± 0.13 0.47 ± 0.05 0.64 ± 0.08 
IL1β 0.73 ± 0.04 0.79 ± 0.04 0.7 ± 0.03 
Data represented as mean ± SEM. * denotes significant difference from control 
(p<0.05). The experiment was done twice with triplicates (n=6). 
 
4.2.5 Blocking direct BCG interaction with a transwell device 
Previously, we observed increase in cellular ROS levels when transwell inserts were used to 
block the direct interaction between BCG and MGH cells. Hence, to investigate the 
consequence to gene expression, the experiment was repeated for the 2 hours time point and 






4.2.5.1 Blocking BCG interaction with MGH cells for 2 hours reduced GSTT2 and 
TNFα expression. 
Interestingly, blocking BCG interaction resulted in significantly reduced GSTT2 levels for 
both cultured and lyo BCG treated samples (Figure 4.8A-B). The same effects were observed 
with TNFα gene expression. However, even though live BCG treatment reduced TNFα 
transcript levels, the difference compared to control were not statistically significant (p=0.07). 
IL1β expression was not affected by the BCG blocking treatment. Hence, the BCG secreted 
factors that brought about the increase in cellular ROS also resulted in reduced GSTT2 and 
TNFα expression in MGH cell line.  
4.2.5.2 Inhibiting tyrosine phosphatase activity with sodium orthovanadate abrogated 
the GSTT2 transcript reduction in BCG blocked samples. 
It was previously demonstrated by Koul et al that M. tuberculosis strains H37Ra and H37Rv 
secretes protein tyrosine phosphatases (MptpA and MptpB) constitutively in the culture media 
[163]. The presence of the phosphatase genes were also detected in the BCG genomic DNA. 
Between the two phosphatases, MptpA is the enzyme with single specificity for 
phosphorylated tyrosine. Hence, to determine if secreted MptpA have a role to play in down-
regulating GSTT2 expression, the BCG blocking experiment was repeated in the presence of a 
tyrosine phosphatase specific inhibitor, sodium orthovanadate (Na2VO4) at 100µM 
concentration. Madhurantakam et al has previously determined the half maximal inhibitory 
concentration (IC50) for wild type MptpA with sodium orthovanadate (28µM) [182]. Only 
GSTT2 expression was studied in this experiment as it was found to be significantly down-
regulated in both the cultured and lyo BCG blocked samples. 
Orthovanadate treatment did not have any effect on GSTT2 expression when compared to 
control (Figure 4.9). Blocking BCG interaction in the presence of 100µM Na2VO4 did not 





orthovanadate control, the BCG blocked samples had significantly lower levels of GSTT2 
transcripts. However, upon quantitative analysis of the level of down-regulation it was found 
that phosphatase inhibition resulted in a lower percentage of GSTT2 down-regulation (35.75% 
and 17.1% for live BCG and lyo BCG blocked samples respectively) compared to the 
orthovanadate free experiment where a huge decrease of 81.8% and 78.5% were observed for 
live and lyo BCG blocked samples respectively (Table 4.9). Hence, it is possible that 
mycobacterial tyrosine phosphatases were responsible for the observed GSTT2 down-
regulation. However, since treatment with 100µM Na2VO4 can inhibit cellular phosphatase as 
well, it is also possible that the down-regulation of GSTT2 by BCG secreted factors requires 
the mediation of cellular phosphatases. Nevertheless, it is worth exploring the role that 
mycobacterial tyrosine phoshatases have to play in manipulating the tumour cell responses 







Figure 4.8 (A-B): Effects of transwell blocking on BCG induced GSTT2, TNFα and IL1β gene regulation in MGH cells. (A) Agarose gel 
analysis of PCR amplified products from the BCG blocked cDNA samples. The experiment was done 3 times in triplicates (n=9).(B) Densitometry 






Figure 4.9: Effects of phosphatase inhibition on GSTT2 down-regulation. Transwell 
blocking experiment was done in the presence of sodium orthovandate to inhibit phosphates 
activity and the effects of GSTT2 down-regulation was determined by RT-PCR. The 




Table 4.9: Effects of phosphatase inhibition on the percentage of GSTT2 down-
regulation. 
 
 Without phosphatase blocking 
 Control Live BCG Lyo BCG 
 0.43 ± 0.09 0.078 ± 0.03* 0.092 ± 0.04* 
% difference wrt control 81.8% 78.5% 
Blocking phosphatase with orthovanadate 
Control Orthovanadate control Live BCG Lyo BCG 
0.78 ± 0.04 0.8 ± 0.01 0.51 ± 0.02♦ 0.67 ± 0.02♦ 
% difference wrt orthovanadate 
control 35.75% 17.1% 
Data represented as mean ± SEM. * denotes significance with respect to control (p<0.005) 






4.3 Effects of GSTT2 silencing on lyo BCG treatment of MGH cells. 
GSTT2 enzyme protects cells against toxic oxygen and lipid peroxidation products. In this 
study, the expression of GSTT2 genes was found to be up-regulated by MGH and J82 cell 
lines after lyo BCG treatment for 2 hours. Hence, it is of interest to investigate the effects of 
GSTT2 silencing on BCG induced ROS changes. Since treatment with lyo BCG, not live 
BCG, significantly enhanced GSTT2 expression in MGH cell line at 2 hours, only lyo BCG 
was used in the knockdown study. 
4.3.1 Transfection with GSTT2 SMARTpool siRNA successfully reduces GSTT2 
expression. 
To ensure successful knockdown of GSTT2 expression, MGH cells were transfected with 
GSTT2 siRNA at concentrations of 5, 10 and 30nM using DOTAP Liposomal Transfection 
reagent for 48 hours. GSTT2 expression was then analysed from cDNA samples by real time 
PCR. 
After relative quantification analysis, only 30nM GSTT2 siRNA concentration exhibited 
GSTT2 knockdown effects on MGH cell line. 5nM and 10nM GSTT2 siRNA concentrations 
increased GSTT2 expression instead. DOTAP reagent alone caused GSTT2 up-regulation 
while the siRNA non-targeting controls and GSTT2 siRNA only controls (without liposomal 
transfer) had no observable effects on GSTT2 expression (Figure 4.10). Hence, the following 
GSTT2 knockdown studies were done with 30nM GSTT2 siRNA with DOTAP and non-







Figure 4.10: Transfection of MGH cells with GSTT2 siRNA using DOTAP Liposomal 
transfection Reagent. MGH cells were transfected with 5, 10 and 30nM GSTT2 siRNA. 
Controls for this experiment include DOTAP control, siRNA non-targeting control (si ctl), as 
well as GSTT2 siRNA only control (si only) without DOTAP delivery agent. GSTT2 
expression was detected by real time PCR. The experiment was done twice in duplicates 
(n=4). 
 
4.3.2 Lyo BCG treatment for 2 hours after GSTT2 knockdown significantly reduced 
ROS levels compared to Dotap control. 
While the DOTAP transfection mixture control did not induce basal ROS changes in untreated 
MGH samples, ROS levels were not significantly reduced after lyo BCG treatment in DOTAP 
samples (Table 4.10). Since DOTAP control displayed a difference from untransfected control 
after lyo BCG treatment, GSTT2 knockdown samples were compared only with the DOTAP 
control values. 
Lyo BCG treatment of GSTT2 knockdown MGH cells showed significantly lowered cellular 
ROS levels when compared with BCG treated DOTAP control whereas non targeting siRNA 





Table 4.10: Effects of GSTT2 silencing on lyo BCG induced High ROS changes in MGH 
cell line. 
 
Sample Groups Control Lyo BCG treated 
Untransfected control 50.6 ± 2.0 27.7 ± 1.1 
DOTAP Control 44.4 ± 2.5 40.7 ± 2.0 
siRNA control 50.7 ± 1.6 35.9 ± 1.2 
GSTT2 siRNA 45.0 ± 1.0 23.8 ± 0.8 * 
Data represented as mean± SEM. * denotes significance with respect to Dotap BCG treated 
control (p<0.005). All lyo BCG values are significantly different from respective untreated 
control values (not indicated in the table, p<0.001 for all except for DOTAP). MGH cells were 
treated with lyo BCG for 2 hours. The experiment was done 3 times in duplicates (n=6) 
 
4.3.3 GSTT2 knockdown increased basal NO levels and lyo BCG treatment for 2 hours 
significantly reduced NO levels compared to untreated knockdown control. 
H2DCFDA measures cellular ROS levels by reacting with hydrogen peroxide and peroxynitrite 
(ONOO-). Nitric Oxide (NO) can combine with superoxide anion to form peroxynitrite. Thus 
the effect of GSTT2 knockdown and lyo BCG treatment on cellular NO levels were 
determined. NO has a very short half life and it is indirectly detected by measuring the 
concentration of its stable end product, nitrite, in the supernatants of the experimental samples 
with Griess Reagent. 
Lyo BCG treatment increased NO concentration in the DOTAP control and non-targeting 
siRNA control samples (Figure 4.11).Interestingly, GSTT2 knockdown elevated NO levels 
significantly in untreated MGH cells compared to DOTAP control. Treatment with lyo BCG 
for 2 hours decreased the NO levels significantly in the GSTT2 silenced samples when 








Figure 4.11: Effects of GSTT2 knockdown and lyo BCG treatment on NO production in 
MGH cell line. Supernatants from the GSTT2 knockdown study were treated with nitrate 
reductase to convert the nitrates to nitrites. Griess Reagent was then added to detect the levels 
of total nitrites in the supernatant. Endogenous nitrite values measured from unreduced 
supernatants were subtracted from the total nitrite values to obtain the nitrate values. * denotes 
significant difference with respect to untreated control (p<0.05) and ** denotes significant 
difference with respect to DOTAP untreated control (p<0.005). The experiment was done 3 
times in duplicates (n=6). 
 
4.3.4 GSTT2 knockdown increased TNFα production after 2 hours of lyo BCG 
treatment. 
TNFα gene expression was previously found to be up-regulated in MGH cell line after lyo 
BCG treatment for 2 hours (Table 4.7 and Figure 4.7A). To investigate if GSTT2 knockdown 
could affect TNFα production, TNFα secretion was measured from the supernatants of the 
GSTT2 knockdown samples by ELISA. 
TNFα production after lyo BCG treatment is not significant for DOTAP and siRNA control 
samples but silencing GSTT2 expression resulted in the significant increase in TNFα 
production after lyo BCG treatment. There seems to be a link between GSTT2 expression and 







Figure 4.12: ELISA measurement of TNFα secretion by MGH cell line after GSTT2 
knockdown and lyo BCG treatment. Supernatants from the GSTT2 knockdown study was 
assayed for the presence of TNFα with R&D Systems human TNFα ELISA kit. * denotes 
significant difference with respect to untreated control (p<0.05). The experiment was repeated 
3 times with duplicates (n=6). 
 
4.4 Discussion 2 
4.4.1  Integrin α5–role in BCG internalization, cytotoxicity and ROS production 
Live BCG treatment has a similar immunogenic potential as lyo BCG in the bladder. In order 
to compare the mechanism of direct interactions between mycobacteria and urothelial cells, 
human bladder cancer cell lines were treated with live and lyo BCG and evaluated for their 
effect on cellular ROS and gene expression. 
Integrin α5β1 has been previously correlated with BCG induced cytotoxicity in a study by 
Pook et al [11]. As β1 integrin expression is consistently high it is α5 expression levels that 
determine the ability of bladder cancer cells internalize BCG. Integrin β1 is important for 
development as it mediates cell-cell and cell-matrix interaction. Knocking out the gene leads to 
lethality in mice [183]. Integrin α5 is associated with increased cancer progression and 





Cells that express low integrin α5 displayed lower endogenous ROS levels (SW780 and RT4 
cells) than cells that expressed high integrin α5.Integrin ligation has been attributed to ROS 
increase via the MAPK pathway. The ROS increase in turn activates metalloproteinases and 
enzymes that are involved in breakdown of membranous proteins mediating cell-cell 
interactions, leading to increased metastatic capability and extravasation of tumour cells 
[187,188]. The uptake of BCG by urothelial cells is largely mediated by integrin α5β1, and 
this disrupts the normal integrin ligation. The cross-linking of BCG to integrin α5β1 have 
previously been shown to exert direct cytostatic effects on human bladder cancer cell lines 
[12]. Cycloheximide is a mammalian protein synthesis inhibitor that inhibits translation [189]. 
Cycloheximide did not block BCG internalization, indicating that receptor recycling probably 
is responsible for BCG uptake and this does not require new protein synthesis. However, 
blocking protein synthesis abrogated BCG induced cytotoxicity, suggesting that new protein 
synthesis is required for BCG induced cell death. As such, we further investigated this with 
gene expression assay in order to further elucidate the mechanisms that facilitate BCG induced 
cytotoxicity. 
Comparing internalization of the two BCG preparations, more Live BCG was taken up at 2 
hours than lyo BCG. It is possible that live BCG preparation possesses more intact and 
undegraded FAP protein to mediate the internalization process. At 24 hours, the internalization 
of both BCG preparations was comparable but lyo BCG treated samples had more BCG on the 
surface than live BCG. This could be due to the degraded components of the lyo BCG 
preparation binding non-specifically to the surface of the cells and in vivo, external BCG 





4.4.2  Live BCG and Lyo BCG differentially regulate cellular ROS. 
Cell lines that internalized BCG well displayed ROS variation after BCG treatment. Lyo BCG 
internalization decreased cellular ROS while live BCG internalization increased ROS. There 
was one exception, UMUC3 cells, had ROS reduction after live BCG treatment. This cell line 
internalizes live BCG most efficiently and the decrease in ROS rather than increase is 
surprising and needs to be further evaluated. ROS decrease in Lyo BCG treatment could be 
attributed to free BCG components that may have ROS quenching effect, such as SOD and 
LAM that may be present in high concentrations in the lyophilized preparations [145,190]. 
Cell lines that do not internalize BCG well (RT4 and SW780) did not display ROS regulatory 
response after BCG treatment, except for RT4 (LyoBCG treatment reduced RT4 cellular ROS 
at 24 hours). This suggests that BCG induced ROS regulation requires internalization to occur. 
To test this theory, we blocked the direct contact of MGH cells with BCG treatment using a 
transwell device. Intererestingly, we observed an increase in cellular ROS with lyo and live 
BCG when there was no direct contact with the cells which indicates the presence of BCG 
secreted proteins that can modulate ROS levels. Further this suggests that the molecules 
secreted by lyo and live BCG generally increase ROS but when lyo BCG enter cells it can 
counteract the effect of these molecules, possibly as a consequence of the exposure of cells to 
BCG non-soluble cytoplasmic contents being exposed by lyophilization. 
4.4.3  Increase in ROS leads to increase in lipid peroxidation end product, MDA. 
Lipid peroxidation was measured by the TBARs assay where MDA, an end product of lipid 
peroxidation, forms a pink adduct with thiobarbituric acid. ROS regulation by live and lyo 
BCG correlates with MDA levels. Blocking BCG interaction with MGH cells resulted in 
increased ROS as well as increased MDA levels. Live BCG which increased ROS in cells also 
had increased MDA levels. Thus MDA levels reflect the cellular ROS state of the urothelial 
cells. The increase of serum MDA levels in bladder cancer patients has previously been 





reduced MDA levels after lyo BCG treatment corresponds to a study by Kaczmarek et al 
where they found decreased MDA in the platelet samples of patients receiving BCG treatment 
along with increased SOD activity, which concomitantly resulted in decreased platelet 
aggregation [192]. The interaction of aggregated platelets with tumour cells plays an important 
role in metastasis [193]. Hence, the antioxidative effects of lyo BCG in reducing ROS and 
MDA levels could contribute to prevention of tumour metastasis. 
4.4.4  Lyo BCG induced more gene up-regulation than live BCG at 2 hours 
Lyo BCG treatment induced significant upregulation of GSTT2, TNFα and IL1β by 2 hours in 
MGH cells while live BCG treatment did not. This is a fairly rapid increase in gene 
expression. Basal gene expression was variable in the control samples. This is perhaps due to 
the low level of transcripts present that sometimes could not be detected by RT-PCR.  
However, upon BCG treatment, the levels are consistently upregulated.  IL1β is a 
proinflammatory cytokine that is a strong chemoattractant for neutrophils and its up-regulation 
after exposure to Lyo BCG may be contributive to the early accumulation of neutrophils in the 
tumour site. GSTT2 expression has previously been demonstrated in colon cancer cells treated 
with apple flavanoids and they confer protection against oxidant induced damage. Thus, in lyo 
BCG treatment, the bacteria seemed to be acting in an antioxidant-like manner by decreasing 
cellular ROS and up-regulating GSTT2 transcripts which can protect the cells from further 
oxidative damage [194-196]. GSTT2 up-regulation was also observed in J82 cell line after lyo 
BCG treatment. J82 cells, while being similar to MGH cells in terms of BCG internalization 
and ROS responses, do not similarly upregulate TNFα an IL1β. It is not unusual however, 
considering that the two cell lines have previously been demonstrated to be distinct in 
producing tumours in nude mice with MGH cells causing more tumours (44 tumours in 54 
mice) compared to J82 cells (1 tumour in 14 mice) [197]. We did not observe significant up-
regulation of genes by live BCG and it is possible that a further incubation time is needed to 





It is interesting to find the up-regulation of Tollip in RT4 cells after live BCG treatment. The 
up-regulation of Tollip gene could signify signalling pathways regulated by TLR or IL1R 
receptors activated on RT4 cell line [198,199]. Tollip are negative regulators of TLR 
signalling and this is possibly one of the reasons that this cell line does not express any 
inflammatory cytokines significantly after BCG treatment, as demonstrated by Zhang et al 
[200,201]. BCG treatment increased GAPDH and β-actin transcripts in MGH and RT4 cell 
line. This observation may imply that BCG treatment resulted in metabolic up-regulation and 
β-actin expression. Normalization of RT-PCR is usually done with these 2 housekeeping genes 
but after BCG treatment neither of these genes would be a good normalization candidate. This 
stresses the importance of choosing the right housekeeping genes for every study. GAPDH 
regulation during BCG treatment in mouse lungs has been previously reported [202]. Up-
regulation of GAPDH was not observed in the mice bladder possibly because BCG treatment 
does not cause up-regulation of GAPDH in the normal urothelium.When we blocked direct 
BCG interaction with MGH cells, significant down-regulation of GSTT2 and TNFα 
expression was observed which appeared to be modulated to some extent by MptpA. 
4.4.5  Higher endogenous ROS levels in MGH cell line leads to basal expression of 
genes. 
We observed basal expression of 3 cytokine genes (TNFα, IL12A and CSF2), 2 chemokine 
genes (Cxcl6 and Ccl20) and 3 GSTs (GSTT2, MGST1 and MGST2) in MGH cell line that 
were absent or expressed in significantly lower levels in RT4 cell line. The difference in 
cytokine and chemokine expression between the 2 cell lines may be attributed to their basal 
ROS levels. The transcriptional regulation of the cytokines and chemokines are controlled by 
the NF-κB nuclear receptor pathway [203-207] and NF-κB activity is found to be stimulated 
by ROS increase due to the degradation of its inhibitor, IκB, and would therefore be 
inadvertently activated in the high ROS intracellular environment in MGH cells. GSTT2 





secondary products of lipid peroxidation [208] MGST1 catalyzes glutathione dependent 
reduction of lipid hydroperoxides and MGST2 exhibits both glutathione transferase and 
peroxidase reactions [209]. Expression of the 3 GST enzymes could thus be a mechanism to 
modulate the high ROS levels in the MGH cell line. 
4.4.6  Silencing GSTT2-DOTAP MBC mediated changes in MGH cells. 
GSTT2 silencing studies were done with DOTAP liposomal transfection reagent and MBC as 
the gene transfer vehicle. Dotap is a cationic lipid and such lipids have been known to mediate 
membrane instability and cytotoxic effects by interfering with survival pathways [210,211]. 
MBC can contribute cholesterol to cell membranes as well as DOTAP and this can affect 
membrane fluidity and lipid raft cholesterol composition. A study by Fillion et al 
demonstrated the abrogative effects of DOTAP treatment on LPS/IFNγ induced NO and TNFα 
production in mouse macrophages [212]. A report by Soenen et al demonstrated that cationic 
lipids induced cytotoxicity by increasing cellular ROS increase [213]. We did not observe 
ROS increase in the DOTAP control samples and it could be that DOTAP lipid formulation is 
less cytotoxic. Also, the study by Soenen et.al treated the cells with cationic lipids for 24 hours 
before ROS analysis, our transfection protocol required only a 2 hour incubation time before 
the removal of the DOTAP mixture and a further incubation for another 24 hours. The 
incubation in DOTAP free media may have helped the cells to regain redox homeostasis after 
24 hours. In human renal proximal tubule cells, cholesterol repletion of lipid rafts keeps 
NADPH oxidase inactive and reduces cellular ROS [214]. It is thus not surprising that DOTAP 
and MBC perturbed the cellular ROS levels themselves. Studies done by Verreault et al 
revealed suppression of Integrin linked kinase (ILK) and Akt pathways after cationic lipid 
treatment [211]. Akt regulates cellular metabolism in part by its regulation of the FOXO 
(Forkhead Box subclass O) family of transcription factors. Akt inactivation by DOTAP 
treatment could have resulted in the release of the FOXO transcription factors into the nucleus, 





MnSOD and CAT [215]. Thus, this might be the mechanism keeping ROS levels at a normal 
concentration in MGH cells after DOTAP MBC treatment albeit a little higher than normal.  
4.4.7  GSTT2 knockdown enhanced basal NO levels but reduced NO and increased 
TNFα after lyo BCG treatment. 
Silencing GSTT2 expression resulted in increased basal NO production by MGH cells. It is 
now known that NO exposure leads to the formation of a dinitrosyl-iron complex bound to 
intracellular proteins, including GSTs [216] and GSTT2 have been postulated to be one of the 
enzymes involved in sequestering the toxic complex. GSH is conjugated to the complex to 
form dinitrosyl-diglutathionyl-iron complex (DNDGIC) with the enzyme, hence stabilizing the 
complex [217]. Knocking down GSTT2 could have possibly reduced the formation of 
DNDGIC complex levels and increase unbound dinitrosyl-iron complex and thus 
bioavailabilty of NO in the cells. 
Iron overload has previously been linked to decrease NO production following Mtb infection 
in macrophages (http://hdl.handle.net/10210/340). This could be due to its gene regulatory 
role on iNOS expression [218]. In a study by Zager et al, they demonstrated that parenteral 
iron does not independently increase plasma levels of TNFα or tissue mRNA transcripts but 
can enhance TNFα production after LPS or muscle injury in mice [219]. Hence, decreased NO 
levels and increased TNFα production could be attributed to increased intracellular iron in the 
GSTT2 silenced cells. The data also suggests that TNFα production is independent of GSTT2 
expression and cellular ROS levels. However, it is important to note that the ROS species 
measured in our studies are hydrogen peroxide, peroxyl radicals and peroxynitrite and that 





4.4.8  RDA vs microarray 
RDA analysis was first employed because it is a powerful tool that can amplify and obtain 
differentially expressed transcripts that may be present in very low levels. We also managed to 
find novel transcripts from the BLAST analysis and the findings are not restricted to classes of 
genes like the microarray. However, validation by RT-PCR was limited by the BLAST 
analysis that sometimes does not provide information on the classes of enzymes from the 
sequence analysed. However, it provided us with an initial direction with the discovery of GST 
subunit 13 upregulated in the lyo BCG sample. Further analysis was then carried out with 
pathway specific micorarrays. As previously discussed, we found the correlation in our in vivo 
studies to be poor. The correlation was even less impressive for the human gene expression 
studies with only 3 out of the 22 genes confirmed to be up-regulated by RT-PCR, while 9 of 
the genes were not up-regulated and 10 of them not detected during RT-PCR analysis. In 
future, repeating the microarray procedure and subjecting the normalized values to statistical 
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 From our previous experiments in Chapter 4, we reported the presence of soluble 
mycobacterial factors that increased cellular ROS levels and downregulate GSTT2 and TNFα 
gene expression in MGH cell line. Mycobacterial phosphatases can act as Fenton type 
catalysts that can increase measurable cellular hydroxyl and peroxyl radicals [220]. 
Furthermore, gene silencing effects induced by bacterial secreted factors have previously been 
demonstrated with Yersinia enterocolitica YOP proteins, where one of the protein, YopH, is a 
tyrosine phosphatase [221]. As such, mycobacterial protein tyrosine phosphatases (Mptp) 
were thought to be possible candidates contributing to the observed ROS and gene silencing 
responses in our study.  
The sequenced genome of Mycobacterium tuberculosis encodes for the expression of two 
PTPs, MptpA and MptpB. However, it does not encode for any known mycobacterial tyrosine 
kinase that acts as a substrate for the phosphatases [162,222]. Thus, mycobacterial Ptps are 
designed to manipulate host response during treatment by interfering with host protein 
signaling components. In this section, we isolated and purified MptpA and studied its effects 
on MGH cell responses with respect to ROS regulation, cell cycle progression and modulation 
of EGF induced signalling events. Also, we explored the ability of MptpA to induce GSTT2 





5.1 Purification and isolation of MptpA 
MptpA has specificity for phosphorylated tyrosine. The MptpA gene was expressed as a 
fusion protein with GST (Figure 5.1A). After Factor Xa cleavage, SDS-PAGE analysis of the 
cleaved products confirms the presence of the 17.5 kDa MptpA protein. Strong proteins bands 
smaller than 17.5kDa were also observed, which may be truncated MptpA proteins (Figure 
5.1B). Faint protein bands between 24-38 kDa detected in the supernatants may be cleaved 
from proteins that were nonspecifically binding to the Sepharose beads during the pull down. 
However, passing the cleavage products through a benzamidine column enriches the MptpA 
fractions thus allowing the collection of eluates with maximum MptpA solution content 
(Figure 5.1C). Fractions that have only the observed 17.5kDa band corresponding to MptpA 
size were collected to be used for further experiments. 
5.2 Phosphatase activity of MptpA with phosphorylated Myelin Basic Protein in 
vitro. 
5.2.1 Purified MptpA dephosphorylates tyrosine on myelin basic protein (MBP) 
MptpA is a tyrosine phosphatase with a cysteine active site that is prone to inhibition by 
oxidation. Pooled fractions were treated with 10mM DTT to reverse any possible active site 
oxidation before dialysis and storage. Phosphatase activity was established by treating 0.5µg 
of tyrosine phosphorylated myelin basic protein (pMBP) with 0.5µg of MptpA for 2 hours. 
MptpA treatment effectively removes phosphotyrosine on MBP, with or without 2mM DTT 
in the reaction buffer (Figure 5.2A), implying that the catalytic site of the purified MptpA is 
active after dialysis and storage. Henceforth, phosphatase assays were carried out in the 







Figure 5.1(A-C): Isolation of MptpA. E.coli BL21 strain was transformed with the pGEX-
mptpA plasmid. (A) After 0.2mM IPTG stimulation for 3 hours, there is an observed enlarged 
band corresponding to the 46.5kDa GST-MptpA. (B) After GST pull down, the Glutathione 
Sepharose  beads were incubated with Factor Xa overnight to cleave the MptpA protein 
from the GST tag. The beads were washed twice to achieve maximum yield of MptpA 
proteins. The supernatant (sup) and the washes were combined before passing through 
HiTrap Benzamidine column. (C) To remove bound Factor Xa, the supernatants were 
passed through a Benzamidine column that will specifically bind Factor Xa. MptpA proteins 
were eluted with high salt buffer. The eluates were collected in 1 ml fractions and ran on 15% 
SDS-PAGE gel. Eluates that contain the 17.5kDa MptpA proteins (10-18) were combined, 





5.2.2 The tyrosine phosphatase activity of MptpA is observed as early as 5 minutes in 
vitro. 
MptpA catalysed tyrosine dephosphorylation occurs as early as 5 minutes and phosphorylated 
tyrosine were mostly removed by 30 minutes. Densitometry analysis of the time dependent 
phosphatase assay shows that the phosphotyrosine/MBP ratio signals decreased in time with 
respect to controls (Figure 5.2B). Even though phosphotyrosine signals were not visibly 
detected at 30 minutes incubation time, the background spot value was obtained for 
quantitative analysis. 
5.3 Treatment of MGH cell line with MptpA in culture 
The phosphatase activity of MptpA in culture with human MGH bladder cancer cell line was 
investigated. The study focused on MptpA modulation of cell cycle progression, and 
phosphotyrosine mediated signalling. 
5.3.1 MptpA does not induce cell cycle changes in MGH cell line. 
MGH cells were treated with MptpA at concentrations from 0.1µg/ml to 10µg/ml for 24 hours 
and then stained with propidium iodide before analysis by flow cytometry. The cell cycle 
phases in the MptpA treated samples did not differ significantly compared to control (Figure 
5.3). MptpA treatment did not have any regulatory effect on cell cycle progression in MGH 






Figure 5.2(A-B): Phosphatase activity of MptpA in vitro. (A) 0.5µg of tyrosine phosphorylated MBP were treated with 0.5µg of purified MptpA for 2 
hours at 37°C in a buffer with or without 2 mM DTT. Purified MBP isoforms range from 13-21.5kDa. (B) The time point phosphatase assay was analysed by 






Figure 5.3: Effects of MptpA on cell cycle progression of MGH cell line. MGH cells 
were treated with MptpA at various concentrations for 24 hours. The experiment was done 
twice with duplicates (n=4). 
 
5.3.2 MptpA does not cause a global change in phosphotyrosine residues in MGH cell 
line but it reduces tyrosine phosphorylation of Epidermal growth factor receptor 
(EGFR) after EGF stimulation. 
MptpA tyrosine dephosphorylation capacity was determined in culture with MGH cell line at 
a treatment time point of 2 hours. MGH cells were pre-treated with 100µM sodium 
orthovanadate for 1 hour to increase the phosphotyrosine signal from the cells by inhibiting 
endogenous tyrosine phosphatase before the addition of MptpA in fresh orthovanadate-free 
media. Cell lysates were collected and 10µg of total proteins were loaded on a 7.5% SDS-
PAGE gel. Treatment with MptpA did not result in a global reduction of cellular 
phosphotyrosine levels at all concentrations tested (Figure 5.4A). Therefore the effect of 
MptpA on a specific mitogenic factor EGF stimulation of EGFR was chosen for further 
evaluation of its function in mammalian cells. Bladder cancer cells have been shown to 
express high levels of EGFR and it is suggested to be a factor in invasive progression. MGH 
cells were pre-stimulated with recombinant human EGF at 10ng/ml for 30 minutes before 





for immunoprecipitation with anti-EGFR antibodies. MptpA treatment reduced tyrosine 
phosphorylation of EGFR at both concentrations tested (Figure 5.4B). Compared to control, 
phosphotyrosine-EGFR levels were decreased by 53.3% and 42.3% at 0.5µg/ml and 5µg/ml 
respectively. This observation implies that MptpA treatment is capable of lowering EGF 
induced tyrosine phosphorylation of EGFR in vitro. 
 
 
Figure 5.4(A-B): Treatment of MGH cell line in culture and its effects on 
phosphotyrosine levels. (A) MptpA treatment at various concentrations for 2 hours did not 
reduce cellular phosphotyrosine levels in MGH cell line. (B) MptpA treatment decreased EGF 





5.4 Investigating the cellular phosphokinase regulation by MptpA treatment in EGF 
stimulated MGH cells. 
Treatment of EGF stimulated MGH cells with MptpA can reduce tyrosine phosphorylation of 
EGFR at 2 hours at both 0.5µg/ml and 5µg/ml MptpA concentrations (Figure 5.4B). Thus, 
downstream components of EGFR mediated signalling may have been perturbed in the 
presence of MptpA. To further study the possible downstream regulation of MptpA treatment, 
a phosphokinase array was used to analyze cellular phosphatase targets. EGF stimulated 
MGH cells were treated with lyo BCG at a 1:100 cell to bacteria ratio, with 5µg/ml MptpA or 
with both BCG and MptpA. 250µg of cell lysates from each sample were used to perform the 
array procedure.  
5.4.1 Combination treatment of MptpA and BCG up-regulates more phosphorylated 
targets than individual treatments alone. 
The human phosphokinase profiler array kit consists of 4 membranes with 2 parts that are to 
be used together for optimal analysis efficiency. Each membrane has positive control spots to 
indicate successful procedure. The signals from the probed membranes were obtained by 
chemiluminescent detection followed by X-ray exposure. The intensity of each spot on the 
arrays was obtained with GeneTools software. Average background values from the negative 
control spots were subtracted from the densitometry readings. Since there is no endogenous 
control in this array, the subtracted values were normalized against the average of positive 
control spots from each membrane to improve the stringency of the quantitative process. The 
normalized values from the treatment samples were divided by control values to obtain the 
fold difference. Phosphoproteins with intensity altered by at least 2-fold difference were 
considered as possible treatment regulated targets. 
Lyo BCG and MptpA induce phosphotargets with greater intensity than individual treatment 





Quantitative densitometry analysis confirms this observation as the combination treatment 
upregulates 15 phosphoproteins compared to MptpA or BCG treatment (5 and 1 respectively). 
BCG treatment, with 11 phosphotargets down-regulated, stimulates the most reduction 
compared to MptpA or combination treatment (4 and 1 respectively). Up-regulation of S392-
p53 and down-regulation of Y118-Paxillin were observed in all the treated samples (Table 
5.1).  
5.4.2  Western blot validation of phosphokinase array 
To validate the phosphokinase array, western blots were performed on the EGF stimulated 
MGH samples. Live BCG treated cells and its combination treatment with MptpA were also 
included in the analysis. 30µg of protein from each sample were loaded on a 10% SDS-PAGE 
gel and transferred to a nitrocellulose membrane. The membranes were then probed for the 
presence of pT180/Y182-p38α, T202/Y204-ERK1/2, pT308-Akt, pY118-paxillin, pS392-p53 
and their non-phosphorylated forms. Phosphorylation levels were compared by normalizing 
with total target protein. 
MptpA and lyo BCG treatment did not affect the phosphorylation of any of the probed 
phosphoproteins. Combination of lyo BCG with MptpA increased p38 phosphorylation only. 
While live BCG treatment by itself had no observable effect, its combination treatment with 
MptpA increased pT180/Y182-p38α and pT308-Akt levels as well as decreased T202/Y204-
ERK1/2 levels (Figure 5.6). Hence, live BCG with MptpA seems to be the most potent 
phosphorylation regulating treatment in our study. Signals from p53 and paxillin 
immunoblotting (both phosphorylated and total proteins) were not detected in our analysis. 
The cellular levels of these proteins may be very low and immunoprecipitation with a larger 







Figure 5.5: Human Phospho-Kinase Profiler Array performed on EGF induced MGH cells treated with MptpA and lyo BCG. EGF stimulated MGH 
cells were treated with lyo BCG, MptpA or both for 2 hours and the lysates from each samples were used to perform a Human Phospho-Kinase Profiler array 
from R&D Systems. Spots from each array were quantified by densitometry with GeneTools software. The combination treatment of BCG and MptpA up-
regulates 15 phosphoproteins while BCG treatment down-regulates the most phosphotargets (11). The proteins that were considered for Western Blot 
validation of the array are circled. 




Table 5.1: Densitometry analysis of Human Phospho-Kinase Profiler Array 
Data is expressed as normalized values ratio with respect to control. Phosphotargets that were 
found to be altered by at least 2-fold difference were considered as possible regulated targets 
in the sample. (       ) denotes targets that are down-regulated and (      ) denotes targets that are 
up-regulated. 
 
Phosphorylation sites Target BCG MptpA BCG + MptpA 
Threonine/Tyrosine Sites     
T180/Y182 p38α 1.19 2.18 2.02 
T202/Y204, T185/Y187 ERK1/2 1.25 2.20 2.08 
T183/Y185,T221/Y223 JNK pan 1.67 0.90 3.78 
T241/S424 p70 S6 kinase 0.35 0.65 0.86 
T389 p70 S6 kinase 0.46 0.88 3.2 
T229 p70 S6 kinase 0.23 0.44 0.82 
T308 Akt 1.25 1.59 2.36 
T198 p27 0.46 1.40 2.78 
Y419 Src 0.81 1.36 2.57 
Y689 STAT2 1.54 1.75 2.08 
Y426 Yes 0.62 1.42 2.26 
Y705 STAT3 1.51 2.02 6.09 
Y699 STAT5b 1.40 1.77 3.07 
Y397 FAK 1.02 1.06 2.24 
Y118 Paxillin 0.24 0.48 0.47 
Y402 Pyk2 0.35 0.45 0.63 
Y783 PLCγ1 0.36 0.53 1.19 
Y701 STAT1 0.25 0.55 1.05 
Y693 STAT4 0.30 0.82 1.18 
     
Serine sites     
S376/S360 MSK1/2 0.97 1.79 5.03 
S78/S82 HSP27 0.74 0.39 1.59 
S392 p53 3.00 3.83 9.50 
S46 p53 1.59 2.02 2.86 
S221 RSK1/2 0.35 0.74 0.94 






Figure 5.6: Western blot validation of phosphokinase array study. Cells were 
treated for 2 hours with 5µg/ml MptpA, lyo BCG, live BCG and BCG with MptpA. 
Proteins were harvested in boiling lysis buffer and 30µg of total proteins were loaded 
on 10% SDS-PAGE gel followed by transfer to nitrocellulose membrane and 
immunoblotting with antibodies. Data is expressed as densitometry analysis of 
phosphorylated proteins normalized against the total proteins levels. The array 






5.5. MptpA does not have ROS regulatory functions but may contribute to the 
downregulation of GSTT2 expression at 2 hours of treatment. 
We have previously shown that blocking direct BCG interaction with MGH cells via a 
transwell device increases ROS levels in the cells and significantly reduced TNFα and GSTT2 
transcripts (Figure 4.8). When the blocking experiments were done in the presence of 100µM 
sodium orthovanadate, a phosphatase inhibitor, the reduction effects on GSTT2 gene 
expression was decreased (Figure 4.9 and Table 4.9). This led us to consider that secreted 
mycobacterial phosphatase may be involved in the observed GSTT2 gene down-regulation. 
Mycobacterial phosphatase may also be responsible for the observed increase in cellular ROS 
when BCG treatment of MGH cells were blocked with a transwell inserts (Figure 4.3 and 
Table 4.4). We investigated the effects of purified MptpA on ROS regulation as well as the 
expression of TNFα and GSTT2 in MGH cell line at the concentrations that induced the 
previously observed reduction of phosphorylated EGFR (Figure 5.4).  
MGH cells were treated with MptpA for 2 and 24 hours before ROS analysis. Treatment with 
MptpA did not induce significant changes in cellular ROS levels at both time points and 
concentrations tested (Table 5.2). Neither were the levels of TNFα transcripts affected by 
MptpA treatment for 2 hours. However, there is an observed drop in GSTT2 expression after 
MptpA treatment at 0.5µg/ml (p=0.028, Table 5.3) and at 5µg/ml concentrations. 
Table 5.2: Effects of MptpA treatment on High ROS levels of MGH cell line 
Sample 2 hours 24 hours 
Control 46.6 ± 2.7 43.0 ± 1.8 
0.5µg/ml  50.3 ± 2.4 39.6 ± 2.2 
5µg/ml  51.3 ± 1.3 42.2 ± 2.5 







Table 5.3: Densitometry quantification of RT-PCR bands from the cDNAs of MGH cell 
line treated with MptpA for 2 hours. 
Gene Control 0.5µg/ml  5µg/ml  
GSTT2 0.53 ± 0.02 0.33 ± 0.05* 0.38 ± 0.06 
TNFα 0.40 ± 0.07 0.34 ± 0.04 0.33 ± 0.03 
Data represented as mean ± SEM. * denotes significant with respect to control (p<0.05). 
Experiment was done twice with triplicates (n=6) 
 
5.6 Discussion 3: 
5.6.1 MptpA is not the secreted factor responsible for ROS increase and TNFα down-
downregulation 
While MptpA treatment of MGH cells did not cause an increase in ROS or downregulate 
TNFα, it may have a role to play in down-regulating GSTT2. The further increase in cellular 
ROS induced by the BCG secreted factor may have resulted in a reduced NF-κB activity by its 
transient degradation in the nucleus, similar to the mechanism described in macrophages 
exposed to mast granules [223]. Also, BCG secreted proteases may have a role to play in 
degrading NF-κB-IκBα complexes in the cytosol. It may be possible that there are other 
secreted bacterial factors that can initiate integrin engagement that has previously been shown 
to generate ROS by the MAPK pathway. Such a possible BCG secreted candidate could be 
Antigen 85complex, that has been known to facilitate binding with human fibronectin and in 
turn activates the integrin signalling and ROS generation [154]. 
5.6.2 MptpA exerts its phosphatase function on the EGFR by possibly 
dephosphorylating inhibitory Y1045 signal. 
Jacobs et al previously demonstrated that MGH cell line expressed functional EGFR that is not 
constitutively activated but responds to exogenous EGF by phosphorylation on Y1068 which 
activates the MAPK pathway [224]. Treatment with MptpA reduced EGF induced EGFR 





phosphotyrosine antibody was used. EGFR kinase domain is very large with numerous 
phosphotyrosine motifs [225]. Besides the activation phosphotyrosine signals which results in 
the downstream signalling pathways upon ligand activation, Tyrosine 1045 (Y1045) site 
signals for inhibition of the protein [226]. Further analysis needs to be done to determine if 
MptpA could have dephosphorylated the inhibitory phosphotyrosine, with pY1045 specific 
antibodies. It is important to note that MptpA treatment may exert its phosphatase activity on 
other protein kinases and phosphatases that are not found on the human phosphokinase array 
and also may modulate the EGFR signalling by influencing the activity of other kinases at 
different steps downstream of the signalling cascade. Furthermore, the entry of MptpA into the 
host cytosol may be a rate limiting event, and the accumulation of the protein at 2 hours may 
not be optimum although it yielded observable effects on the phosphokinase array. 
5.6.3 MptpA with BCG treatment has more signalling modulatory potential 
The combination treatment of MptpA with BCG seems to have more phosphoregulatory 
function. It is possible that there may be secreted components from the BCG preparations that 
facilitate entry of MptpA into the host cytosol and augment its concentration within the 
cellular environment. It was previously demonstrated that BCG treatment of epithelial Hep-2 
cells activated the ERK and p38 signalling pathway to induce the Cxcl8 production [227]. In 
lung epithelial cells, BCG induced Cxcl10 release by activating the PI3K/Akt pathway [228]. 
However, in both the BCG preparations we did not observe significant increase in ERK, 
p38and Akt phosphorylation suggesting that EGF stimulation along with BCG treatment does 
not act in synergy to increase p38, ERK and Akt activation. A study done by Blagoev et al 
revealed the temporal nature of EGFR signalling with p38 and ERK showing different 
activation profiles even though they both share the same position in the signalling cascade and 
translocate to the nucleus [229]. EGF induced ERK phosphorylation was observed as early as 
1 minute whereas p38 phosphorylation was only observed at 5 minutes and by 20 minutes the 





increased both phospho-p38 and phospho-Akt compared to EGF treated control. This 
observation suggests that MptpA treatment mediated the increase in p38 and Akt 
phosphorylation by inactivating phosphastases that serves to down-regulate p38 and Akt 
signalling, some of which are shown in Figure 7.2 It is important to note that MptpA with live 
BCG treatment, although down-regulated the mitogenic ERK signalling pathway, strongly 
enhanced phosphorylation of Akt which is responsible for mitogenesis and survival. 
Furthermore, even though MptpA may be found in the lyo BCG preparation or secreted by live 
viable BCG, the amount present is probably lower than that used in our study and thus the data 
should be interpreted with this caution in mind. Also, BCG treatment was previously found to 
upregulate MKP-1expression that, opposing to its phosphatase activity, positively regulates 
p38/ERK signalling [230]. 
5.6.4 Phosphokinase array vs western blot 
With the phosphokinase array, the spot intensity values were blanked with a negative control 
spot value and normalized against a general positive control spot but in the western blot 
studies, the phosphoprotein intensity were analysed against the total amount of the protein 
present. Thus, fold difference values with respect to control differs between the two techniques 
and it is the western blot analysis is the more accurate reflection of the fold difference. 
We did not manage to detect signals from phosphorylated and total paxillin and p53 in our 
samples. While 250µg of proteins were used for the array, only 30µg were transferred to a 
nitrocellulose membrane for immunoblotting. Hence, the presence of these proteins may be 
below the detection limit and could not be detected by western blot. Imunoprecipitation of 
these proteins from 250µg of cell lysates may be required in order to pull down the maximum 
amount of the target proteins for analysis. Furthermore, MGH cells were reported to express a 





or undetectable by ELISA [231,232]. The ability of the p53 antibody used to detect mutant p53 
is not known. 
 
Figure 5.7: Proposed MptpA modulated events in EGFR signalling.  MptpA treatment 
dephosphorylated inhibitory tyrosine signals at Y1045 preventing the endocytosis mediated 
receptor downregulation and proteasomal degradation.  MptpA with Live BCG increased 
phospho-Akt by inhibiting PTEN activity that is a negative regulator for Akt signalling.  
Phospho-p38 signal increased in the MptpA with BCG (both preparations) possibly by MptpA 
inhibition of phosphatases Wip1 and MKP1 that are known down-regulators for p38 
signalling. MptpA with live BCG reduced phospho-ERK levels possibly by direct 
dephosphorylation of tyrosine residues on the EGFR Y1068, Y1086 or Y1148 to downregulate 
the MAPK/ERK pathway or by direct dephosphorylation of the Y204 site on ERK. Also, 
MptpA could have possibly induced the activation of phosphatases PP2A and DUSP6, known 
ERK signalling downregulators. It is important to note that MptpA exerts its signalling 
modulatory effects by dephosphorylation of tyrosine residues. Phosphatases have varied post-
translational modification mechanism. Phosphorylation of a phosphatase may inhibit rather 
than activate a phosphatase, such as PTEN. It is inhibited by phosphorylation at Ser370 and 
Ser385 by CK2 [233]. Hence, MptpA possibly exerts its phosphatase activity on many protein 
modulators before leading to inhibition of the phosphatases above. However, it is also possible 
that MptpA has specific substrates within the cells resulting in the increase of phosphorylated 















The influx of neutrophils to the bladder wall after BCG immunotherapy was previously found 
to be essential for BCG induced anti-tumour effects [26,27,45]. Neutrophils are considered as 
components of innate immunity and they respond quickly to microbial invasion by bacterial 
phagocytosis. In BCG immunotherapy, neutrophils released cytokines and chemokines in the 
bladder environment to mediate the recruitment of other immune cell effectors and they 
release TRAIL ligands that can cause tumour cell apoptosis [46-48]. A study published by 
Morel et al demonstrated that neutrophils may have an important role to play in coordinating 
DC responses in BCG vaccination by augmenting IL-2 production and T cell stimulation by 
the DCs [53]. As such, neutrophils are important in orchestrating the immune responses 
within the bladder environment in BCG immunotherapy. 
Certain bacterial phosphatases have been found to be involved in immune responses during 
infection. SerB, a serine phosphatase from Porphyromonas gingivalis, can inhibit the 
production of IL-8 [234]. Yersinia YopH protein, a tyrosine phosphatase, is responsible for 
the inhibition of early phosphorylation events in murine T and B lymphocytes during 
infection resulting in suppression of IL-2 production in T cells and B7.2 surface expression of 
B cells [235]. As such, mycobacterial protein tyrosine phosphatases may have a similar 
impact on neutrophil and DC responses. In this section, we investigated the effects of MptpA 
treatment on DCs and neutrophils as well as their interaction in co-cultures in terms of 






6.1 Characterization of isolated DCs generated from GM-CSF conditioned media. 
6.1.1 Generated DCs are semi-mature phenotype and expressed low activation markers. 
DCs harvested after 9 days of culture in GM-CSF conditioned media were analyzed for 
surface marker expression by antibody staining and flow cytometry. The generated DCs were 
uniformly CD11c+ (Chapter 2 section 2.2.8.2.2). DCs expressed low to intermediate levels of 
antigen presenting MHCI, activation markers CD86 and maturation marker CD83 while 
MHCII expression was high (Figure 6.1).  
 
Figure 6.1: Surface marker expression of purified DCs. DCs were analysed for MHCI, 
MHCII, CD86 and CD80 expression after 9 days of culture. The levels of the surface marker 
(no fill) and isotype controls (grey fill) were analysed by flow cytometry.  
 
6.1.2 Neutrophils internalized BCG more efficiently than DCs. 
Neutrophils can rapidly respond to bacterial invasion by taking up the bacterial cells. We 
compared the BCG internalizing efficacy of neutrophil and DC with FITC labelled BCG. In 
this study, we used live BCG in order to make our observations comparable with those of 





BCG FITC in a 1:5 cell to bacteria ratio and incubated for 2 and 24 hours. FITC signal was 
detected with and without trypan blue quenching of signal from surface bound BCG.  
Mean fluorescence intensities (MFI) were comparable for both populations for internalized 
BCG. When the internalized values were expressed as a percentage over total MFI, 
neutrophils were found to take up BCG more efficiently than DC, with overall higher 
percentage of internalized BCG. Thus, DC may have a higher capacity to bind BCG on the 
surface, but neutrophils have a higher BCG internalizing rate than DC.  
Table 6.1: BCG internalization profiles of neutrophils and DCs. 
 
2 hours 24 hours 
Neutrophil DCs Neutrophil DCs 
Surface + internalized a 124 ± 4.7 270.5 ± 10.8* 494.5 ± 107.2 869.8 ±39.2* 
Internalized b 66.5 ± 13.8 53.2 ± 3.0 221.5 ± 82.9 130.8 ± 3.4 
% Internalized c 53.6 19.7 44.8 15 
Data are represented as mean MFI ± SEM. * denotes significant difference compared to 
neutrophils (p<0.05). a Total MFI, b MFI after trypan blue quenching of external FITC 
signal, c % Internalized (a/b x 100). The experiment was repeated twice with duplicates 
(neutrophil, n=4) and triplicates (DCs, n=6) 
 
6.2 Investigating the effects of MptpA on neutrophil-DC cooperation. 
Morel et al previously demonstrated that neutrophil treated BCG enhanced DC response to 
BCG by augmenting cytokine production in vitro. Hence, we decided to investigate the 
effects of the MptpA on DC-neutrophil cooperation during BCG treatment. BCG mediated 





6.2.1 MptpA does not induce cytokine production in DC and neutrophil nor affect 
cytokine production in DC-neutrophil co-culture samples. 
Compared to untreated control, BCG induced increased production of all the cytokines 
(TNFα, IL12p40, IL12p70, IL10 and IL2) by the DCs. In neutrophils, only IL10 and TNFα 
production was increased after BCG treatment. When compared to BCG treated DCs (DB), 
DCs incubated with BCG treated neutrophils [D(NB)] had enhanced production of TNFα, 
IL12p40 and IL2 (Figure 6.2). BCG with MptpA treated neutrophils [D(NBA)] did not affect 
the augmentation of cytokine production by the DCs but the secretion of IL12p40 and IL2 
from these treatment groups were not significantly different from BCG treated DCs. IL23 
cytokine levels were not detected in any of the supernatant samples (data not shown). DCs are 
observed to be the sole producers of IL12p40, IL12p70 and IL2 in the DC-neutrophil 
cocultures. 
6.2.2 DC activation and CD40 up-regulation induced by BCG treatment is not affected 
by MptpA. 
BCG treatment increased CD86 activation marker but not the surface expression of CD40 co-
stimulatory molecule. MptpA with BCG treatment did not affect BCG induced CD86 up-
regulation in both DC and DC-neutrophil co-cultures. CD40 expression was significantly 
enhanced in BCG and BCG with MptpA treated neutrophil-DC co-cultured samples (Table 
6.2) when compared to direct DC treatment with BCG. Thus, in our study, BCG treated 
neutrophils induced CD40 expression on DCs better than the direct treatment of DCs with 
BCG. There are no differences in the expression of MHCII, CD80 and CD83 in all the groups 








Figure 6.2: Effect of BCG treated neutrophils on DC cytokine production. Unit expressed 
as total picograms. DCs [D], were treated with 5µg/ml MptpA [DA], BCG [DB], neutrophils 
[DN], BCG treated neutrophils [D(NB)] or BCG with MptpA treated neutrophils [D(NBA)]. 
Neutrophils [N] were also treated with BCG [NB], MptpA [NA] or BCG with MptpA 
[NAB].BCG treatment in the all samples were done for 2 hours followed by incubation with 
gentamicin to remove excess bacteria before the addition of DCs (for D(NB) and D(NBA) 
only) and further incubation for 18 hours. Supernatants were collected the next day and 
assayed for cytokine production by ELISA. 5x105 neutrophils and 2.5x105 DCs were used in 
this assay while BCG treatment is constantly done with 2.5x106 cfu. The total volume was 





Table 6.2: Effects of MptpA treatment on DC surface marker expression of CD86 and 
CD40. 
 
Group CD86 CD40 
DC 42.9 ± 4.6 19.3 ± 1.7 
DC + BCG 78.1 ± 5.0♦ 15.5 ± 5.4 
DC + 5µg/ml MPTPA 51.3 ± 5.6 29.1 ± 3.9 
DC + MptpA+ BCG 76.9 ± 4.9♦ 26.1 ± 0.9 
DC + (neutrophil+BCG) 72.2 ± 3.3♦ 31.1 ± 1.7* 
DC + (Neutrophil+ BCG + MptpA) 73.3 ± 4.4♦ 38.0 ± 0.6* 
DC + Neutrophil 38.4 ± 6.5 25.7 ± 2.3 
Data represented as percentage mean± SEM. ♦ denotes significant difference from DC and * 
denotes significant difference with respect to BCG treated DC (DC+BCG, p<0.05). The 
experiment was done 4 times (n=4). 
 
6.3 Discussion 4 
DCs generated from GM-CSF conditioned media after 9 days of culture exhibit a semi-mature 
phenotype with BCG endocyting capacity. When the BCG internalizing efficiency was 
compared, neutrophils were found to take up BCG better than the isolated DCs.  
DC or neutrophil treatment with MptpA did not induce cytokine production from both cell 
types and did not regulate CD86 and CD40 surface expression on the DCs. DCs, when co-
cultured with BCG treated neutrophils, showed enhanced production of TNFα, IL12p40 and 
IL2 when compared to DC directly treated with BCG. However, IL12p40 and IL2 production 
in DC cocultured with BCG and MptpA treated neutrophils were not significant compared to 
BCG treated DC. Direct BCG treatment with DCs or indirectly through BCG treated 
neutrophil-DC cocultures, induced up-regulation of surface CD86 expression. Treatment of 
BCG with MptpA did not affect this observed CD86 increase. However, BCG treatment failed 
to up-regulate CD40 expression in direct BCG treated DCs. Increase in CD40 expression was 
observed only in BCG (with or without MptpA) treated neutrophil-DC co-cultures. In 





does not exhibit immunogenicity in terms on regulating cytokine productions in neutrophil and 
DCs or stimulating surface marker expressions on DCs. 
In comparisons with the study done by Morel et al, Connaught strain BCG treated neutrophil-
DC co-cultures exhibited similar augmentation of TNFα, IL12p40 and IL2 production. 
However, there are some differences in the amount of cytokines produced in our study. TNFα 
production was much greater in our case, with BCG stimulating TNFα production higher than 
10000 pg/ml levels compared to 2500 pg/ml levels in their study. While they did not observe 
IL10 production in their studies, we detected IL10 in our BCG treated supernatants. However, 
IL2 production in our case was much lower (less than 10pg/ml versus 200pg/ml in their study). 
At this point, it is unclear if the differences in our observations are due to the 2 different strain 
of BCG used (Connaught strain versus Pasteur strain in Morel’s study) or due to the 
maturation state of the DCs. The DCs generated in our studies expressed high MHCII 
compared to the intermediate levels expressed in the study by Morel et al. Finally, Morel et al 
observed that DCs up-regulated CD40 surface expression upon BCG treatment and that BCG 
treated neutrophils increased CD40 expression at similar levels to direct BCG treated DCs. In 
our studies, direct BCG treatment did not induce significant CD40 expression in DCs but BCG 
(with or without MptpA) treated neutrophils mediated significant CD40 up-regulation 
compared to BCG treated DCs.  
For IL12p40, IL2 and TNFα, we had experimental controls to demonstrate that neutrophil do 
not express these cytokines even after BCG stimulation. However, in the future, to ensure that 
the cytokine production comes from the DCs, a double fluorescent flow cytometry approach 
can be used, labelling the DCs or neutrophils with antibodies against a cell specific surface 
marker and intracellular immunofluorescence staining with cytokine antibodies. 
Reports on the known functions of MptpA are few. Current literature finding show that MptpA 





While they may have observed roles in inhibition of phagocytosis, our studies revealed that 
MptpA did not exhibit any immunostimulatory properties with neutrophils and DCs and that 
the combination treatment of MptpA did not affect the immunoregulatory effects of BCG. 
Furthermore, as previously discussed, there are differences in the cytokine response in the DC-
neutrophil co-cultures between the Connaught strain used in our studies and the Pasteur strain 
in Morel’s study. While, both Pasteur and Connaught strain are both classified as ‘early shared 
strains’ with similar immunostimulating activities on human alveolar epithelial cells and 
primary mouse bone marrow cells [236], a report by Ganguly et al revealed the presence of 
ESAT6 gene cluster in the Pasteur strain [237]. While this may be unconventional since 
ESAT6 is a virulency factor and its genetic cluster, the RD1 region, was found to be lost in 
attenuated strains, this might explain the differences in responses between the 2 strains in DC-
neutrophil co-culture. The study by Morel et al. did not measure IL12p70 levels and only 
reported IL12p40 levels. As IL12p40 can dimerize with p19 subunit to form IL23 and p35 to 
form IL12p70, in this study IL23 and IL12p70 levels were also measured. The low levels of 
IL12p70 and IL23 suggests that BCG treatment resulted in IL12 p40 homodimer formation 
which is believed to be biologically inactive [238]. This indicates that caution should be 










General Discussion, Implications 
and Future Directions 
 
 
Science cannot solve the ultimate mystery of nature. And that is because, 
in the last analysis, we ourselves are a part of the mystery that we are 







Lyophilized BCG has been used for the immunotherapy of superficial bladder cancer and has 
been shown to improve the recurrence and progression free status for bladder cancer patients. 
However, side effects are common and some patients do not respond to BCG therapy [239]. 
There is a need to find ways to improve the response rate and the quality of life for the bladder 
cancer patients. Lyophilized preparations contain soluble BCG antigens, dead bacteria and 
viable BCG and it induces a strong immune response in patients. It may not be the best form of 
BCG for therapy and comparing its effects with live BCG will provide insights for 
improvement. 
We investigated the effects of intravesical live BCG treatment in normal non-tumour bearing 
mice as it was previously demonstrated that cytokine expression during the 6 weeks of 
intravesical lyo BCG treatment was similar to the induction patterns observed in the urinary 
cytokine of patients receiving BCG immunotherapy [171]. In our studies, we found that live 
BCG treated mice produce a predominantly chemokine gene expression response in the 
bladder compared to the cytokine response that is well characterized in lyo BCG therapy. 
However, the immunogenic potential in vivo is similar as live BCG induced the influx of 
immune cells such as macrophages, NK cells and CD8+ T cells to the bladder which has 
previously been observed in lyo BCG studies [26,27,33]. While the use of healthy mice gives 
us insight on the participation of the normal urothelium in BCG induced immune responses in 
the bladder, the presence of tumour cells contributes to the nature of the response by inducing 
tumour specific cytokine expression such as IL-4, IFNγ, TNFα and IL-6 [240,241].   For 
C57BL/6 mice, MB49 murine bladder cancer cell line is used for the syngeneic orthotopic 
model. MB49 cells express high levels of integrin α5 (data not shown) that could facilitate 
BCG binding and internalization at the neoplastic site. Furthermore, we have demonstrated in 
our studies that tumour cells expressing high integrin α5 levels internalize BCG which 
subsequently results in direct cytotoxic effects. Tumour cell debris can induce the 





improving the efficiency of immune response [242]. The types of immune cell infiltrating the 
neoplastic lesions also have an important role to play in determining the nature of immune 
response within the tumour microenvironment. Tumour cells set up a hostile 
immunosuppressive environment for the attracted infiltrating immune cells through a milieu 
that is usually rich in transforming growth factor β, vascular endothelial growth factor and IL-
10 amongst other factors that may diminish anti-tumoural efficiency [243]. This immune 
suppression endowed by the tumour cells may be overcome by BCG treatment. Comparing the 
two BCG preparations in vivo using the orthotopic tumour model as well as the BCG induced 
response in the normal versus the tumour bearing mice will be a better way to dissect the anti-
tumoural response of BCG treatment.  
In vivo comparisons between the two BCG preparations reveal differences in gene expression 
profiles and to elucidate the mechanisms further, we used a panel of human bladder cancer cell 
lines for gene expression studies in vitro. Using a SuperArray, 64 genes were upregulated by 
both live and lyo BCG at in MGH cell line after 2 hours of treatment even though their ROS 
regulatory effects are contrasting. Even though the microarray analysis did not show 
significant differences between the two BCG preparations, the transcripts were induced to 
differing extents. For example, lyo BCG induced higher GSTT2 transcript expression than live 
BCG (5.5± 2.4 vs 2.1± 1.1 respectively). RT-PCR validation of GSTT2, TNFα and IL1β also 
showed upregulation in both BCG preparation treated samples. While tumour cells may 
contribute to cytokine gene expression, immune cells are major contributors of cytokines. Both 
neutrophils and DCs expressed TNFα and IL10, 18 hours after a 2 hours initial exposure to 
live BCG and neutrophils isolated from the urine of lyo BCG treated patients were a major 
source of IL8, growth related oncogene-alpha (Gro-α or CXCL1), macrophage inflammatory 
protein-1 alpha (MIP-1α or CCL3) and the macrophage migration inhibitory factor (MIF) [45] 
. Live BCG is also capable of inducing cytotoxicity in BCG internalizing cell line, UMUC3 





[11,169]. The data altogether indicates that ROS effects have no influence in BCG induced 
gene expression and cytotoxicity in tumour cells. However, in our study, we measured the 
ROS species hydrogen peroxide (H2O2), peroxynitrite (ONOO•) and peroxyl radical (ROO•). 
Superoxide anion (O2•-) is another free radical species that we did not look into and both lyo 
and live BCG have previously been demonstrated to stimulate superoxide anion formation 
within the first 20 minutes of treatment in MGH cell line and macrophages respectively 
[169,244]. Hence, it is possible that the surge of superoxide anion in BCG treated cells 
induced the similar gene expression profile observed. Both ROS depletion as well as ROS 
increase strategies was proposed as anti-cancer therapies [245]. Studies done in our lab showed 
that co-treatment of lyo BCG with a ROS scavenger, N-acetylcysteine, resulted in further ROS 
decrease with subsequent increase in cytotoxicity as well when compared to lyo BCG treated 
cells alone [169]. Live BCG, which induced ROS increase, is also capable of cytotoxicity. 
When separated with a transwell device, both live and lyo BCG soluble factors induced ROS 
increase in MGH cells. However, ROS induced cytotoxicity was not observed in these samples 
(data not shown). Hence, ROS increase is only effective in cells that have internalized BCG 
and the cause for concern involving soluble BCG factors is that they induce ROS increase that 
is inadequate in crossing the ROS threshold that triggers cell death but may be enough to cause 
oxidative DNA damage, protein alterations and other processes that promote tumour 
progression and metastasis [246]. ROS species may also have differing roles in cytotoxicity by 
inducing death via distinct pathways. Thus, investigating the exact ROS species involved in 
both live and lyo BCG treatment as well as by BCG soluble factors is one of the aspects to 
focus on in the future.  
Further efforts needs to be taken to fully understand the effect of GSTT2 gene silencing in 
vitro as well as in vivo. While we have demonstrated that GSTT2 silenced MGH cells 
experience further ROS reduction and decreased NO production after lyo BCG treatment, its 





to be determined. Inhibition of NO production by BCG may be beneficial in vivo by a) 
reducing the death of immunocytes surrounding and regulating the tumour growth and by b) 
promoting healing of the bladder tissue and improving tumour regression [247]. To test the 
first hypothesis, it is feasible to measure the cellular viability of splenocytes after being co-
cultured via a transwell device with GSTT2 silenced MGH cells treated with lyo BCG. Protein 
activity of GSTT2 after silencing should also be determined to validate silencing efficacy. 
Determining the GSTT2 expression of the murine MB49 tumour cell line after lyo BCG 
expression should also be conducted for future in vivo studies in order to assess effects of 
GSTT2 silencing on BCG treatment.  
Genetic variants of other GSTs have been implicated in risk of developing transitional cell 
carcinoma (TCC) of the bladder. Polymorphisms of the GSTP1 gene at codon 105 (Ile/Val), 
GSTM1 null genotype and GSTT1 null genotype are associated with increased risk for bladder 
carcinoma [248]. Comparisons between urinary bladder TCC specimens and the normal 
urothelium showed increased cytosolic GSTT1 and GSTP1 enzyme activity in the malignant 
phenotype that might result in resistances to both chemotherapy and apoptosis respectively 
[249]. We have showed GSTT2 upregulation in both live and lyo BCG treated MGH cells. As 
such, studying GSTT2 genetic polymorphisms, cytosolic activity and their effects on BCG 
therapy failure and tumour progression is a reasonable area for future investigation. 
The interactions occurring in the bladder during BCG instillation is dynamic and soluble BCG 
factors are secreted or present in both live and lyo BCG that can induce responses in tumour, 
urothelial and immune cells. As observed in our experiments, BCG secreted factor(s) are 
capable of inducing ROS increase and gene silencing without direct contact between the 
bacteria and the tumour cell line. We decided to investigate the exact component responsible 
for these observations and isolated mycobacterial MptpA for treatment with MGH cell line, 
neutrophils and DCs. MptpA treatment of MGH cells for 2 hours partially reduce GSTT2 gene 





effect on cellular ROS. Hence, MptpA may contribute, in part, to the GSTT2 gene silencing 
that we observed in MGH cells in the presence of the transwell which blocked BCG 
interaction with the cells. Furthermore, MptpA has no immunostimulatory effect on 
neutrophils and DCs in terms of inducing cytokine expression and cell surface activation 
markers. While there are limited studies published on MptpA, it is currently known that 
MptpA has a role to play in actin polymerization during infection so as to establish stable 
infections in macrophages by interfering with phago-lysosome fusion via its interaction with 
human Vacuolar Protein Sorting 33B (VSP33B), a component of vesicle trafficking [167]. It is 
postulated that its role is in limiting the number of mycobacteria engulfed by the host cells, in 
order to keep sufficient nutrients and favour their own growth [165]. Hence, it is interesting to 
speculate if using MptpA knock out BCG strain may trigger excessive bacterial internalization 
in host or tumour cells thereby inducing rapid cytotoxicity. Isolated MptpA in culture reduced 
tyrosine phosphorylated EGFR in our studies end even though its effects downstream of EGFR 
signalling is yet to be defined, MptpA in combination with other mycobacterial components 
can regulate the host signalling proteins. Also, isolating the triple specificity phosphatase 
MptpB and studying its role in vitro, alone or in combination with MptpA, in MGH cells with 
respect to signalling modulation, localisation and their precise substrates will shed light on the 
role of mycobacterial phosphatases in BCG therapy.  
In our experiments, the lyo BCG suspension was washed and the soluble extracts were 
discarded and only the lyo BCG particles were used for treatment. Hence, the major 
components of the soluble factors present in the assay are secreted by the viable bacteria, 
rather than from cytosolic BCG components that are released during the lyophilisation process. 
Studying the effects of the soluble components of the lyo BCG preparation will provide more 
insights on the events it induced in the bladder after BCG instillation. A previous study done 
by Pook et al. in our lab showed that pre-treatment with the soluble extract of the lyophilized 





to the studies done with MptpA [165,167]. The removal of MptpA and/or the soluble BCG 
components from the lyophilize mixture may be desirable for two reasons. Firstly, BCG 
internalization of tumour cells correlates with direct cytotoxicity resulting in the release of 
necrotic debris that can stimulate immune cells such as macrophages and dendritic cells. 
Although it has yet to be quantified, MptpA is constitutively expressed and may be present in 
high concentrations in the soluble extract. The second reason is that while MptpA treatment 
reduced tyrosine phosphorylated EGFR, downstream phopho p38 (p-38), phospho ERK (p-
ERK) and phospho AKT levels was not subsequently reduced as well. This leads us to 
hypothesize that MptpA treatment induced dephosphorylation of tyrosine 1045 of EGFR. 
Phosphorylation at Tyrosine 1045 signals for endocytosis mediated receptor downregulation 
and proteosomal degradation [226]. Thus, MptpA can induce prolonged EGFR mediated 
signalling. However, this theory needs to be confirmed with further study which is feasible 
with Tyr1045 EGFR specific antibodies. It is also important to note that prolonged EGFR 
activation is induced by oxidative stress in the form of hydrogen peroxide and in this aspect, 
treatment with lyo BCG is more beneficial than live BCG since the former reduces cellular 
ROS levels [250]. Conversely, there is aso a positive aspect to MptpA treatment. In our 
studies, MptpA by itself did not induce p-p38/p-ERK ratio and had no effect on cell cycle 
progression. However, MptpA treatment in combination with live or lyo BCG particles 
increased p-p38/p-ERK ratio when compared to control, MptpA or BCG alone and higher p-
p38/p-ERK ratio favours cancer cell arrest [251]. Hence, cytotoxic effects of combination 
treatment of MptpA with BCG on MGH cells need to be further determined. 
The expression of cytokines and chemokines detected in the urine and bladders of patients 
after BCG therapy may be attributed to the immune cells infiltrating the bladder especially 
neutrophils, as they are the first to arrive at the bladder site. DCs are potent antigen-presenting 
cells and are capable of directing immune responses towards the cancer clearing TH1 type via 





induced high amounts of IL12p40 when compared to IL12p70 and lyo BCG induced similar 
levels of IL12p70 in macrophages upon stimulation [253]. IL12p40, when present as a 
monomer or a homodimer can bind the IL12 receptor and antagonize the action of the 
bioactive IL12p70. Binding of IL12p70 to the IL12 receptor is one of the cascades of events 
resulting in the differentiation of naïve CD4+ T cells into TH1 helper cells. Furthermore, 
previous reports have stated that IL12 has remarkable anti-tumour capacity mediated by IFNγ 
secretion by CD4+ T cells, CD8+ T cells and NK cells [254]. Recombinant IL-12 therapy has 
been demonstrated safely in certain cancers such as head and neck squamous cell carcinoma, 
ovarian cancer, primary peritoneal carcinoma and melanoma [255-257]. In fact, a phase I study 
of the intravesical administration of recombinant IL12 in patients with recurring superficial 
bladder carcinoma have previously been evaluated [258]. In this study, Weiss et al. reported 
that while the agent was well tolerated, there was no evidence of immunological or anti-
tumourigenic effects but as previously stated the anti-tumourigenic capacity of IL12 is 
dependent on IFNγ production by other activated immune cells and in their report, 
recombinant IL12 alone did not induce IFNγ production. Since live and lyo BCG induced low 
levels of IL12p70, a combination treatment of BGC with recombinant bioactive IL12 may be 
beneficial.  
The exact mechanisms of BCG immunotherapy remain elusive and till now treatment regiment 
is empirically based. The areas to focus on for research include identifying the patients who 
will not benefit from the initial adjuvant BCG therapy, understanding the phenomena behind 
BCG failure and developing alternate adjuvant therapies that are more efficient in tumour 
clearance and increasing remission from the disease. While this dissertation have identified a 
few avenues for improving BCG therapy, the anti-tumour efficacy in vitro has to be 
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